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Summary 
 
Cyclooxygenase (COX) is the rate limiting enzyme that catalyses the production of 
prostanoids, which are crucial to vascular homeostasis. Evidence suggests that COX-mediated 
pathways play a role in aging and diabetes.   
 
Aging is associated with endothelial dysfunction, which is characterized by impaired 
endothelial-dependent relaxation responses. The exact causes of age-related endothelial 
dysfunction are not clear. Previous animal studies by our laboratory at RMIT University 
reported enhanced COX expression with aging in rat aortas. Potentially, this may result in an 
imbalanced prostanoid production favoring the synthesis of vasoconstrictors such as TXA2 
and hence increase the risk of cardiovascular events in the aging population. Very little is 
known about the regulation of altered COX expression in aging. It has been suggested that 
histone hyperacetylation may be an important mechanism that regulates COX levels during 
the aging process as increased histone acetylation has been shown to occur with aging.  
 
In the case of diabetes, studies have reported that the development of diabetes and its 
complications is associated with persistent inflammatory activity, evident with increased 
inflammatory markers in the circulation. COX-mediated pathways may be involved in this 
inflammatory process in diabetes. Furthermore, the formation of advanced glycation end 
products (AGEs) is accelerated in diabetes. AGEs can bind to receptors for AGEs (RAGE), 
which has also been suggested to play a role in inflammation in diabetes.   
 
The present study aimed to investigate firstly, whether previously observed enhanced COX 
expression in aging is modulated by histone hyperacetylation and secondly, whether there are 
changes in COX and RAGE levels in platelets and monocytes in Type 1 and Type 2 
diabetes.   
         xxi 
The present study reported that  
i) in cultured endothelial cells, COX expression was up-regulated in response to the treatment 
of a histone de-acetylase inhibitor, Trichostatin (TSA). COX up-regulation was accompanied 
by an increase in histone H4 acetylation status, suggesting that COX gene expression is 
modulated through histone acetylation/de-acetylation. This could be a potential mechanism by 
which increased COX expression in aging is regulated.  
 
ii) an initial study in Zucker rats, an animal model that has the characteristics of Type 2 
diabetes, found increased COX levels in platelets and monocytes, an observation that was not 
found in the human Type 2 diabetic study. This suggests that changes in COX levels in these 
inflammatory cells may be species-dependent. In addition to unaltered platelet COX-1 and 
monocyte COX-2 levels in Type 2 diabetes, the present human study further reported elevated 
plasma PGE2, but not plasma TXB2 in Type 2 diabetes, suggesting an overall increase in 
inflammatory activity in human Type 2 diabetic subjects. Treatment with non steroidal 
anti-inflammatory drugs (NSAIDs) in Type 2 diabetes reduced both COX expression and 
COX activity. This re-affirms the previous observation that inflammation was increased in 
human Type 2 diabetic subjects.  
 
In addition, monocyte acetylated histone H4 expression was unaltered in human Type 2 
diabetes, which was consistent with the lack of changes in monocyte COX-2 levels. This 
supports the hypothesis that COX expression is modulated through hyperacetylation of the 
core histones. The use of NSAIDs resulted in a reduction in monocyte acetylated histone H4 
levels in Type 2 diabetes. To the best of our knowledge, this is a novel finding suggesting 
potentially COX expression may be regulated by NSAIDs via histone modifications.  
 
         xxii 
iii) in human Type 1 diabetic subjects, the COX-2-mediated pathway was altered as indicated 
by increased monocyte COX-2 expression. In plasma, elevated PGE2 levels were also 
observed in Type 1 diabetes. Treatment with NSAIDs in Type 1 diabetes reduced both COX 
expression in platelets and monocytes and COX activity shown by reduced plasma COX 
metabolite levels. These data suggest an overall increase in inflammatory activity in Type 1 
diabetes.  
 
Concurrent with increased monocyte COX-2 levels was an increase in acetylated histone H4 
expression in monocytes in Type 1 diabetes, suggesting hyperacetylation of the core histones 
is associated with COX up-regulation. The use of NSAIDs down-regulated monocyte 
acetylated histone H4 levels in Type 1 diabetes. This is a novel finding suggesting that 
NSAIDs may regulate COX expression via histone acetylation/de-acetylation.  
 
iv) RAGE levels were moderately increased in platelets and monocytes in both human Type 1 
and Type 2 diabetic subjects. Increased RAGE levels were reduced by the treatment of 
NSAIDs in human diabetic subjects, suggesting RAGE may be a crucial player in the 
inflammatory process in diabetes. The ability of NSAIDs to down-regulate RAGE may be of 
importance in the management of diabetic complications. 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 1 
GENERAL INTRODUCTION 
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1.1 THE CIRCULATORY SYSTEM 
The heart and blood vessels form the basis of the circulatory system whose function is to 
provide adequate blood supply to organs and tissues within the body. Several mechanisms 
including neural, endocrine and various local factors control the circulatory system by 
regulating blood flow to organs and tissues. For instance, by altering the rate and force of its 
contraction, these mechanisms modulate pumping function in the heart. Similarly, these 
mechanisms can alter blood vessel diameter hence, influencing vascular resistance, pressure 
and the rate of blood flow. Control of the circulatory system is essential in achieving a 
physiological homeostasis (Fox 1996; Guyton & Hall 2001).  
 
1.1.1 FACTORS AFFECTING CARDIAC FUNCTION 
Under the regulation of the central nervous system, the autonomic nerves exert their control 
over the heart by modulating its rate and force of contraction. The autonomic nervous system 
processes information collected by sensors, which respond to various changes in the body 
through autonomic reflexes. For instance, baroreceptors in arteries detect changes in blood 
pressure, chemoreceptors monitor oxygen, carbon dioxide and pH level in the bloodstream, 
visceral and cardiopulmonary reflexes respond to changes in blood flow and cardiac 
stretch/pressure, respectively (Sherwood 1989; Fox 1996). In response to the sensory 
information transmitted to the brain, the sympathetic nervous system releases 
neurotransmitters such as noradrenaline to enhance the rate and force of heart contraction via 
β–adrenoceptor activation (see Review by Xiao et al. 1999). In contrast, the parasympathetic 
nervous system opposes its effect by releasing acetylcholine, which in turn activates 
muscarinic receptors and reduces heart rate (see Review by Hill et al. 2001).  
 
In addition to the autonomic nervous system, factors associated with the coronary and 
systemic circulation also influence the actions of the heart. Through both myogenic and 
metabolic mechanisms and neural input from the sympathetic nervous system, the coronary 
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circulation regulates the amount of blood supply to the heart whilst the systemic circulation 
determines output resistance into which the heart is pumping (Fox 1996; Marieb 1998).  
 
1.1.2 THE ARTERIAL CIRCULATION 
The arterial circulation consists of large conduit arteries branching repeatedly into smaller 
vessels, arterioles and capillaries. It is at the level of capillaries where nutrients and 
low-pressure oxygen exchange takes place (see Review by Hill et al. 2001). The composition 
of the arteries includes three layered walls, tunica adventitia, media and intima, surrounding a 
hollow lumen with the tunica adventitia being the outermost layer. The tunica adventitia 
consists mainly of collagen with lymphatic vessels, nerves and vasa vasorum (only in larger 
arteries). Stimulation of nerves located in the tunica adventitia can result in the release of 
vasoconstrictor and vasodilator neurotransmitters affecting vascular tone (see Review by 
Fernández-Alfonso 2004). A large portion of the arterial wall comprises the elastic lamina 
interspersed with smooth muscle cells and collagen, and is known as the tunica media. A 
single layer of endothelial cells lying upon a basal elastin layer forms the innermost tunica 
intima (see Review by Cohn 1999). The smooth muscle and endothelial cells are capable of 
releasing various mediators and substances such as prostanoids that modulate vascular tone 
(Berne et al. 1998; see Review by Luscher & Barton 1997). 
 
1.1.3 CONTROL OF ARTERIAL CIRCULATION 
Mechanisms that control blood vessel diameter are complex. Changes in blood vessel 
diameter via neural, hormonal and other various factors ultimately affect the supply of 
nutrients and oxygen to tissues and cells in various organs. The vascular smooth muscle cells 
(VSMCs) also have a crucial influence on arterial blood flow as stimuli from hormones, local 
mediators and neural transmitters can lead to a series of signal transduction cascades via 
receptors on VSMCs (Berne et al. 1998). 
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1.1.3.1 The neural system 
A network of neurons infiltrates the adventitial layer in most blood vessels. The dense neural 
network regulates the underlying medial smooth muscle layer by releasing neurotransmitters 
causing either a vasoconstriction or vasorelaxation response. While noradrenaline-activated 
α1- and α2-adrenoceptors are the principal sympathetic contractile influences in VSMCs, 
sympathetic nerves can also release a variety of substances such as neuropeptide Y and 
adenosine triphosphate (ATP), which can either directly cause a contractile response or 
achieve a contractile response through modulation of noradrenaline activity (see Review by 
Hill et al. 2001). In the case of vasodilatation it is regulated by both sensory neurons and 
vasodilator nerves. Sensory neurons can release peptides such as substance P, calcitonin 
gene-rated peptide, neurokinin A and neurokinin B, which are all capable of inducing 
vasorelaxation. Vasodilator nerves on the other hand are found in some blood vessels. For 
instance, parasympathetic nerves are present in the pelvic viscera and produce acetylcholine 
and vasoactive intestinal peptide, leading to receptor-mediated vasorelaxation (see Review by 
Holzer & Lippe 1992).  
 
1.1.3.2 The endocrine system 
Hormonal influence from the endocrine system contributes greatly to the regulation of smooth 
muscle contractility in blood vessels and kidney. For example, adrenaline and noradrenaline 
are released into the blood stream in response to sympathetic nerve and adrenal medulla 
stimulation. They activate α- and β-adrenoceptors hence the vasoconstriction and 
vasodilatation, respectively, of blood vessels (Marieb 1998). In the kidney, renin is released 
when arterial pressure is low. The release of renin leads to the conversion of angiotensinogen 
to angiotensin I, which is subsequently converted to angiotensin II in the endothelium. 
Angiotensin II is a potent vasoconstrictor (see Review by Touyz & Schiffrin 2000).   
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1.1.3.3 Regulatory factors 
Endothelial cells release vasorelaxant factors including nitric oxide (NO), prostacyclin (PGI2) 
and endothelium-derived hyperpolarizing factor (EDHF) in response to physiological and 
hormonal stimuli. While these vasorelaxation modulation factors relax VSMCs, endothelial 
cells also produce contracting factors such as endothelin, thromboxane A2 (TXA2) and 
angiotensin II. Modulation factors can also be released by smooth muscle and blood elements 
in the circulation, which further modulate and maintain vascular tone (Ramadan et al. 1990; 
see Review by Luscher & Barton 1997). PGI2 and TXA2 are products of cyclooxygenase 
(COX)-mediated pathways (for more details, see Section 1.2). Previous studies by our 
laboratory at RMIT University found that COX-mediated pathways were involved in the 
aging process in rat aortas (Kang et al. 2001). These changes may potentially result in an 
imbalanced prostanoid production favoring the synthesis of vasoconstrictors such as TXA2 
and contribute to endothelial dysfunction.  
 
1.2 CYCLOOXYGENASE (COX) SIGNALING PATHWAYS  
Cell membrane phospholipids can be cleaved by phospholipase A2 (PLA2) to release 
arachidonic acid, which is the precursor of a variety of signaling molecules that include 
prostaglandins and thromboxanes. Prostaglandins were first discovered in human semen in 
1930 (Lawrence et al. 1999) with the biosynthesis mechanism outlined thirty-seven years later 
by Hamberg and Samuelsson (1967). The key event in the proposed mechanism involved the 
production of bicyclic peroxide (endoperoxide) from polyunsaturated fatty acid oxygenation 
(arachidonate) catalyzed by the enzyme termed prostaglandin endoperoxide H synthase, 
which is also known as cyclooxygenase (COX) (Hamberg & Samuelsson 1967; see Review 
by Lawrence et al. 1999). COX is coupled to a range of synthases. The products of this COX 
enzymatic pathway are prostanoids including various prostaglandins and thromboxanes, 
which play important roles in modulation of vascular tone in both physiological and 
pathophysiological conditions (see Figure 1-1). 
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Prostanoid synthesis pathway  
Arachidonate is cleaved free by phospholipase A2 (PLA2) from the lipid membrane and is 
converted to PGH2 via two major steps by COX enzymes: oxygenation of arachidonic acid into 
PGG2 and reduction of PGG2 into PGH2. Isomerization or reduction of PGH2 by terminal 
prostanoid synthases in tissues then results in the production of various prostanoids. 
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1.2.1 COX-MEDIATED PATHWAYS 
The production of prostanoids via COX-mediated pathways is dependent on the availability of 
substrates and the activity of COX (see Figure 1-1 for the pathway). Three naturally occurring 
polyunsaturated fatty acids, trienoic (dihomo-γ-linoic) acid, tetraenoic (arachidonic) acid and 
pentaenoic acid, are substrates for COX enzymes. The predominant substrate however, is 
arachidonic acid since it is the most abundant in animal tissue (see Review by Crawford 1983). 
Arachidonic acid is derived from membrane phospholipids predominantly by the action of 
phospholipase A2 (PLA2). Following the cleavage of arachidonic acid from the sn-2 position 
of the membrane phospholipids, COX catalyzes arachidonic acid, resulting in the formation of 
endoperoxide prostaglandin G2 (PGG2) (see Review by Crofford 2001). This reaction takes 
place in the COX active site of the catalytic domain where arachidonic acid enters the channel 
via the hydrophobic compartment created by the membrane-binding domain and forms a 
hairpin turn between C9 and C11. A tyrosyl radical from the oxidized Tyr-385 then removes 
the pro(S) hydrogen from C13 of arachidonic acid. Molecular oxygen forms the endoperoxide 
bridge connecting C9 and C11 followed by the ring closure between C8 and C12 resulting in a 
bicyclic cytopentyldioxygen prostaglandin structure (see Review by Garavito & DeWitt 1999). 
The second molecular oxygen is then added to C15 producing PGG2. PGG2 then moves to the 
peroxidase subunit of the catalytic domain to be reduced to PGH2. PGH2 is the common 
precursor for many biologically active eicosanoids such as TXA2, PGI2 and other 
prostaglandins. The production of different prostanoids converted from PGH2 depends on 
individual cell types and the presence of specific enzymes in those cells. For example, PGI2 
production is catalyzed by PGI2 synthase in the endothelial cells. TXA2 generation catalyzed 
by TXA2 synthase is observed in the platelets. Several other prostaglandins including PGD2, 
PGE2 and PGF2α are produced from PGH2 mainly in the mast cells, macrophages and smooth 
muscle respectively (Reddy & Herschman 1996). Figure 1-1 details the biochemical pathways 
by which prostanoids are produced. Specific roles of prostanoids in the vasculature are further 
discussed in Section 1.3. 
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1.2.2 PROSTANOID RECEPTORS 
Prostanoids produced from COX-mediated pathways exert their effects through the activation 
of prostanoid receptors. Prostanoid receptors belong to the rhodopsin superfamily of G 
protein-coupled receptors. There are eight types and subtypes of membrane prostanoid 
receptors in mammals from mouse to human (Table 1-1). They include the PGD (DP), PGF 
(FP), PGI (IP), TXA (TP) and four subtypes of PGE receptors (EP1-4). Prostanoid receptors 
can be divided into three categories based on their signal transduction and action. The DP, IP, 
EP2 and EP4 receptors have been termed the “relaxant” receptors, because they stimulate 
adenylate cyclase, resulting increased cyclic adenosine monohosphate (cAMP) levels via Gs 
to exert their inhibitory effects. In contrast, FP, TP and EP1 receptors are coupled to 
phospholipase C via Gq to induce calcium mobilization hence they are referred to as 
“contractile” receptors. Among the prostanoid receptors, EP3 receptors have the most complex 
molecular biology with the existence of seven isoforms through RNA splicing in humans 
(Adam et al. 1994). EP3 receptors are usually coupled to Gi and inhibit cAMP production. EP3, 
however can also increase cAMP production by coupling with Gs (see Review by Hatae et al. 
2002). This vast diversity in receptor biology has further added complexity to COX-mediated 
signaling pathways. 
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Table 1-1 
Prostanoid receptors in mammals 
Prostanoid 
receptors 
Activators Species References 
DP PGD2 Human, mouse Hirata et al. 1994; Boie et al. 1995 
EP1 PGE2 Mouse, rat, 
human 
Funk et al. 1993; Watabe et al. 1993; Boie et al. 1997 
EP2 PGE2 Mouse, human Regan et al. 1994; Katsuyama et al. 1995 
EP3 PGE2 Mouse, human, 
rat, rabbit, 
bovine 
Sugimoto et al. 1992; Namba et al. 1993; Takeuchi et al. 
1993; Adam et al. 1994; Breyer et al. 1994; Regan et al. 
1994a; Yang et al. 1994 
EP4 PGE2 Mouse, human, 
rat 
An et al. 1993; Honda et al. 1993; Bastien et al. 1994; Sando 
et al. 1994;  
FP PGF2α Mouse, human, 
bovine, rat, 
sheep 
Abramovitz et al. 1994; Kitanaka et al. 1994; Sakamoto et al. 
1994; Sugimoto et al. 1994; Graves et al. 1995 
IP PGI2 Mouse, human, 
rat 
Boie et al. 1994; Katsuyama et al. 1994; Nakagawa et al. 
1994; Namba et al. 1994; Sasaki et al. 1994 
TP TXA2 Mouse, rat, 
bovine 
Namba et al. 1992; Abe et al. 1995; Muck et al. 1998  
 
 
    10
1.2.2.1 PGD receptors (DP) 
DP receptor expression is the least abundant and least well characterized among the 
prostanoid receptors. It is expressed in platelets, lung, uterus, stomach, ileum and small 
intestine of humans (Hirata et al. 1994; see Review by Coleman et al. 1994). Despite its low 
receptor expression, the activation of DP receptor by its endogenous ligand, PGD2, leads to 
increased cAMP and intracellular Ca2+ levels (Wright et al. 2000). The activation of DP 
receptor by PGD2 has also been implicated in many physiological processes including the 
induction of sleep (Matsumura et al. 1994), regulation of body temperature (Sri Kantha et al. 
1994), inhibition of platelet aggregation (Negishi et al. 1993) and is a mediator of allergic 
disorders such as allergic rhinitis (Johnston et al. 1993).  
 
1.2.2.2 PGE receptors (EP) 
There are four subtypes of EP receptors identified, namely EP1, EP2, EP3 and EP4 receptors. 
Depending on the subtype, the activation of EP receptors by the endogenous ligand, PGE2 can 
result in a diverse range of effects. EP1 receptor has a limited tissue distribution and is found 
in the kidney, lung and stomach (Watabe et al. 1993). Their activation via calcium 
mobilization leads to constriction of smooth muscle in the gastrointestinal tract and trachea 
and together with EP3 and EP4, EP1 receptor activation is associated with regulating kidney 
function particularly with water re-absorption (Breyer et al. 1993; Sugimoto et al. 1994).  
 
In a similar fashion, EP2 receptor expression is also less than abundant; in fact the EP2 
receptor is the least abundant among the PGE receptors. EP2 receptor expression, however, 
can be effectively upregulated in response to stimuli. For instance, EP2 expression is induced 
significantly by LPS in macrophage cell line (Negishi et al. 1995). The activation of this PGE 
receptor subtype, which is coupled to stimulation of cAMP, leads to vascular, bronchial and 
reproductive smooth muscle relaxation (Negishi et al. 1995).  
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With its capacity to couple to multiple G proteins including Gi, Gs and Gβγ, EP3 receptor 
subtype has a more complex pharmacological profile than the other three EP subtypes (Hatae 
et al. 2002). EP3 receptor is also widely distributed in many tissue types. For example, EP3 
mRNA is expressed in neurons of the myenteric ganglia, in fundic gland epithelial cells, both 
in parietal cells and in chief cells, in smooth muscle cells in longitudinal muscle throughout 
the gastrointestinal tract. Thus, EP3 receptor activation has been linked to regulate smooth 
muscle contraction, particularly the vascular and uterine smooth muscle, reduce gastric acid 
secretion and hence affecting the cytoprotection in the gastrointestinal tract (Sugimoto et al. 
1992; Sugimoto et al. 1994a; Morimoto et al. 1997).  
 
The expression of EP4 mRNA has been found in the neurons of the hypothalamus, lower 
brainstem (Momiyama et al. 1996) and in the gland of the gastric antrum (Morimoto et al. 
1997). It is through cAMP stimulation that this Gs-protein-coupled EP4 receptor subtype 
exerts relaxant effects on vascular smooth muscle including human cerebral artery (Davis et 
al. 2004). 
 
1.2.2.3 PGF receptors (FP) 
There are two FP receptor isoforms: FPA and FPB. The FPB isoform differs from the FPA 
isoform in that it lacks the last 46 amino acids at the C-terminus. Coupled to Gq, both receptor 
isoforms are activated by their endogenous ligand PGF2α, although FP receptors can also be 
activated by PGF2α, PGE2 and PGD2. Once engaged, FP receptors can activate 
phosphatidylinositol signaling pathways and the activation of protein kinase C (PKC) (Graves 
et al. 1995; Pierce et al. 1997; Pierce et al. 1999). The organ that most abundantly expresses 
FP mRNA is the corpus luteum (Powell et al. 1974). When the expression pattern of FP 
mRNA in luteal cells was investigated in a gonadotropin-primed pseudopregnant mouse 
model, it was found that the granulosa cells in the ruptured follicles began to express FP 
mRNA once ovulation was induced (Hasumoto et al. 1997). FP mRNA level then decreased 
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when the luteal cells underwent apoptosis, suggesting FP mRNA expression is influenced by 
the estrous cycle. In contrast, FP mRNA expression in the kidney, heart, stomach and lung of 
mouse does not change with the estrous cycle (Hasumoto et al. 1997).  
 
1.2.2.4 Prostacyclin receptors (IP) 
Distribution of IP mRNA has been examined in various mouse organs by Oida et al. (1995) in 
an in situ hybridization study. It was reported that IP mRNA was expressed in the kidney, 
megakaryocytes, smooth muscle of arteries, neurons of the dorsal root ganglion, matured 
thymocytes and splenic lymphocytes. This widespread localization of IP mRNA suggests IP 
receptors, activated by PGI2 are involved in a diverse range of physiological processes. For 
instance, Murata et al. (1997) used carrageenan-induced paw swelling and acetic acid-induced 
writhing as models to demonstrate that IP receptors are involved in acute inflammation and 
pain, respectively. It was also reported that these IP-deficient mice, although viable, 
reproductive and normotensive, were susceptible to thrombosis. Detection of IP mRNA in 
megakaryocytes and the smooth muscle of arteries is consistent with the action of PGI2 in the 
cardiovascular system, another example demonstrating the involvement of IP receptors in 
diverse physiological processes. 
 
1.2.2.5 Thromboxane receptors (TP) 
The TP receptor is primarily coupled to Gq, which activates phospholipase C (PLC) (Hirata et 
al.1996). In human platelets, two TP isoforms, TPα and TPβ have been identified based on the 
differences in the C-terminal sequence (Kinsella 2001). Although both TPα and TPβ have the 
same G protein-dependent coupling to PLC and are both activated by TXA2 and PGH2, they 
do display differential regulation of cAMP (Walsh et al. 1998; Kinsella 2001).  
 
TP receptors can be activated by the endogenous ligand, TXA2, the precursor of TXA2, PGH2 
and isoprostane, a prostaglandin-like substance produced from free radical oxidation of 
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arachidonic acid without the involvement of COX enzymes (Negishi et al. 1995; Kinsella et 
al. 1997). Once activated, TP receptors mediate numerous cellular responses including 
platelet aggregation, stimulation of VSMC growth and VSCM contraction (Morinelli et al. 
1994; see Review by Narumiya et al. 1999). These potent effects are localized due to the 
instability and rapid metabolism of TXA2 and PGH2, which reduce their potential dangerous 
impacts on the systemic circulation. In addition to their well-known actions in the 
cardiovascular and respiratory systems, TP receptors may also play a role in the immune 
system. Namba et al. (1992) found that TP mRNA was abundantly expressed in thymus and 
spleen of mice. Furthermore, a study using the radio-ligand binding assay by Ushikubi et al. 
(1993) found that immature thymocytes express TP receptors at a density as high as that in 
platelets. Once T-cells mature, TP receptor expression then declines with the exception of 
peripheral T-cells, which still express high levels of TP receptors. Thus, TP receptors may in 
fact be involved in thymocyte differentiation and development.  
 
1.2.3 COX ISOFORMS 
There are at least two COX isoforms that have been identified and they are COX-1 and 
COX-2. COX enzymes are encoded by separate genes located in human chromosome 9 and 1, 
respectively (see Reviews by Smith & DeWitt 1996; Hla et al. 1999). COX-1 and COX-2 are 
found in the lumen of the endoplasmic reticulum (ER) where they catalyze prostanoid 
production. The prostanoids are released from the cell and act on G-protein-coupled receptors. 
Although COX-2 is found in the cytoplasm, it is also present in the nuclear envelope. 
Nuclear-located COX-2 synthesizes prostanoids that may act through the nucleoplasmic or 
nuclear membrane targets related to cell differentiation and replication (Parfenova et al. 
2001). 
 
Studies of the structure of COX have revealed the two isoforms share approximately 60% 
homology. Structurally, COX is a homodimeric, heme-containing, glycosylated protein 
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comprising three domains, an epidermal growth factor domain, a membrane-binding domain 
consisting of a spiral of four amphipathic helices and a globular catalytic domain (see 
Reviews by Smith et al. 1996; Garavito & DeWitt 1999; Marnett et al. 1999). The catalytic 
domain further contains two subunits, the COX active site and the peroxidase active site 
separated by the heme prosthetic group (see Reviews by Garavito & DeWitt 1999; Marnett et 
al. 1999). COX is a monotopic integral protein and it interacts with the ER membrane by 
penetrating its membrane-binding domain into only one leaflet of the lipid bilayer (see 
Review by Garavito & DeWitt 1999). In addition to anchoring to the lipid bilayer, the 
membrane-binding domain also creates a hydrophobic compartment that forms the mouth of 
the COX active site. The active site is a long, hydrophobic channel linked with a residue 
Tyr-385 (Picot et al.1994). Within the channel, two polar residues are found, Arg-120 and 
Ser-530. Arg-120 is located about midway between the mouth and the apex of the COX active 
site and Ser-530 is the site acetylated by aspirin, a COX inhibitor (Loll et al.1995). Arg-120 is 
important for COX-1 activity, because it interacts with the carboxylic moieties of most non 
steroidal anti-inflammatory drugs such as aspirin, which are known to inhibit COX activity 
(Picot et al.1994). Arg-120 also interacts with the carboxylic moieties of arachidonic acid 
(Mancini et al.1995), which is crucial for prostanoid synthesis. 
 
1.2.3.1 COX expression  
COX-1, a 69-kD protein which in cultured cells is expressed at constant levels throughout the 
cell cycle, is termed a constitutive isoform. COX-1 has a “house-keeping” role such as 
maintaining gastric integrity and renal function. In contrast, COX-2 is an inducible isoform 
whose expression under normal physiological conditions is not usually detected, although 
very often it is co-expressed in the same cell in which COX-1 is expressed (see Review by 
Smith et al. 1996). COX-2 expression, however, can be upregulated transiently in response to 
a variety of agents such as hormones, growth factors, bacterial endotoxin, tumor promoters 
and pro-inflammatory stimuli (see Review by Garavito & DeWitt 1999). The ability of 
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anti-inflammatory cytokines interleukin (IL)-4, IL-12 and glucocorticoids to suppress COX-2 
expression, but not COX-1 demonstrates the important role that COX-2 plays during 
inflammation (see Review by Herschman 1996).  
 
COX-2 is also found constitutively expressed, although in limited tissue types only; notably in 
brain (Yamagata et al. 1993), testes (Neeraja et al. 2003), tracheal epithelia (Walenga et al. 
1996) and the macula densa in kidney (Harris et al. 1994; see Reviews by Smith et al. 1996; 
Garavito & DeWitt 1999). COX-2 is also responsible for a variety of physiological stimuli 
and plays a role in postsynaptic signaling of excitatory neurons (Yamagata et al. 1993; 
Kaufmann et al. 1996), ovulation, fertilization and implantation in ovary (Lim et al. 1997), 
regulating salt, volume and blood pressure homeostasis in kidney (Harris et al. 1994). 
Furthermore, mice that lack COX-2 develop nephropathy (Morham et al. 1995), suggesting 
that the COX-2 isoform plays a physiological role in the renal system. 
 
With the advancement of molecular biology, emerging data indicate the possible existence of 
a third COX isoform based on its unique selectivity for paracetamol (Willoughby et al. 2000; 
see Review by Botting 2000). Recently this isoform has been found to be an alternative 
splicing of COX-1 with its biological role still under investigation (Chandrasekharan et al. 
2002; Senior 2002; Schwab et al. 2003). This isoform has been termed as both COX-3 and 
COX-1 variant, which has caused some confusion in the literature. As possibly more COX 
isoforms will be identified in the future, a more consistent system to name newly identified 
isoforms is urgently needed.    
 
1.2.3.2 COX regulation 
COX-1 is known as the constitutive isoform, because it is constantly expressed throughout the 
cell cycle and the COX-1 gene lacks a TATA box, which is crucial for regulation (Yokoyama 
& Tanabe 1989; see Review by DeWitt & Meade 1993). Little is known about the regulation 
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of COX-1 expression, although several putative transcription factor-binding sites such as Sp-1, 
AP-2 and GATGA-1 have been identified on the COX-1 gene (Wang et al. 1993), suggesting 
the presence of potential regulatory mechanisms. A study by Taniura et al. (2002) has reported 
that in neurons, COX-1 expression can be regulated at the transcriptional level via histone 
acetylation, possibly through Sp-1 binding site on COX-1 promoter. More details on histone 
regulation mechanisms are discussed in Chapter 2.  
 
Unlike COX-1, COX-2 expression is regulated by a wide variety of stimuli including 
oncogenic factors (see Review by Wu 1995), mitogens such as phorbol ester (Schuette & 
LaPointe 2000), cytokines such as IL-1α and tumor necrosis factor-α (TNF-α) (Nakagawa et 
al. 1999; Vlahos & Stewart 1999), hypoxia (Ji et al. 1998), growth factors (Kawaguchi et al. 
1995) and glucocorticoids such as dexamethasone (Newton et al. 1997). Given the diversity 
of the stimuli involved, the signaling pathways associated with COX-2 regulation and the 
interactions between transcription factors and COX-2 promoter are also complex. For 
example, growth factors including epidermal growth factor, platelet-derived growth factor and 
fibroblast growth factor up-regulate COX-2 expression via the tyrosine kinase signaling 
pathway (see Review by O’Banion 1999). In human fibroblasts and vascular endothelial cells, 
IL-1β-induced COX-2 expression has been shown to be associated with p38 
mitogen-activated protein kinase pathways, which are known to regulate cellular processes 
including inflammation, cell differentiation, cell growth and cell death (Ridley et al. 1997). 
On the COX-2 promoter region, transcriptional activation sites such as nuclear factor-κB 
(NF-κB) and NF-IL-6 (C/ERPβ) sites are the targets for TNF-α activation subsequently 
up-regulation of COX-2 in mouse osteoblastic cells (Yamamoto et al. 1995). New 
mechanisms such as histone acetylation/de-acetylation have also been shown to regulate 
COX-2 expression in macrophages (Park et al. 2004), airway smooth muscle (Nie et al. 2003), 
colon cancer (Tong et al. 2004), inflammation and diabetes (Miao et al. 2004). It is clear that 
the range of stimuli that regulate COX-2 expression is diverse and the signaling pathways 
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involved are complex.  
 
1.2.4 COX ACTIVITY 
Although there is about 60% homology between the two COX isoforms within a species, the 
activity and expression of the different COX isoforms are differentially regulated. Several 
distinctions can be made in regards to the activity of the COX isoforms. Firstly, COX activity 
requires low levels of lipid peroxides for activation and then continued activation of the 
enzyme is achieved autocatalytically by the newly generated PGG2. There is a difference in 
the threshold for hydroperoxide activation between COX-1 and COX-2 in which COX-2 
requires 10-fold lower concentrations of hydroperoxide for activation. This low 
hydroperoxide activation requirement may explain how these two isoforms are able to 
function independently of each other within the same cell. Secondly, the requirement for 
substrate is also different between two COX isoforms. At low concentrations of arachidonic 
acid (500 to 1000 nmol/L) the enzymatic activity of COX-1 is lower compared with that of 
COX-2. Thus, under conditions of low arachidonate concentrations, COX-2 activity allows 
for a greater prostanoid synthesis (Spencer et al. 1998, see Review by Smith et al. 2000). 
 
Although a direct effect of NO on COX activity in an isolated enzyme preparation has not 
been demonstrated, there are reports suggesting that COX activity may be influenced by NO. 
For instance, NO has been shown to increase COX activity in various cell types including 
vascular endothelial cells (Davidge et al. 1995). It has also been suggested that COX 
activation by NO may occur via intermediary pathways, for example, peroxynitrite, a product 
resulting from interaction between NO and superoxide anions, can activate COX (Landino et 
al. 1996). Indeed, the influence of COX activity by NO is complex and the result may vary 
depending on the COX isoforms, quantity and/or source of NO (Davidge et al. 1999; Onodera 
et al. 2000). This is supported by the findings in which exogenous NO donors enhance 
COX-1 activity in non-activated bovine aortic endothelial cells. In contrast, exogenous NO 
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donors led to decreased COX-2 activity in bovine aortic endothelial cells activated by serum 
or phorbol ester (Onodera et al. 2000). Details of the NO influence on COX activity are 
further discussed in Section 1.3.3. 
 
The COX-mediated pathway has been identified as one of the sources of free radical 
production. It was found that the primary source of oxygen free radicals in piglet cerebral 
cortex with ischemia/reperfusion is due to the release of superoxide anions formed by the 
activation of COX (Armstead et al. 1988). Based on these observations, it has been suggested 
that there may be a feed-forward loop for COX activation via lipid peroxidation and/or 
peroxynitrite formation (Figure 1-2).  
 
On the other hand, even though COX activation is a source of superoxide anions, specific 
induction of COX-2 has been shown to limit oxidative damage caused by hydrogen peroxide 
in cardiomyocytes due to production of PGI2 (Adderley & Fitzgerald 1999). It has been 
therefore suggested that COX-2 induction may be beneficial at sites of endothelial injury to 
replace the protective actions of COX-1 (see Review by Mitchell & Evans 1998), although 
future studies are needed to confirm this suggestion. 
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Endothelial cell 
Vascular smooth muscle cell 
Lipid peroxidase
PGI2 synthase 
NO- + O2- 
ONOO- COX activity PGH2 TXA2
Isoprostanes
Vasorelaxation 
PGH2/TXA2 receptor
Vasoconstriction
Figure 1-2  
Potential role of COX and altered vascular function 
Superoxide anions (O2-) released from COX pathway initiate membrane lipid peroxidation. When O2- react 
with NO, peroxynitrite (ONOO-) is produced, which deplete NO reserve. ONOO- and/or lipid peroxides can 
also activate COX resulting in enhanced production of PGH2 and TXA2, as well as a feed-forward mechanism 
contributing further to O2- production. Meanwhile, PGH2 and TXA2 bind to the same receptor causing a 
vasoconstriction. Although not required usually, COX activity (possibly via O2- production) can initiate 
isoprostane synthesis which are products of a free radical–mediated pathway from arachidonate. In addition, 
prostacyclin (PGI2) is reduced due to extensive lipid peroxidation and/or ONOO- (which preferentially 
inhibits PGI2 synthase activity), leading to reduced vasorelaxation.  
Figure 1-2 
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1.3 COX AND VASCULAR FUNCTION 
COX enzymes play a crucial role in maintaining homeostasis in the vasculature. This is 
achieved through modulation of vascular tone, platelet adhesion and aggregation via the 
production of prostanoids such as PGI2 and TXA2. More details are discussed below.  
 
1.3.1 LOCALIZATION OF COX IN VASCULATURE 
COX enzymes are found both in the endothelium and smooth muscle cells, although 
endothelial cells contain up to 20 times more COX than smooth muscle cells (DeWitt et 
al.1983). Using immuno-labeling microscopy, COX-1 and COX-2 have been found to be 
present in equal proportions in the luminal surface of ER and in the inner and outer 
membranes of the nuclear envelope in human umbilical endothelial cells (HUVECs) (Spencer 
et al.1998). Interestingly, PGI2 synthase and COX-1 were found to co-localize in the nuclear 
envelope and ER in bovine aortic endothelial cells. This relationship did not exist between 
COX-2 and PGI2 synthase in bovine aortic endothelial cells (Liou et al. 2000).  
 
Some cells express both COX-1 and COX-2, a perplexing observation, however, several 
explanations have been put forward. A review by Smith and DeWitt (1996) suggested that 
COX-1 may be part of an ER prostanoid biosynthesis system. Prostanoids produced via this 
system may function extracellularly as paracrine factors, acting through G protein-coupled 
receptors on the cell surface to maintain house-keeping responses. The roles that COX-2 play, 
in contrast, are more complex. It is thought that two sub-populations of COX-2 exist. The first 
COX-2 sub-population co-localizes with COX-1 on the luminal surface of the ER, which 
augments COX-1-mediated effects or takes on the role of COX-1 in cells lacking COX-1. The 
second COX-2 sub-population is part of a nuclear prostanoid synthesis system. This latter 
sub-population is located in the luminal surface of the inner membrane of the nuclear 
envelope, catalyzing prostanoids that target cell differentiation and replication (see Review by 
Smith & DeWitt 1996). It is also possible that the temporal localization of COX expression 
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simply means that the constitutive COX-1 isoform regulates house-keeping functions that do 
not require COX-2, whose expression is only induced under special conditions. The notion 
that these two isoforms act independently of each other has also been suggested. It was found 
that COX-1 and COX-2 use different arachidonate substrate pools and their prostanoid 
productions are coupled to different extracellular stimuli, possibly also different 
phospholipase systems (Reddy& Herschman 1996; see Review by Murakami et al. 1995). It 
is, however, possible that the two COX isoforms function at different locations within the 
same cells, because subtle differences do exist to differentiate COX-1 from COX-2 even 
though COX-1 and COX-2 appear to be localized in the same sub-cellular locations. For 
instance, COX-2 is more concentrated on the nuclear envelope than COX-1 and histochemical 
staining for enzyme activity in intact cells showed that the staining attributable to COX-1 was 
primarily in the cytoplasm whereas staining attributable to COX-2 was both in the cytoplasm 
and over the surface of the nucleus (Morita et al.1995).  
 
1.3.2 PRODUCTS OF COX IN VASCULATURE 
COX enzymes linked to a variety of synthases including PGD2, PGE2, PGF2α, PGI2, and 
TXA2 synthases can produce a wide variety of prostanoids, which are important vascular 
regulators. Under normal physiological conditions, COX-1-linked PGI2 is the main prostanoid 
product released by non-activated endothelial cells, which is responsible for maintaining 
vasorelaxation and preventing platelet aggregation (Moncada et al.1976; Dusting et al.1977).  
 
Although VSMCs also have the ability to release PGI2, the concept that the endothelium is the 
main source of PGI2 production by vessel wall was reinforced by MacIntyre et al. (1978) who 
demonstrated that incubation of aortic medial smooth muscle or aortic adventital fibroblasts 
with arachidonic acid did not prevent platelet aggregation. In 1984, Dejana et al. reported for 
the first time that PGI2 production was induced by IL-1 from vascular cells. Many other 
studies later also confirmed that pro-inflammatory cytokines induce PGI2 production and/or 
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enhance the effects of other agonists including histamine, thrombin and calcium ionophore, 
all of which result in increased PGI2 release by endothelial cells. More importantly, these 
agents/substances are also associated with COX-2 expression (Albrightson et al.1985; 
Kawakami et al. 1986; Zavoico et al.1989; Breviario et al.1990; Bull & Dowd 1990; 
Camacho et al.1998). At the time the assumption was that PGI2 is the main prostanoid 
generated by endothelial cells when COX-2 is over expressed. But when the synthesis of 
other prostanoid types was also evaluated, it was found that PGI2 was not the prostanoid being 
produced in most abundance in endothelial cells after exposure to IL-1. In fact after IL-1β 
treatment of HUVECs, PGE2, PGF2α and PGD2 were produced via the COX-2-mediated 
pathway while PGI2 synthase was inactivated. This was confirmed by Camacho et al. (1998) 
who found that over-expression of COX-2 actually reduced the ability of endothelial cells to 
produce PGI2. This reduction was more pronounced when an excess of substrate was provided. 
This phenomenon was partially explained by speedy PGI2 synthase inactivation in 
IL-1β-treated cells compared with the resting cells (Camacho & Vila 2000) possibly due to 
accelerated suicide inactivation (Wade et al.1995). The reduction in PGI2 synthesis could also 
be NO-dependent. In HUVECs, IL-1β treatment did not affect PGI synthase mRNA levels, 
but PGI2 synthase activity was partially inactivated. With the treatment of various scavengers 
and inhibitors, it was postulated that NO, peroxynitrite and hydroxyl radicals were involved in 
this process (Mehl et al. 1999; Camacho & Vila 2000; Zou et al. 2000).  
  
PGE2 has a role in diverse physiological and pathological processes due to its receptors being 
able to couple to complex signaling transduction pathways (details see Section 1.2.2.1). 
Depending on tissue types and stimuli, PGE2 can either mediate a constriction or relaxation of 
blood vessels, stimulate or inhibit water and sodium re-absorption in the kidneys and play a 
role in both pro- and anti-inflammatory reactions (see Reviews by Negishi et al. 1995; James 
et al. 2001).  
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Although PGD2 is mainly produced by mast cells upon immunological challenge (Lewis et al. 
1982), PGD2 production has been detected in endothelial cells in response to hypoxia 
(Michiels et al. 1993). PGD2 has the ability to act on thromboxane receptors in the airways 
causing bronchial smooth muscle to constrict hence; PGD2 plays a role in the pathogenesis of 
asthma (McKenniff et al. 1988; Coleman & Sheldrick 1989). In contrast, PGD2 is a 
vasodilator in vascular smooth muscle when acting through PGD2 receptors (Giles et al. 
1989).  
 
PGF2α plays a crucial role in both renal and reproductive functions by regulating contractile 
activities in both vascular and non-vascular tissues and luteolysis when pregnancy fails to take 
place (see Reviews by Smith1992; Negishi et al. 1995). In the vasculature, PGF2α has been 
released in response to cardiac tissue injury causing coronary vasoconstriction and is linked to 
the occurrence of coronary vasospasm (Cannon 1984; Rigel & Shetty 1997; Dallas & Khalil 
2003). 
  
The discovery of TXA2, which has an opposing biological role to PGI2, later prompted a 
hypothesis to explain the interactions between platelets and the vascular wall. TXA2, mainly 
produced by platelets, is a potent vasoconstrictor and stimulates platelet aggregation. 
Enhanced production of TXA2 subsequently causes platelet hyperactivity thus increasing the 
risk of thrombosis, which is discussed further in Section 3.4.1.2. 
 
1.3.3 COX AND AGING  
Aging, a process accompanied by alterations in both structure and function of tissues and 
organs, is a risk factor that contributes to the development of cardiovascular disease 
(Australian Institute of Health and Welfare 1999). Aging is associated with endothelial 
dysfunction, which is characterized by impaired endothelial-dependent relaxation to 
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acetylcholine (more details see Section 2.1). The exact causes of age-related endothelial 
dysfunction are not clear, but it is clear that the balance between vasoconstriction and 
vasodilatation mediated by various vasoactive mediators is altered (Reckelhoff et al. 1994). 
Studies have shown that COX-mediated pathways are involved in endothelial dysfunction in 
the aging process. Previous animal studies by our laboratory at RMIT University reported an 
increase in both COX -1 and COX-2 expression with aging in rat aortas (Kang et al. 2001). 
Potential consequences of enhanced COX expression in aging may result in an imbalanced 
prostanoid production favoring the synthesis of vasoconstrictors such as TXA2 and hence 
increase the risk of cardiovascular events in aging population. More details on COX 
involvement in the aging is discussed in Chapter 2.  
 
1.3.4 COX AND DIABETES 
Diabetes mellitus, characterized by hyperglycemia and by disturbances of carbohydrate, fat 
and protein metabolism, is associated with a deficiency in insulin secretion from the 
pancreatic β cells, defective insulin action, or both. Two major types of diabetes are Type 1 
and Type 2, the former type dependent on daily insulin treatment for survival. Long term 
consequences of diabetes are the development of micro- and macro-vascular complications in 
the eyes, kidneys, nerves, heart and blood vessels (see Reviews by Barcelo 1996; Schuster & 
Duvuuri 2002). Although the etiology of diabetes is unknown, it is clear that the cause of the 
disease is not due to a simple factor. In fact, the etiology of diabetes is complex, involving 
genetic factors, which are further precipitated by environmental factors (see Chapter 3 for a 
detailed review).  
  
Increasing evidence suggests that the development of diabetes and its complications is 
associated with persistent inflammatory activity, which is shown by increased inflammatory 
markers such as TNF-α, CRP and IL-6 in the circulation (Yudkin et al. 1999). It has been 
suggested that COX-mediated pathways may be involved in this inflammatory process in 
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diabetes. For example, TXA2 and PGE2 released by platelets and monocytes due to the action 
of COX-1 and COX-2, respectively are important prostanoids involved in thrombosis and 
atherosclerosis development in diabetes (for more details, see Section 3.4). COX expression 
has been shown to alter in both Type 1 and Type 2 diabetic animal models. For instance, both 
COX-1 and COX-2 was increased in diabetic rat kidney (Nasrallah et al. 2003). In contrast, 
reduced COX-1 and increased COX-2 in renal cortex of diabetic rats was also reported 
(Komers et al. 2005). In vasculature, COX-2, but not COX-1 expression was down-regulated 
in diabetic rat aortas (Takahashi et al. 2004) whilst platelet COX-1 was increased in diabetic 
rats (Raju et al. 2006). More details on the involvement of COX in Type 1 and Type 2 
diabetes are discussed in Chapters 4 and 5, respectively. 
 
In addition to altered COX-mediated pathways, the formation of advanced glycation end 
products (AGEs) is also enhanced in diabetes when glucose forms irreversible cross-links 
with the amino groups on the macromolecules such as proteins, lipids and nucleic acids 
(Brownlee et al. 1988). AGEs can bind to receptors for AGEs (RAGE) and activate complex 
signaling pathways involving p21ras, erk 1/2 kinases and NF-κB (Kislinger et al. 1999). 
Strong evidence further suggests that RAGE plays a role in inflammation (Hou et al. 2004), 
which is often observed in diabetes. Interestingly, it was reported that RAGE was able to 
induce COX-2 expression in plaque macrophages isolated from diabetic mice (Bucciarelli et 
al. 2002). An increase in both RAGE and COX-2 expression was also found in atherosclerotic 
plaques in human diabetic subjects (Cipollone et al. 2003), suggesting RAGE may also be 
implicated in the development of diabetic complications. More details on the involvement of 
RAGE in diabetes are discussed in Chapter 6. 
 
    26
1.4 OVERALL AIMS 
Given that little is known about COX regulation, which has been found to be increased 
previously in aging and its possible involvement in diabetes, the first part of the study focused 
on COX-mediated pathways followed by the investigation of RAGE-mediated pathways, 
which may contribute to the development of vascular complications in diabetes. The overall 
aims of the study were to examine: 
i) the regulatory mechanisms of COX by studying histone acetylation status in 
endothelial cells, platelets and monocytes; 
ii) possible changes in COX-1 and COX-2 levels in platelets and monocytes, respectively 
in diabetes; and 
iii) possible changes in RAGE levels in platelets and monocytes in diabetes. 
 
 
 
 
 
 
 
 
 
CHAPTER 2 
MODULATION OF COX EXPRESSION 
BY HISTONE ACETYLATION  
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2.1 INTRODUCTION 
2.1.1 AGING AND ENDOTHELIAL FUNCTION 
The endothelium is very important in the preservation of blood vessel integrity. It acts as a 
modulator in a variety of processes including coagulation, platelet activation, vascular tone, 
angiogenesis and chemotaxis (see Review by Luscher & Barton 1997). Endothelial cells 
produce numerous substances such as enzymes, vasoactive substances, mitogens and 
chemotactic factors, which are crucial in modulating endothelial functions (Ramadan et al. 
1990). For example, endothelial cells produce nitric oxide (NO), which is a potent vasodilator 
and also inhibits platelet aggregation. The stimulus for NO production is an increase in 
intracellular Ca2+ in the endothelial cells, which activates NO synthase. The increase in 
intracellular Ca2+ can be brought about by receptor activation such as acetylcholine 
muscarinic receptors and bradykinin receptors, or through distention of the endothelium. In 
addition, the endothelium can produce endothelin-1, which is a potent peptide constrictor (see 
Review by Luscher & Barton 1997). Prostanoids are also important in endothelial function 
and the endothelium is an important source of PGI2, which is a potent vasodilator and inhibits 
platelet aggregation. The endothelium, thus acts to modulate vascular tone and inhibit platelet 
aggregation. Another potent vasodilator is EDHF, which is probably a Ca2+-activated 
potassium channel activator or a prostanoid (Urakami-Harasawa et al. 1997), which 
hyperpolarizes and relaxes VSMC predominantly through activation of Ca2+-dependent K+ 
channels. This EDHF response was reduced in the arteries of aging rats (Goto et al. 2004), 
although conflicting results have been reported (Alvarez de Sotomayor et al. 1999). 
 
Aging is a risk factor that contributes to the development of cardiovascular disease 
(Australian Institute of Health and Welfare 1999), which is accompanied by alterations in both 
structure and function of tissues and organs. Aging is associated with endothelium injury or 
dysfunction as seen by impaired endothelial-dependent relaxation to acetylcholine in the 
coronary artery of dogs and rats (Donoso et al. 1994), aorta of rabbits (Ragazzi et al. 1995) 
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and human coronary arteries in vivo (Vita et al.1990; Yasue et al. 1990; Egashira et al. 1993; 
Zeiher et al. 1993).  
 
The exact causes of age-related endothelial dysfunction are not clear, but current theories have 
surrounded the mechanisms mediated by NO and oxidative stress. NO is synthesized from 
L-arginine via NO synthase. In aging, there is a decrease in L-arginine availability coupled 
with changes in activity or expression of endothelial NO synthase (Reckelhoff et al. 1994), 
which may contribute to a reduction in NO production. The generation of reactive oxygen 
species (ROS) including superoxide production is increased in aging (see Review by Terman 
& Brunk 2006). These species can react with NO to not only reduce its bioavailability (see 
Review by Schulz et al. 2004) and protective effects, but also, as in the case of superoxide, 
producing peroxynitrite to cause widespread cellular damage through protein nitration 
(Bouloumié et al. 1997; see Review by Stadtman 2001). COX-mediated pathways may also 
be involved in the process of aging. In addition to COX being a potential source of ROS (see 
Review by Adibhatla & Hatcher 2005), COX metabolites such as TXA2 and PGI2 can also 
play an important role in maintaining endothelial function (more details are discussed in 
Section 2.1.1).  
 
2.1.1.1 COX and the aging process 
COX enzymes play a crucial role in modulating endothelial function. PGI2 synthesized by the 
endothelium acts on PGI2 receptors resulting in increased cAMP in VSMCs and 
vasorelaxation. In contrast, COX-mediated generation of TXA2 production in platelets leads 
to platelet aggregation and vasoconstriction though decreasing cAMP and mobilization of 
intracellular Ca2+ in VSMCs. A balance in prostanoid production via these two 
COX-mediated pathways is crucial to vascular homeostasis.  
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Evidence suggests that COX-mediated pathways are altered in the aging process. An early 
study by Koga et al. (1989) investigated the relaxation responses to acetylcholine in aortas 
isolated from young (4 to 6 weeks), adult (3 to 6 months) and old (12 to 35 months) 
hypertensive and normotensive rats. In endothelium-intact vessels, high concentration of 
acetylcholine resulted in vasoconstriction in adult and old hypertensive and old normotensive 
rats, which was inhibited by the non-selective COX inhibitor, indomethacin. Davidge et al. 
(1996) also tested the hypothesis that increased arachidonate metabolism was associated with 
an impairment of endothelium-dependent vascular function in the mesenteric arteries of 
female Sprague-Dawley rats between 20 and 40 weeks old. In this study, 
phenylephrine-induced constriction of mesenteric arteries was reduced by COX inhibition in 
the 40-week-old rats, but not 20-week-old rats. Furthermore, 40 week-old mesenteric arteries 
showed a reduction in the sensitivity to the methacholine-mediated relaxation response 
compared to 20 weeks. This was restored with COX inhibition or blockade of TXA2 receptors. 
Furthermore, aortas from the 40-week-old rats had a higher expression of COX enzymes. 
These data suggest that COX-mediated pathways are altered in the blood vessels of aging 
female Sprague-Dawley rats.  
 
COX-2, but not COX-1 expression has been shown to increase with aging in rat hearts (Kim 
et al. 2001). Since COX-2 up-regulation has been associated with inflammation, it is not 
surprising that Casolini et al. (2002) also reported an increased production of 
pro-inflammatory markers including IL-1β, TNF-α and PGE2 with age in the hippocampus. 
The link between inflammation and aging via COX-mediated pathways was evident when 
chronic administration of celecoxib, a selective COX-2 inhibitor, resulted in the reduction of 
these pro-inflammatory markers in the hippocampus. The effect of enhanced 
COX-2-mediated activity in the aging process may, however, be greater than originally 
anticipated. For instance, increased oxidative stress is associated with aging resulting in 
oxidative modification of macromolecules and endothelial dysfunction (see Review by 
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Stadtman 2001). Potentially, increased COX-2 activity may provide an additional oxidative 
source further promoting endothelial injury. In comparison to COX-2, changes in COX-1 in 
the aging process are less well defined. Among a few studies, one reported COX-2, but not 
COX-1 expression was altered in aging rat aortas and mesenteric arteries (Stewart et al. 2000) 
while two others reported age-related increases in both COX-1 and COX-2 expression in 
these blood vessels (Heymes et al. 2000; Matz et al. 2000).  
 
Despite the effort, much is still unknown in regards to regulation of COX synthesis, 
particularly with COX-1 since the COX-1 gene lacks a TATA box (Smith et al. 1996). 
Interestingly, for the first time in 2002, Taniura and his colleagues reported that COX-1 
expression was up-regulated by histone hyperacetylation, induced by the use of histone 
de-acetylase inhibitors in human astrocytes. Several other groups have reported that histone 
acetyltransferase activity is increased in aging mice, rats and elderly human subjects (Sarg et 
al. 1999; Li et al. 2002; Sourlingas et al. 2002). It is clear that histone acetylation may 
regulate COX expression during the aging process.  
 
2.1.2 HISTONES 
Histones, discovered over a century ago, are small proteins that act as the structural scaffold 
for the organization of nuclear DNA into chromatin. A histone has an N-terminus, a globular 
domain, and a C-terminus. There are four core histones, H2A, H2B, H3 and H4. These share a 
common motif known as the histone fold, which consists of a long central helix flanked on 
either side by a loop and a short helix. In addition to the central histone fold, histones H2A 
and H3 also contain additional helices at the N-terminus; whereas histone H2B contains an 
additional helix at the C-terminus (see Review by Ramakrishnan 1997). Two copies each of 
the four core histones form an octameric protein, which is wrapped around by 146 base pairs 
of DNA in approximately two turns, forming the nucleosome, the simplest level of 
organization found in chromosomes. Each of the core histones exists as part of a dimer, which 
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is their most stable structural entity. The association of an H3-H4 dimer to form a tetramer, in 
the initial step in nucleosome assembly, determines nucleosome positioning (Dong & van 
Holde 1991; Hayes et al. 1991; Karantza et al. 1995). The final association of an H2A-H2B 
dimer on the each side of the (H3-H4)2 tetramer completes the formation of the histone 
octamer. A fifth linker histone H1 then binds to the nucleosome and organizes nucleosomes 
into a high-order structure, the 30-nm filament (Luger et al. 1997; see Review by 
Ramakrishnan 1997).  
 
The N-terminal tails of the core histones are lysine-rich. These tails extend out beyond the 
nucleosome core particle and are subject to a range of post-translational modifications by the 
actions of enzymes in both the nucleus and cytoplasm. Although most histone modifications 
occur at the N-terminal tails, the C-terminal tails and globular domains can still be modified. 
The most commonly studied and best understood modifications are acetylation, 
phosphorylation, methylation and to a lesser extent ubiquitination, addition of ubiquitin. 
These modifications allow processes such as transcription, DNA repair, recombination and 
replication to be regulated (see Reviews by Bradbury 1992; Wade et al. 1997). 
 
2.1.2.1 Histone modifications 
Chromatin structures are strictly regulated by histones. It is through these modifications that 
histones are able to influence the accessibility of transcription factors to DNA. 
 
2.1.2.1.1 Acetylation 
Acetylation and de-acetylation is the best understood histone modification, which occurs on 
the epsilon amino group of lysine residues of all four core histones. The highly conserved 
histone H3 lysines at positions 9, 14, 18 and 23, and histone H4 lysine residues 5, 8, 12 and 
16, are frequently targeted for modification (Roth et al. 2001). Catalyzed by histone 
acetyltransferases, acetylated histones are usually associated with transcriptionally active 
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chromatin and de-acetylated histones with inactive chromatin (Allfrey et al. 1964; Review by 
Ng & Bird 2000). Histone acetyltransferases are transcriptional coactivators/adaptors, which 
interact with DNA-bound activators leading to recruitment of the transcriptional apparatus. 
For example, when the N-terminal tail of histone H4 contains 4 lysine residues at lysines 5, 8, 
12 and 16 is acetylated by histone acetyltransferases, the positive charge on the basic side 
chain of the lysine residue is eliminated reducing its interaction with the negatively charged 
phosphate backbone of the DNA. In general, it is believed that by weakening the interaction 
between histone H4 tail and DNA, the remodeling of chromatin required for gene 
transcription is facilitated (see Review by Wade et al. 1997). Histone acetyltransferases exist 
in large complexes consisting of several subunits. These subunits may help to target 
promoters, provide substrate specificity and possess regulatory functions. In addition to 
histones, some transcription activators, such as p53 are also substrates of histone 
acetyltransferases. Therefore, hyperacetylation is correlated strongly with increases in gene 
expression (Figure 2-1).  
 
In addition to gene transcription, histone acetylation also plays key roles in processes such as 
replication, nucleosome assembly, higher-order chromatin packing and interactions of 
non-histone proteins with nucleosomes (see Review by Grant & Berger 1999). 
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Figure 2-1
Histone acetylation/de-acetylation and gene expression (adapted from Chang & Min 2002)
Histones are hyperacetylated and hypoacetylated at the N-terminal tails by histone 
acetyltransferases and de-acetylases. Histone hyperacetylation results in the opening of 
nucleosomal structures (open state), which gives transcription factors better access to 
transcription sites and therefore, is associated with active gene transcription. In contrast, histone 
hypoacetylation leads to the “closed” state of DNA structures preventing the binding of 
transcription factors to DNA and is associated with gene silence.
Figure 2-1
DNA in the “closed” state; 
transcriptionally repressed
DNA in the “open” state; 
transcriptionally active
Histone acetyltransferase
Histone de-acetylase
Chromosome
Histone complex with 
DNA wrapping around
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2.1.2.1.2 Phosphorylation 
Despite the wealth of information about the large number of histone acetyltransferases and 
histone de-acetylases, much less is known about other histone modifications. Histone 
phosphorylation, however, also plays a role in processes such as transcription, DNA repair, 
apoptosis and chromosome condensation (see Review by Cheung et al. 2000). Histone 
phosphorylation of serine residues in the amino termini of all four core histones and in 
multiple regions of histone H1 is an important regulatory mechanism during cell division 
(Goto et al. 1999; de la Barre et al. 2000; Review by Thomson et al. 1999). Histone 
phosphorylation also regulates transcriptional activation during heat-shock responses in 
Drosophila (Nowak & Corces 2000). In quiescent fibroblasts treated with epidermal growth 
factor, serine 10 of histone H3 N-tail was phosphorylated rapidly, coincident with the 
induction of early response genes including c-fos and c-jun. The key enzyme involved in this 
phosphorylation is the Rsk-2 kinase, and cells derived from Rsk-2-deficient Coffin-Lowry 
Syndrome patients do not undergo serine 10 phosphorylation or c-fos induction in response to 
the epidermal growth factor (Sassone-Corsi et al. 1999). 
 
The actual mechanism by which histone phosphorylation contributes to transcriptional 
activation is not well understood. It is, however, being proposed that the addition of 
negatively charged phosphate groups neutralizes the histone basic charge hence, possibly 
reduces their affinity for DNA. Interestingly, it has been found that in some cases 
phosphorylation can enhance the activity of several histone acetyltransferases to serine 
10-phosphorylated substrates (Cheung et al. 2000a; Lo et al. 2000). Thus, it is likely that 
histone phosphorylation works in conjunction with histone acetylation in order to modulate 
transcription.  
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Histone H3 phosphorylation is also known to facilitate DNA repair. The phosphorylation 
process starts after activation of DNA-damage signaling pathways. A conserved motif found 
in the C-terminus of yeast histone H2A and the mammalian histone H2A variant H2A is 
rapidly phosphorylated upon exposure to DNA-damaging agents. Instead of the usual serine 
10, another residue was involved in this modification. Serine 139 is phosphorylated by 
phosphatidylinositol-3-OH kinase, Mec1, in yeast in response to damage and is crucial to the 
repair of DNA (Rogakou et al. 1999; Downs et al. 2000). 
 
2.1.2.1.3 Methylation 
Histone methylation, a process described in 1964, can occur on both lysine and arginine 
residues (Murray 1964). It was not until the histone H3 arginine-specific histone 
methyltransferase CARM1 was found to interact and cooperate with the 
steroid-hormone-receptor coactivator GRIP-1 in transcriptional activation that a direct link 
between methylation and transcription was established (Chen et al. 1999).  
 
Studies have indicated that lysines 4, 9 and 27 of histones H3 and lysine 20 of histone H4 are 
frequently preferentially methylated (Strahl et al. 1999). Once these lysines are modified, they 
have the ability to be mono-, di- or tri- methylated, which dramatically increases potential 
complexity to the posttranslational status of H3 and H4 tails. 
 
Certain histone methyltransferases have been classified as gene repressors. These 
methyltransferases include human SUV39H1, murine Suv39h1 and fission yeast Clr4 proteins, 
which methylate lysine 9 of histone H3 selectively (Rea et al. 2000; Nakayama et al. 2001). It 
has been found that over-expression of SUV39H1 increased the formation of heterochromatin, 
a transcriptionally inactive region of chromatin, in a normally genetically active location 
(Melcher et al. 2000).  
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2.1.2.1.4 Ubiquitination 
Ubiquitination, a process involving the addition of ubiquitin to a protein, which acts as a 
signal to protein degradation by proteasome and results in the inactivation of the protein, is 
the least understood of the histone modifications. Histones H1, H3, H2A, and H2B can be 
ubiquitinated in vivo, but the most prevalent are histones H2A and H2B. Histone 
ubiquitination occurs on the C-terminal tails of affected histones. In yeast, for example, the 
loss of the ubiquitination site on the C-terminus of histone H2B leads to defects in mitosis and 
meiosis (Robzyk et al. 2000). In some cases, enzymes that are capable of facilitating other 
histone modifications also possess ubiquitination ability. The transcription factor TAFII250, a 
histone acetyltransferase, has the ability to both ubiquitinate and acetylate histones (Pham & 
Sauer 2000). Therefore, it is not unreasonable to anticipate the complex interactions between 
histone modifications, which can affect the chromosomal environment profoundly. 
 
2.1.2.2 Histone acetylation/de-acetylation and the aging process 
The cellular aging process involves accumulation of DNA damage in response to oxidative 
stress (Sedelnikova et al. 2004) and resulting in shortening of telomeres (see Reviews by 
Campisi 2001; Harrington & Robinson 2002). Since histones, through post-translational 
modifications, have the ability to control and regulate gene expression, it is reasonable to 
hypothesize that histones also contribute to aging progression. Among the four modifications, 
histone acetylation/de-acetylation has received the most attention and has been associated 
with the aging process in both insects and mammals.  
 
Several studies have shown that histone de-acetylases are involved in aging. It is believed that 
histone de-acetylases silence aging genes and hence prolong the life span. Kang et al. (2002) 
reported that feeding Drosophila with a general histone de-acetylase inhibitor, phenylbutyrate 
increased the lifespan of the flies. In this study, treating Drosophila with phenylbutyrate 
altered the expression of several hundreds of genes. While hundreds of genes such as fatty 
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acid synthase, cycline-dependent kinase 9 and glyceraldehyde-3-phosphate dehydrogenase-1 
were repressed by phenylbutyrate, a large number of genes reported to enhance longevity 
were induced. These include superoxide dismutase (Parkes et al. 1998; Sun & Tower 1999), 
glutathione S-transferase and cytochrome P450 (Dudas & Arking 1995; see Review by 
Mannervik 1985).  
 
Lin and colleagues in 2000 reported another histone de-acetylase, which is involved in the 
aging process. Silent information regulator 2 (Sir2) is a NAD+-dependent protein de-acetylase 
(Imai et al. 2000), which contains a silencing protein, Sir2p. Sir2 was found to control 
longevity in lower eukaryotes such as Saccharomyces cerevisiae and Caenorhabditis elegans 
as increased Sir2 activity extended the lifespan in these organisms (Kaeberlein et al. 1999; 
Tissenbaum & Guarente 2001). Through histone modifications at telomeres, the Sir2 protein 
also played a critical role in heterochromatic gene silencing, ribosomal DNA clusters, and 
mating-type loci in yeast (see Review by Lustig 1998). A mammalian Sir2-homologue, sirtuin 
family consisting of seven protein members, was identified in humans (Cohen et al. 2004). 
Limited data is available regarding biological functions or cellular localizations of the sirtuin 
family. It is possible, however, that the sirtuin family, which shares the Sir2 catalytic domain 
(see Reviews by Blander & Guarente 2004; North & Verdin 2004) may regulate the aging 
process in a similar fashion in both humans and in lower eukaryotes. 
 
Histone de-acetylases act on histones to silence aging genes. Histone de-acetylase inhibitors 
such as trichostatin A (TSA), cause hyperacetylation of histones and are associated with 
terminal differentiation, a process that is tightly coupled with cell arrest and cell death (see 
Review by Yoshida et al. 1995).  
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Despite reports showing a positive link between increased histone acetylation and aging, 
decreased histone acetylation in aging has also been demonstrated. For example, Matuoka et 
al. (2001) reported that in human diploid fibroblasts, nicotinamide induced rapid and 
reversible reversion of aging phenotypes in terms of cell morphology and 
senescence-associated β-galactosidase activity. It was found that histone H4 acetylation and 
histone acetyltransferase activity were lowered in aged cells in comparison to elevated histone 
acetyltransferase activity seen in nicotinamide-exposed cells. This reduction in histone 
acetyltransferase activity in aging is not an isolated observation. When Li et al. (2002) studied 
two particular proteins, cyclic adenosine monophosphate-regulated enhancer-binding protein 
(CBP) and its homologue p300 that both possess intrinsic histone acetyltransferase activities, 
in various tissues of fetal, young and old mice, it was found that the histone acetyltransferase 
activities of CBP and p300 actually decreased with aging in liver, muscle and testes. In 
contrast, the histone acetyltransferase activities of these proteins remained to be relatively 
stable in most of other tissues with aging. Furthermore, the histone acetyltransferase activities 
of CBP and p300 were high in the brain and liver of fetal and newborn mice compared to the 
old animals. These findings suggest that alteration in histone acetylation with aging is species- 
and tissue-specific, which may explain why contradictory findings were reported as data 
showing increased histone acetylation with aging were observed in flies. Despite 
contradictory/conflicting findings on the level of histone modifications in aging, evidence to 
date has indicated that acetylation of histones play an important role in the process of aging.  
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2.2 AIMS 
Previous studies from our laboratory have shown that in aortas of 54-week-old 
Spraque-Dawley rats, there was an increase in both COX-1 and COX-2 levels compared to 
those of 8-week-old aortas (Kang et al. 2001). Increased COX-1 and COX-2 levels were also 
observed in the platelets and mononuclear cells, respectively, with aging in Spraque-Dawley 
rats with the same age groups (Kang et al. 2001a). Changes in COX protein expression in the 
aging process may result in an imbalance of prostanoid production and thus impair 
endothelial functions. The underlying regulatory mechanisms to these changes in COX levels, 
in particular with COX-1 expression in aging are not well understood. Studies have suggested 
that histone acetylation/de-acetylation is altered in aging and this may be a mechanism by 
which COX enzymes are regulated.  
 
Little information about the possible role of histones in regulating COX is available. 
The aim of this study was to investigate if increased COX expression in endothelial cells were 
modulated by histone modification. We hypothesized that hyperacetylation of histone H4 
contributes to up-regulation of COX proteins, which have been previously observed in the 
aging process.  
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2.3 METHODS 
2.3.1 CELL CULTURE OF ENDOTHELIAL CELLS 
2.3.1.1 Cell culture of murine SVR endothelial cell line  
SVR cells, a murine pancreatic islet endothelial cell line, were donated by Dr. Ian Darby 
(RMIT University). The cell line was cultured in 6-well plates containing Dulbecco's 
modified Eagle's medium (DMEM) with supplementation: 4 mM L-glutamine adjusted to 
contain 18 mM NAHCO3, 25 mM glucose, 20% fetal bovine serum (FBS), gentamicin sulfate 
(50 µg/mL) and streptomycin (100 µg/mL) (Invitrogen, CA, USA). SVR cells were grown to 
100% confluence in a 37°C, 5% CO2 humidified incubator before ready for experiment (see 
Section 2.3.1.3 for details).  
 
2.3.1.2 Cell culture of human umbilical vein endothelial cell line (HUVEC) 
Human umbilical vein endothelial cells (HUVECs) were purchased from Cambrex Bio 
Science (MD, USA). Prior to cell culture, 6-well plates were coated with 0.1% (v/v) gelatin 
(Sigma, St Louis, USA) in phosphate-buffered saline (PBS) containing 1 mM KH2PO4, 154 
mM NaCl, and 5.7 mM Na2HPO4 (Invitrogen, CA, USA) for 30 minutes at 37°C. 
Gelatin-coated plates were washed twice with pre-warmed PBS (37°C) before seeding 
HUVECs. Cells were cultured using Clonetics® Endothelial Cell System (catalogue No. 
CC-3214) developed by Cambrex Bio Science (MD, USA), supplement pack containing 2% 
FBS, 0.4% bovine brain extract and 1 ml/L of each of the following: human epidermal growth 
factor, hydrocortisone, GA-1000 (aqueous solution of gentamicin Sulfate and 
amphotericin-B). Cells were grown to 100% confluence in a 37°C, 5% CO2 humidified 
incubator before ready for experiment (see Section 2.3.1.3 for details).  
 
2.3.1.3 Histone de-acetylase inhibitor treatment  
When endothelial cells were grown to 100% confluence, they were treated with either the 
histone de-acetylase inhibitor, trichostatin A (TSA, 100 nM in 0.1% DMSO; Sigma, St Louis, 
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USA) or 0.1% (v/v) DMSO for 48 hours. A third group of cells was left untreated. After 48 
hours, medium was removed and cells were washed twice with ice-cold PBS (Invitrogen, CA, 
USA) before being collected for histone extraction and Western blotting (see Section 2.3.1.4 
Cell lysis and protein extraction). Another set of cells treated with TSA was reserved for cell 
viability test/count (see Section 2.3.1.5 Cell viability test). 
 
2.3.1.4 Cell lysis and protein extraction 
To prepare for cell collection for Western blotting experiments, endothelial cells were placed 
on ice and washed with ice cold PBS to remove media. Modified radioimmunoprecipitation 
(RIPA) buffer (10 mM Tris, pH 7.2, 0.1% SDS, 1.0% Triton X-100, 1% Deoxycholate, 5 mM 
EDTA, 150 mM NaCl), which contained a mixture of protease inhibitors (1 mM 
phenylmethylsulfonylfluoride (PMSF), 10 μM leupeptin, 20 μM pepstatin) was used for cell 
lysis and protein extraction. Cells were incubated in ice cold RIPA buffer (100 μL per well) 
for 1 minute and were scraped off the well. Scraped cells were suspended in RIPA buffer and 
transferred to an eppendorf tube and centrifuged at 15,000 g for 3 minutes. The pellet was 
discarded and supernatant was removed for protein assays. 
 
2.3.1.5 Cell viability test 
2.3.1.5.1 SVR endothelial cell trypsinization 
SVR endothelial cells were incubated with trypsin/EDTA solution (0.25% trypsin/0.03% 
EDTA solution, 37°C; Invitrogen, CA, USA) for two minutes. Detachment of cells was 
monitored under a microscope. After two minutes, 10 mL of culture medium with 20% FBS 
was placed in the culture flask to neutralize the action of trypsin. The cell suspension was 
centrifuged at 220 g for 5 minutes followed by aspiration of supernatant after the spin. The 
pellet was re-suspended in DMEM with FBS and supplements and the cell suspension was 
ready for subculturing and the trypan blue exclusion assay for cell viability. 
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2.3.1.5.2 HUVEC trypsinization 
To collect HUVECS, a ReagentPack™ (catalogue No. CC-5034) from Clonetics® 
Endothelial Cell System (Cambrex Bio Science, MD, USA) was used. This reagent pack 
included trypsin/EDTA (trypsin 0.025%/EDTA 0.01%), trypsin neutralizing solution (TNS) 
and HEPES buffered saline solution (HEPES-BSS). HUVECS were rinsed with 5 mL of room 
temperature HEPES-BSS followed by the incubation of cells with 2 mL of trypsin/EDTA 
solution, which was pre-warmed to 37°C. The cell layer was examined microscopically to 
ensure trypsinization continued until approximately 90% of the cells were rounded up and 
released from the culture surface. To neutralize the action of trypsin, room temperature TNS 
(4 mL) was added to the cell suspension, which was collected and centrifuged at 220 g for 5 
minutes to pellet the cells. Most of the supernatant was aspirated except for 100-200 μl, which 
was used to loosen the pellet. The cell suspension was then diluted with growth medium (5 
mL, details see Section 2.3.1.2) and was ready for subculturing and trypan blue exclusion 
assay. 
 
2.3.1.5.3 Trypan blue exclusion assay 
Approximately 20 μL of cell suspension was mixed with an equal amount of trypan blue vital 
stain solution (0.4%; Cambrex Bio Science, MD, USA) in an eppendorf tube. Using the 
pipette, the cell suspension (10 μL) was transferred to the edge of the hemacytometer. The 
suspension spread evenly by capillary action, which covered the area within the chamber of 
the hemacytometer. The chamber was divided by grid lines forming nine 1 mm squares with 
each of them being surrounded by three grid lines. Trypan blue vital stain allowed for 
differentiation between viable cells and non-viable cells as non-viable cells were stained blue. 
Using the 10x objective of a microscope, cells within all four corner grids were counted and 
averaged to obtain number of cells (n). For every 1 mm square, cells that lay on the top and 
the left-hand lines of each square were counted, but not those on the bottom or right-hand 
lines. This prevented cells from being counted twice. For standard subculture, counts between 
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100 and 300 cells per mm2 are ideal. If necessary, the cell suspension was further diluted with 
PBS or HEPES-BSS depending on cell types and re-counted to ensure accuracy of counting 
was not affected by over populated cell number. When only few cells (<100/mm2) were 
present, additional squares surrounding the central square were counted. Cell viability was 
then calculated using the following equation: 
% cell viability = total viable cells (unstained) / total cells (stained plus unstained) x 100 
 
2.3.2 HISTONE EXTRACTION 
A separate set of cells was grown to 100% confluence in gelatin-coated 6-well plates as 
detailed previously. Cells were washed twice with ice-cold PBS and lysed with 1 mL of 
histone extraction lysis buffer (10 mM Tris-HCl, pH 6.5, 50 mM sodium bisulfite, 10 mM 
MgCl2, 10 mM sodium butyrate, 8.6% sucrose, 1% Triton X-100) and homogenized by 
repeated pipetting. The homogenates were centrifuged at 1,000 × g for 5 min at 4 °C, and the 
pellets were washed with 0.5 mL of suspension buffer (10 mM Tris, pH 8.0, 13 mM EDTA). 
The pellets were then re-suspended in 125 µL of ice-cold distilled water, sulphuric acid was 
added to a final concentration of 0.4 N (100 µL). Subsequently, lysates were incubated on ice 
for 1 h followed by centrifugation at 10,000 g for 5 min. The supernatants were precipitated 
with 10 volumes of acetone at -20 °C overnight. The precipitated histones were collected by 
centrifugation, dried with a stream of nitrogen, and re-suspended in histone extraction lysis 
buffer. Protein concentration was measured by using the micro BCA protein assay reagent.  
 
2.3.3 WESTERN BLOTTING 
2.3.3.1 Protein assay 
The total protein concentration of the endothelial cell suspension was determined by using the 
micro bicinchoninic acid (micro BCA) assay system from the Pierce micro BCA kit (Pierce, 
Rockford, IL, USA). The suspension was diluted 400X with modified RIPA lysis buffer (see 
Section 2.3.1.4). Protein standard concentrations ranging from 5 to 20 μg/mL were prepared 
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from the stock of 2 mg/mL bovine serum albumin protein (Pierce, Rockford, IL, USA) and 
diluted with lysis buffer. Blanks were prepared with lysis buffer without any protein content. 
The micro BCA reagents were mixed and added to protein samples, standards and blanks 
according to the manufacturer’s protocol followed by incubation at 60 °C for 1 hour before 
determination of total protein content with a micro plate reader at 562 nm absorbance 
wavelength.  
 
2.3.3.2 Western blot in cultured endothelial cells (acetylated histone H4) 
The samples were diluted with homogenizing buffer and reducing buffer (Section 2.3.3.1). 
Samples and molecular weight markers (Sigma, St Louis, USA) were denatured at 100 °C for 
3 minutes on a heating block. Samples in duplicate and molecular weight markers with a final 
total protein concentration of 10 μg per well were electrophoresed on a 15% 
SDS-polyacrylamide gel (200 V, 40 minutes) and transferred onto nitrocellulose membranes 
(100 V, 70 minutes). The membranes were then blocked with washing buffer containing 1% 
(w/v) skim milk powder for 1 hour followed by incubation with anti-rabbit polyclonal 
anti-acetyl histone H4 antibody (Upstate, NY, USA) overnight. Next day the membranes were 
washed 5 times with washing buffer and were incubated with an anti-acetyl histone secondary 
antibody for 1 hour at room temperature. Selective acetylated histone H4 protein levels were 
visualized by enhanced chemiluminescence, quantified by densitometry using the 
ChemiDoc™ XRS system (Biorad, CA, USA) and values were expressed as a percentage of 
internal control. 
 
2.3.3.3 Western blot in endothelial cell lines (COX) 
The samples were diluted with homogenizing buffer (50 mM Tris base, pH 7.6, 1.0% Triton 
X-100, 1 mM EGTA, 2 mM MgCl, 1 mM PMSF, 10 μM leupeptin, 20 μM pepstatin) and 
reducing buffer (1 mg/mL bromophenol blue, 20% glycerol, 100 mM dithiothreitol, 2% 
sodium dodecyl sulphate, pH 6.8). Samples and molecular weight markers (Sigma, St. Louis, 
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USA) were placed in eppendorf tubes and denatured at 100 °C for 3 minutes on a heating 
block. Samples were loaded in duplicate with a final total protein concentration of 10 μg per 
well. The protein samples and molecular weight markers were electrophoresed on a 10% 
SDS-polyacrylamide gel (200 V, 40 minutes), transferred onto nitrocellulose membranes (100 
V, 70 minutes). The membranes were then blocked with washing buffer containing 1% (w/v) 
skim milk powder (20nM Tris base, 137 mM NaCl, pH 7.5, 1% Tween-20) at room 
temperature for 1 hour followed by incubation with selective COX-1 and COX-2 antibodies 
(Cayman Chemical, Ann Arbor, MI, USA; BD Biosciences, San Jose, CA, USA) overnight. 
Next day the membranes were washed 5 times with washing buffer and were incubated with 
anti-COX-1 and anti-COX-2 secondary antibodies for 1 hour at room temperature. COX 
protein levels were visualized by enhanced chemiluminescence, quantified by densitometry 
using the ChemiDoc™ XRS system (Biorad, CA, USA) and values were expressed as a 
percentage of internal control.  
 
2.3.4 DRUGS AND CHEMICALS 
Drugs were obtained from the following sources: ColorBurst protein markers, leupeptin, 
pepstatin A, phenylmethylsulfonylfluoride (PMSF); Sigma (St. Louis, USA). Polyclonal 
rabbit anti-murine COX-1 antibody, monoclonal mouse anti-ovine COX-1 antibody; Cayman 
Chemical (Ann Arbor, MI, USA). Monoclonal mouse anti-rat COX-2 antibody; BD 
Biosciences (San Diego, CA, USA). Anti-rabbit acetyl-histone H4 (lys 16) antibody; Upstate 
(NY, USA). Peroxidase conjugated swine anti-rabbit immunoglobulins, peroxidase conjugated 
goat anti-mouse immunoglobulins; Chemicon International (Temecula, CA, USA).  
 
Chemicals were obtained from the following sources: Ethanol; Selby-Biolab (Melbourne, 
Victoria, Australia). Bromophenol blue, calcium chloride (CaCl2), dithiothreitol, methanol, 
developer solution, fix solution, D-glucose, glycerol, 
N-2-hydroyethylpiperazine-N’-2-ethanesulfonic acid (HEPES), sodium bicarbonate 
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(NaHCO3), N, N, N’, N’-tetramethylethylenediamine (TEMED), sodium chloride (NaCl); 
Sigma (St. Louis, USA). Magnesium sulphate (MgSO4), potassium chloride (KCl), sulphuric 
acid; Ajax Chemicals (Auburn, NSW, Australia). Tris-base; Boehringer Mannheim (IN, USA). 
EDTA, KH2PO4, Na2HPO4; BDH Chemical (Kilsyth, Victoria, Australia). Glycine, sodium 
dodecyl sulphate; ICN Biomed (Aurora, OH, USA). Ammonium persulphate, 
bis-polyacrylamide; Biorad Laboratories (Hercules, CA, USA).  
 
2.3.5 STATISTICAL ANALYSES 
All values are given as the mean ± standard error of mean (S.E.) and n indicates the number 
of observations. Differences in the percentage densities of Western blot bands were analyzed 
using 1-way ANOVA (repeated measure) and post-hoc test (Tukey’s multiple comparison tests) 
whenever applicable. SPSS (SPSS Inc., IL, USA) and Prism (GraphPad Software, Inc., CA, 
USA) statistical packages were used in statistical analyses.  
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2.4 RESULTS 
2.4.1 ENDOTHELIAL CELL VIABILITY 
2.4.1.1 Murine SVR endothelial cell viability 
Murine SVR endothelial cells were cultured to 100% confluence followed by treatment with a 
histone de-acetylase inhibitor, TSA for 48 hours. To assess the effects of TSA, which was 
prepared in 0.1% DMSO on cell viability, murine SVR endothelial cells were subjected to cell 
count and trypan blue exclusion assay procedures. There was no difference in cell numbers 
and cell viability between the control, DMSO- and TSA-treated groups (Figure 2-2). Cell 
images for each study group were taken to show the cells were proliferative and healthy and 
continued to grow to confluence (Figure 2-2).  
 
2.4.1.2 HUVEC viability 
HUVECs were cultured to 100% confluence followed by the treatment with a histone 
de-acetylase inhibitor, TSA for 48 hours. Cell count and trypan blue exclusion assay 
procedures were then performed to assess cell viability in response to TSA treatment. There 
was no difference in cell numbers and cell viability between the control, DMSO- and 
TSA-treated groups (Figure 2-3). Cell images for each study group were taken to show the 
cells were proliferative and healthy and continued to grow to confluence (Figure 2-3).  
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Figure 2-2
SVR endothelial cell viability assessment  
Murine SVR endothelial cells were grown to 100% confluence before being treated with a 
histone de-acetylase inhibitor, TSA (100 nM). After 48 hours cells were trypsinized for cell count 
(Panel A) and trypan blue exclusion assay (Panel B). Panel C: Images of murine SVR endothelial 
cells after 48h TSA treatment. Murine SVR endothelial cells were grown to 100% confluence 
before being treated with a histone de-acetylase inhibitor, TSA (100 nM). From left to right: 
Control group was incubated in culture medium without any treatment. DMSO group  was 
treated with 0.1% DMSO for 48 hours,. TSA group was treated with 100 nM TSA in 0.1% 
DMSO for 48 hours. Values represent the mean, S.E. and number of independent experiments. 
There was no significant difference in cell numbers and cell viability between all groups, p>0.05, 
1-way ANOVA (repeated measures ).
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Figure 2-3
HUVEC viability assessment  
HUVECs were grown to 100% confluence before being treated with a histone de-acetylase 
inhibitor, TSA (100 nM). After 48 hours cells were trypsinized for cell count (Panel A) and 
trypan blue exclusion assay (Panel B). Panel C: Images of HUVECs after 48h TSA treatment. 
HUVECs were grown to 100% confluence before being treated with a histone de-acetylase 
inhibitor, TSA (100 nM). From left to right: Control group was incubated in culture medium 
without any treatment. DMSO group  was treated with 0.1% DMSO for 48 hours,. TSA group 
was treated with 100 nM TSA in 0.1% DMSO for 48 hours. Values represent the mean, S.E. and 
number of independent experiments. There was no significant difference in cell numbers and cell 
viability between all groups, p>0.05, 1-way ANOVA (repeated measures ).
A. Cell count B.  Trypan blue exclusion assay
Figure 2-3
C. HUVECs
Control DMSO                      TSA
control DMSO TSA
0
50
100
150
4 4              4
C
el
l v
ia
bi
lty
 (%
)
control DMSO TSA
0
50
100
150
4 4              4
C
el
l c
ou
nt
 (x
10
5 /m
L)
 51
2.4.2 WESTERN BLOT METHOD VALIDATION 
2.4.2.1 Western blot validation for acetylated histone expression in endothelial cell lines 
2.4.2.1.1 Specificity of primary antibody (acetylated histone H4) 
The specificity of the acetylated histone H4 primary antibody (Upstate, NY, USA) was tested 
on the samples collected from cultured murine SVR endothelial cells and HUVECs. Western 
blotting for acetylated histone H4 protein was performed with the omission of the acetylated 
histone H4 primary antibody but in the presence of the secondary antibody. Western blots 
presented in Figure 2-4 show that omission of acetylated histone H4 primary antibody failed 
to detect acetylated histone H4 protein in murine SVR endothelial cells. The same results 
were obtained in HUVECs (Figure 2-4). 
 
2.4.2.1.2 Molecular weight (acetylated histone H4) 
To ensure the bands detected on the gels corresponded to acetylated histone H4 protein, 
molecular weight standards were run parallel to all samples. Detected protein bands shown in 
Figure 2-4 was compared with the manufacturer’s values of molecular weight standards 
corresponding to approximately 10 kD, which is the established molecular weight for 
acetylated histone H4 protein. 
 
2.4.2.1.3 Sample loading determination (acetylated histone H4) 
A series of protein concentrations was performed in selected samples to determine the most 
suitable sample loading concentration. In murine SVR endothelial cells and HUVECs, it was 
found that 10 μg of total protein from cultured cell samples produced one clear 10 kD band of 
acetylated histone H4 protein expression (Figure 2-4). Acetylated histone H4 expression at 
protein load above 10 μg became over-saturated and the density reading failed to show a 
linear relationship corresponding to increased protein loading concentration (Figure 2-4). 
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2.4.2.1.4 Internal standard (acetylated histone H4) 
In every gel, an internal standard, acetylated histone H4 (Upstate, NY, USA) was run parallel 
to all samples. To normalize possible density differences between gels, the densities of all 
acetylated histone H4 bands were expressed as a percentage of the respective acetylated 
histone H4 standard band, which was standardized at 100%. 
 
2.4.2.2 Western blot validation for COX expression in endothelial cell lines    
2.4.2.2.1 Specificity of primary antibodies (COX) 
The specificity of the COX primary antibodies was tested on the samples collected from 
cultured murine SVR and human umbilical vein endothelial cells. Western blotting for COX-1 
and COX-2 protein was performed with the omission of the COX primary antibodies but in 
the presence of the secondary antibodies. Western blots presented in Figure 2-5 show that 
omission of COX primary antibodies failed to detect COX protein in murine SVR endothelial 
cells. The same results were observed in HUVECs (Figure 2-6). 
 
2.4.2.2.2 Molecular weight (COX) 
In order to verify that the bands detected on the gels corresponded to COX-1 and COX-2 
proteins, molecular weight standards were run parallel to all samples. Detected protein bands 
(Figures 2-5 and 2-6) were compared with the manufacturer’s values of molecular weight 
standards corresponding to approximately 70 kD (69 kD for COX-1 and 72 kD for COX-2; 
see Review by Davidge 2001), which is the established molecular weight for both COX-1 and 
COX-2 proteins (see Reviews by Smith et al. 1996; Golden & Abramson 1999).  
 
In HUVECs, Western blotting failed to detect COX-2 protein expression although COX-2 
protein was expressed in the internal standard suggesting the failure of COX-2 protein 
detection was not due to unsuccessful experimental protocol (Figure 2-6).  
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2.4.2.2.3 Sample loading determination (COX) 
A series of protein concentrations was performed in selected samples to determine the most 
suitable sample loading concentration. In murine SVR endothelial cells, it was found that 10 
μg of total protein from cultured cell samples produced one clear 69 kD band of COX-1 and 
72 kD band of COX-2 protein expression, respectively (Figure 2-5). COX expression at 
protein loads above 10 μg became over-saturated and the density reading failed to show a 
linear relationship corresponding to increased protein loading concentration (Figure 2-5). 
 
In HUVECs, it was found that 10 μg of total protein from cultured cell samples produced one 
clear 69 kD band of COX-1 protein expression, respectively (Figure 2-6). COX expression at 
protein loads above 10 μg became over-saturated and the density reading failed to show a 
linear relationship corresponding to increased protein loading concentration (Figure 2-6).  
 
2.4.2.2.4 Internal standard (COX) 
In every gel, an internal COX standard prepared from 8 week-old, male Sprague-Dawley rats 
was run parallel to all samples. To normalize possible density differences between gels, the 
densities of all COX-1 and COX-2 bands were expressed as a percentage of the respective 
COX standard band, which was standardized at 100%. 
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A.  Acetylated histone H4 SVR
Figure 2-4
B.  Acetylated histone H4 negative control SVR
E.  Acetylated histone H4 sample loading SVR
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Figure 2-4
Western blot validation: acetylated histone H4 protein levels in endothelial cells
Panels A and C: A signal for acetylated histone H4 in murine SVR and human endothelial cells, 
respectively, was evident at 10 kD according to molecular weight markers. Panels B and D: Acetylated 
histone H4 immuno-reactivity was verified by negative controls, which were performed with omission of 
the acetylated histone H4 primary antibody but in the presence of the secondary antibody. Lane a: internal 
standard, lanes b + c: duplicate samples from control group, lanes d + e: duplicates samples from DMSO 
group (0.1%), lanes f + g: duplicate samples from TSA group (100 nM). A series of sample loading 
concentrations was performed to determine the final protein loading for acetylated histone H4 in murine 
SVR (Panels E and F) and human endothelial cells (Panels G and H). Lanes h to k represent 5, 10, 15 and 
20 μg protein loading. A final protein loading of 10 μg per lane was chosen, because this was the 
concentration at which the minimal amount of sample was required to produce a reliable and clear band. 
Higher protein loading resulted in the risk of signal saturation.
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A.  COX-1 SVR
Figure 2-5
B.  COX-1 negative control SVR
E.  COX-1 sample loading SVR
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G.  COX-2 sample  loading SVR
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Figure 2-5
Western blot validation: COX protein levels in endothelial cells (SVR)
Panels A and C: A signal for COX-1 and COX-2, respectively in murine SVR endothelial cells was 
evident at 70 kD according to molecular weight markers. Panels B and D: COX immuno-reactivity was 
verified by negative controls, which were performed with omission of the COX primary antibodies but in 
the presence of the secondary antibodies. Lane a: internal standard, lanes b + c: duplicate samples from 
TSA group (100 nM), lanes d + e: duplicates samples from DMSO group (0.1%), lanes f + g: duplicates 
from control group. A series of sample loading concentrations was performed to determine the final 
protein loading for COX-1 (Panels E and F) and COX-2 (Panels G and H) in murine SVR endothelial 
cells, respectively. Lanes h to k represent 5, 10, 15 and 20 μg protein loading. A final protein loading of 
10 μg per lane was chosen, because this was the concentration at which the minimal amount of sample 
was required to produce a reliable and clear band. Higher protein loading resulted in the risk of signal 
saturation.  
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A.  COX-1 HUVECs
Figure 2-6
B.  COX-1 negative control HUVECs
E.  COX-1 sample loading HUVECs
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Figure 2-6
Western blot validation: COX protein levels in endothelial cells (HUVECs)
Panels A and C: A signal for COX-1 and COX-2, respectively in HUVECs was evident at 70 kD
according to molecular weight markers. Panels B and D: COX immuno-reactivity was verified by 
negative controls, which were performed with omission of the COX primary antibodies but in the 
presence of the secondary antibodies. COX-2 expression was not present in un-stimulated 
HUVECs. Lanes a + b: duplicates from control group, lanes c + d: duplicates samples from DMSO 
group (0.1%), lanes e + f: duplicate samples from TSA group (100 nM), lane g: internal standard. 
Panels E and F: A series of sample loading concentrations was performed to determine the final 
protein loading for COX-1 in HUVECs, respectively. Lanes h to k represent 5, 10, 15 and 20 μg
protein loading. A final protein loading of 10 μg per lane was chosen, because this was the 
concentration at which the minimal amount of sample was required to produce a reliable and clear 
band. Higher protein loading resulted in the risk of signal saturation. 
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2.4.3 ACETYLATED HISTONE EXPRESSION IN TSA-TREATED 
ENDOTHELIAL CELLS 
2.4.3.1 Acetylated histone expression in TSA-treated endothelial cells 
The level of acetylated histone H4 was assessed in cultured murine and human endothelial 
cells treated with the histone de-acetylase inhibitor, TSA. In murine SVR endothelial cells, 
TSA treatment resulted in increased acetylated histone H4 levels in the TSA-treated group 
compared with the DMSO-treated group. Acetylated histone H4 levels remained unchanged 
between the control and DMSO-treated cells (Figure 2-7). 
 
Similar results were found in HUVECs. There was no difference in acetylated histone H4 
expression in the control group compared with the DMSO-treated group. Acetylated histone 
H4 levels, however, were increased significantly in TSA-treated group compared with 
DMSO-treated group in response to 48-hour TSA treatment (Figure 2-7).  
 
2.4.4 COX EXPRESSION IN TSA-TREATED ENDOTHELIAL CELLS 
2.4.4.1 COX-1 expression in TSA-treated endothelial cells 
There was no significant difference in COX-1 expression between the control and 
DMSO-treated group. In contrast, COX-1 expression increased significantly in the 
TSA-treated group compared with DMSO-treated group in both murine SVR and human 
umbilical vein endothelial cell lines (Figure 2-8). 
 
2.4.4.2 COX-2 expression in TSA-treated endothelial cells 
There was no difference in COX-2 expression between the control and DMSO-treated groups 
in the murine SVR endothelial cells. COX-2 expression was found to increase in response to 
TSA treatment compared to those cells treated with DMSO only. In HUVECs, COX-2 
expression was not detectable in any of the groups regardless of the treatment (Figure 2-8). 
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Figure 2-7
Quantitative densitometry of acetylated histone H4 protein expression in cultured 
endothelial cells
Analysis of acetylated histone H4 expression in cultured endothelial cells treated with TSA 
(100 nM). The control group was incubated in culture medium without any treatment. The 
DMSO group was treated with 0.1% DMSO for 48 hours. The TSA group was treated with 
100 nM TSA in 0.1% DMSO for 48 hours. Panel A: acetylated histone H4 protein expression 
was measured in murine SVR endothelial cells. Panel B: acetylated histone H4 protein 
expression was measured in HUVECs. A histone H4 standard control was run with each 
Western blot and the density of all sample bands was expressed as a percentage of the 
corresponding standard control. Values represent the mean, S.E. and number of independent 
experiments. * represents significant difference from DMSO group, p<0.01, 1-way ANOVA 
(repeated measure; Tukey’s multiple comparison test).
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Figure 2-8 
Quantitative densitometry of COX protein expression in cultured endothelial cells
Analysis of COX expression in cultured endothelial cells treated with TSA (100 nM). 
The control group was incubated in culture medium without any treatment. The DMSO 
group was treated with 0.1% DMSO for 48 hours. The TSA group was treated with 100 
nM TSA in 0.1% DMSO for 48 hours. Panel A: COX-1 protein expression was measured 
in murine SVR endothelial cells. Panel B: COX-2 protein expression was measured in 
murine SVR endothelial cells. Panel C: COX-1 protein expression was measured in 
HUVECs. A rat COX standard control was run with each Western blot and the density of 
all sample bands was expressed as a percentage of the corresponding standard control. 
Values represent the mean, S.E. and number of independent experiments. * represents 
significant difference from DMSO group, p<0.01, 1-way ANOVA (repeated measure; 
Tukey’s multiple comparison test).
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2.5 DISCUSSION  
Previous studies from our laboratory found enhanced COX-1 and COX-2 expression in aging 
rat aortas. Functionally, when the endothelium was removed in 54-week rat aortas, an increase 
in vasoconstriction of the blood vessel was observed compared with those of 8-week rat 
aortas, a process which was found to be both COX-1- and COX-2-dependent (Kang et al. 
2001). Further study in human male subjects found monocyte COX-2 expression was 
increased with aging (Kang et al. 2003). Very little is known about the underlying 
mechanisms by which increased COX levels are regulated in aging. Evidence has suggested 
that histone H4 acetylation is increased with aging in human lymphocytes after TSA treatment 
(Sourlingas et al. 2002; Kypreou et al. 2004). The aim of the current study was to test the 
hypothesis that changes in COX-1 and COX-2 expression in the endothelium is modulated by 
histone hyperacetylation, a post-translational modification that is frequently associated with 
active gene transcription. Murine SVR and human umbilical vein endothelial cell lines were 
cultured and treated with a specific histone de-acetylase inhibitor, TSA. Acetylated histone H4 
and COX levels were assessed using Western blotting techniques.   
 
2.5.1 ACETYLATED HISTONE H4 EXPRESSION IN TSA-TREATED 
ENDOTHELIAL CELLS 
TSA, a specific histone de-acetylase inhibitor is known to increase histone acetylation levels 
(Yoshida et al. 1990). The present study reported that histone H4 extracted from TSA-treated 
murine and human endothelial cells had a higher level of histone acetylation in comparison to 
non-TSA-treated cells. This verified the efficacy of TSA as a histone de-acetylase inhibitor. 
Further studies were then performed to determine whether histone hyperacetylation was 
associated with changes in COX expression in endothelial cells in response to TSA treatment. 
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2.5.2 COX PROTEIN EXPRESSION IN TSA-TREATED ENDOTHELIAL CELLS 
The present study tested the hypothesis that up-regulation of COX-1 expression was 
associated with histone acetylation/de-acetylation mechanism in endothelial cell lines.  
Enhanced COX-1 expression in both murine and human endothelial cell lines was found after 
48 hour TSA treatment, suggesting COX-1 expression may be affected by histone acetylation. 
This finding is in agreement with the findings of Taniura et al. (2002) using neural cells. 
Enhanced COX-1 expression was found in normal human astrocyte cells and glioma cell lines 
after treatment with TSA for 24 and 48 hours. Taniura et al. further suggested that TSA 
upregulates COX-1 level by acting on the two Sp1-binding sites and the proximal Sp1-binding 
site located at the COX-1 promoter.  
 
In the case of COX-2, the current study reported that COX-2 levels were enhanced in 
response to TSA in the murine SVR endothelial cell line, a phenomenon not observed in 
HUVECs. In fact, COX-2 expression was not detected in HUVECs in either TSA-treated and 
-untreated groups, an observation verified by the positive COX-2 internal standard, 
suggesting it was not due to failure of experimental protocol. This finding is consistent with 
the report by Caughey et al. (2001), who noted that un-stimulated HUVECs only expressed 
COX-1, but not COX-2. In another report, Norata et al. (2004) found that COX-2 expression 
in un-stimulated HUVECs was very low. The detection of enhanced COX-2 expression in the 
tumor cell line but not in un-stimulated HUVECs after TSA treatment suggests that histone 
acetylation may only promote COX-2 expression in some cells, which have an intrinsic 
capacity to express COX-2.  
 
Increasing evidence suggests that COX-mediated pathways are altered during the aging 
process. The COX-2-mediated pathway has been shown to be increased with aging indicated 
by enhanced production of PGE2 in the hippocampus of rats. This was reduced with the 
treatment of celecoxib, a selective COX-2 inhibitor (Casolini et al. 2002). Previous study 
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from our group at RMIT University also demonstrated an age-dependent increase in 
monocyte COX-2 expression in healthy human male subjects (Kang et al. 2003). The 
biological effects of changes in COX-mediated pathways in aging may be profound and are 
discussed in Section 2.1.1.1. 
 
The data from the present study show that COX-1 and COX-2 expression was increased after 
histone hyperacetylation in endothelial cells. This is a potential explanation for increased 
COX in aging since in aging there is histone hyperacetylation. For instance, studies have 
reported that histone acetyltransferase activity is increased in aging mice, rats and elderly 
human subjects (Sarg et al. 1999; Li et al. 2002; Sourlingas et al. 2002). Furthermore, histone 
H4 acetylation was found to increase in response to TSA treatment in human lymphocytes 
with advancing age (Sourlingas et al. 2002; Kypreou et al. 2004). In contrast, an early study 
in rats showed that histone H4 acetylation was reduced with aging in neurons (Pina et al. 
(1988). Although it is unclear why conflicting data have been reported, it is possible that the 
effect of histone acetylation in aging is cell/tissue/species-specific. 
 
2.6 CONCLUSIONS 
The present study found firstly, that COX-1 expression in both murine and human endothelial 
cells was increased in response to TSA incubation, which was accompanied by an increase in 
histone H4 acetylation status. During aging, increased COX-1 expression may also be 
regulated through enhanced histone acetylation. Secondly, COX-2 expression was increased 
in a murine tumor cell line after TSA treatment with concomitant increased histone H4 
acetylation. In contrast, COX-2 expression was not detected in un-stimulated HUVECs and 
TSA treatment had no effect on COX-2 expression in this case. The fact that COX-2 was only 
up-regulated in the murine tumor cell line, but not in un-stimulated HUVECs after TSA 
treatment suggests that pathological process such as tumor growth and inflammation may 
serve as triggers that enhance histone acetylation resulting in increased COX-2 expression.   
 
 
 
 
 
 
 
 
 
CHAPTER 3 
DIABETES REVIEW 
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3.1 HISTORY OF DIABETIC DISEASES 
The earliest known record of diabetes mellitus was documented in the Ebers Papyrusan 
Egyptian document in 1500 B.C. Described by physician Hesyra, the article noted that 
diabetes was a chronic systemic disease with a symptom of frequent urination (see Review by 
King & Rubin 2003). The term “diabetes” was first noted by Araetus of Cappodocia around 
81-133 A.D. (see Review by Majumdar 2001). Thomas Willis in 1675 re-discovered, after the 
ancient Indians, the sweetness of urine and blood of diabetic individuals, hence the word 
“mellitus” was introduced. Willis’ observation was then confirmed by Dobson in 1776, who 
identified the presence of excess sugar in urine and blood as the cause of their sweetness. 
Eventually, the role of the pancrea in the pathogenesis of diabetes was discovered by Mering 
and Minkowski in 1889, which led eventually, to the extraction of insulin by Frederick 
Banting and John Macleod in 1921, who later received the Nobel Prize in 1923 for their 
contribution (see Reviews by Majumdar 2001; Ahmed 2002; King 2003; King & Rubin 
2003).  
 
Diabetes mellitus is a group of chronic metabolic diseases characterized by hyperglycemia 
and by disturbances of carbohydrate, fat and protein metabolism. It is associated with absolute 
or partial deficiency in insulin secretion from the pancreatic β cells of the islets of Langerhans 
and/or defective insulin action (Barcelo 1996; see Review by Schuster & Duvuuri 2002). 
Insulin, acting on insulin receptors in the membrane of cells, promotes the uptake of glucose 
from the circulation into muscle and adipose tissue through the glucose transporter proteins. 
According to the World Health Organization (1994), the two major types of diabetes mellitus 
are insulin-dependent diabetes mellitus (or Type 1 diabetes) and non-insulin-dependent 
diabetes mellitus (or Type 2 diabetes). Type 1 diabetes, characterized by defective insulin 
production, is most common in children and young adolescence whereas Type 2 diabetes, 
characterized largely by defective insulin action, tends to appear in adults over forty. Among 
the two, Type 2 diabetes is the more common form, accounting for about 85% of all cases 
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(World Health Organization 1994). 
 
3.2 TYPE 2 DIABETES MELLITUS 
Type 2 diabetes mellitus, also known as non-insulin dependent diabetes mellitus, is the most 
common form of diabetes and occurs with increasing frequency with age. The condition is 
often associated with insulin resistance, a condition in which the cells fail to respond to 
insulin, and always with either relative or absolute insulin deficiency (see Reviews by Efendic 
& Luft 1986; Zimmet 1992; Gerich 1998). When insulin secretion is insufficient, glucose 
uptake in muscle is reduced and the liver increases glucose production. Adipose tissue also 
enhances free fatty acid mobilization. All of these contribute to prolonged elevation of 
glucose levels in the circulation after meals in Type 2 patients. Insulin resistance can also 
promote the development of Type 2 diabetes. As the tissue sensitivity to insulin is reduced, the 
pancreas compensates by increasing in insulin production. Hence, hyperinsulinemia and 
insulin resistance are frequently found even before the clinical onset of Type 2 diabetes (see 
Reviews by Zimmet 1989; Charles et al. 1991; Leboritz 1998). Eventually, hyperinsulinemia 
leads to insulin deficiency particularly in those patients whose pancreatic β cells have limited 
secretory reserve. Although the metabolic disturbance is complex, Type 2 diabetes individuals 
usually do not require insulin treatment for survival. 
 
3.2.1 ETIOLOGY OF TYPE 2 DIABETES 
The etiology of Type 2 diabetes is complex. Genetic inheritance is strongly associated with 
the disease development, which is further precipitated by environmental factors.  
 
3.2.1.1 Genetic influence 
Genetic factors are important in the etiology of Type 2 diabetes. A single-gene disorder known 
as maturity-onset diabetes of the young (MODY), characterized by autosomal dominant 
inheritance and an age of onset of twenty five years or younger (Froguel et al. 1993; Hanis et 
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al. 1996; see Reviews by Fajan 1989; Ledermann 1995) has been found to account for 2-5% 
of the Type 2 diabetic population. MODY genes have been localized on chromosomes 7, 12 
and 20 (Bell et al. 1991; Froguel et al. 1993; Vaxillaire et al. 1995) and mutations in these 
genes can lead to progressive pancreatic β cell failure, decreased glucose-regulated secretion 
of insulin and decreased glucose stimulation of insulin gene transcription leading to defective 
insulin production (Byrne et al. 1996 and see Reviews by Polonsky 1995; Hattersley 1998).  
 
In contrast to the rare case of MODY, there is a poorly defined genetic component in Type 2 
diabetes etiology for 70-85% of Type 2 diabetic population and the degree of genetic 
influence may vary according to ethnicity and geography. The genes involved in Type 2 
diabetes may also vary. For instance, there is a great difference in the two diabetes 
susceptibility genes for Type 2 diabetes identified. NIDDM 1, found in Mexican Americans 
(Hanis et al. 1996) is different from NIDDM 2, which was found in Finnish families (Mahtani 
et al. 1996). Although the pathogenesis of the majority of Type 2 diabetes cases is unclear, it 
is generally agreed that in addition to the genetic influence, there is a strong environmental 
component involved (see Section 3.2.1.2 and Reviews by Hamman 1992; Kahn 1994; 
Bouchard 1995; Yki-Järvinen 1995). 
 
3.2.1.2 Environmental influence 
Whilst the genetic influence is an important component in the development of Type 2 diabetes 
(see Section 3.2.1.1), environmental factors such as nutrition, obesity and physical inactivity 
also influence the clinical expression of genetic defects and are often required for the clinical 
expression of the polygenic defects, a term used to describe the need for the simultaneous 
presence of several abnormal genes for disease development. Barker et al. (1993) reported a 
higher prevalence of insulin resistance, obesity and Type 2 diabetes in adults who had a low 
birth weight and postulated a link with fetal malnutrition.  
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Ravussin et al. (1994) observed the lifestyle of Pima Indians who live in Arizona. They have a 
sedentary lifestyle with high calorie diets and are also quite obese with an extremely high 
prevalence of Type 2 diabetes. In contrast, Pima Indians who live in the mountains of northern 
Mexico have an intense and active lifestyle with low calorie diets. The prevalence of Type 2 
diabetes in this tribe is low and approximately equal to the general Mexican population. This 
suggests that diet and exercise are strongly linked to Type 2 diabetes. 
 
3.3 TYPE 1 DIABETES MELLITUS 
Insulin-dependent diabetes mellitus or Type 1 diabetes is an autoimmune disease. It is 
characterized by an inflammatory process, with the presence of T lymphocytes, B 
lymphocytes and macrophages (Imagawa et al. 1999) in the pancreas and selective destruction 
of the pancreatic β cells (Tabatabaie et al. 2000). The consequence of pancreatic β cell 
destruction is a failure of insulin production by the pancreas resulting in elevated blood 
glucose levels. As a result, Type 1 diabetic patients depend on daily insulin therapy.  
 
3.3.1 ETIOLOGY OF TYPE 1 DIABETES 
The development of Type 1 diabetes cannot be explained simply by one single factor. The 
gradual progression of the disease involves several stages including genetic predisposition, 
environmental factors, active autoimmunity, progressive pancreatic β cell destruction and 
presentation of the symptoms of Type 1 diabetes (see Review by Devendra et al. 2004), which 
are further discussed below.  
 
3.3.1.1 Genetic pre-disposition 
Individuals with Type 1 diabetes have a genetic pre-disposition to the disease as the familial 
occurrence of Type 1 diabetes has been long observed. According to Redondo et al. (2001), a 
sibling of Type 1 diabetes has a risk of developing Type 1 diabetes about 12 to 100 fold 
greater than the risk in the general population. The best studied genes in Type 1 diabetes are 
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the insulin gene and the ones found in the human leukocyte antigen (HLA) region. HLA 
region, a primary region of susceptibility for Type 1 diabetes, is located in chromosome 6 and 
contains more than 150 genes. Genes that are found in the class II sub-region of HLA such as 
DR, DQ and DP loci account for 40 to 50 percent of the diabetes risk that people inherit from 
their parents. It has been documented that at least 90% of patients who develop Type 1 
diabetes have either DR3, DQ2 or DR4, DQ8 haplotypes, closely linked alleles inherited as a 
unit. In contrast, less than 40% of normal controls have these haplotypes (Noble et al. 1996; 
Dubois-Laforgue et al. 1997; Atkinson & Eisenbarth 2001, see Review by Dorman & Bunker 
2000).  
 
The variable number of tandem repeats (VNTR), a repeated section of DNA forming the 
insulin gene, which is the region of DNA that codes for the protein insulin may also be 
involved in the genetic pre-disposition of Type 1 diabetes. Different numbers of DNA repeats 
forms either the smaller VNTR regions containing only 26 to 63 DNA repeats or the long 
VNTR regions containing 140 to 200 repeats. Owerbach & Gabbay (1993) suggested that a 
person with two short VNTR regions is two to five times more susceptible to the development 
of Type 1 diabetes than a person with least one long VNTR.  
 
3.3.1.2 Environmental influence 
Genetic pre-disposition of Type 1 diabetes is profoundly influenced by environmental factors 
triggering the disease. Data obtained from studies of identical twins with Type 1 diabetes have 
confirmed this observation. Srikanta and colleagues (1983) found that when one twin had 
Type 1 diabetes, the other twin developed the condition only half of the time. If the cause of 
Type 1 diabetes were purely genetic, both identical twins would always have Type 1 diabetes.  
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One environmental trigger is thought to be the infection by picornaviruses such as Coxsackie 
B virus as a possible etiology of Type 1 diabetes by inducing more subtle, long-term changes 
in the pancreatic β cells. In 1994, Tian and colleagues reported that Coxsackie viruses trigger 
Type 1 diabetes in genetically susceptible mice, but not in those that had a different genetic 
profile. Another study in the same year showed that the autoimmune reaction observed in 
Type 1 diabetes was triggered by a similarity between a Coxsackie virus protein and a protein 
in the pancreas, subsequently shown by Kaufman and others to be an enzyme called glutamic 
acid decarboxylase (GAD) (Kaufman et al 1992; Atkinson et al. 1994). GAD is found on the 
surface of insulin-producing pancreatic β cells and a small segment of GAD is structurally 
similar to a segment of a Coxsackie B protein. It has been suggested that when the immune 
system attacks a Coxsackie infection, it also inadvertently attacks GAD leading to destruction 
of insulin-producing pancreatic cells (Atkinson et al. 1994).  
 
3.3.1.3 Autoimmunity  
Autoimmunity, a condition in which the immune system produces antibodies against the 
body's own tissues, plays a role in Type 1 diabetes etiology. Environmental factors can trigger 
the production of auto-antibodies such as GAD (also known as 64-K) antibody and the ICA 
512 antibody causing damage to the pancreatic β cells (see Review by Devendra & Eisenbarth 
2003). Maternal exposure to vial infections such as mumps, rubella, Coxsackie B4 during 
pregnancy (Dahlquist et al. 1995; Hyoty et al. 1995), exposure to cow’s milk in infancy, 
nitrosamines (Akerblom et al. 2002) or vitamin D supplementation (EURODIAB Substudy 2 
Study Group et al. 1999) have all been shown to trigger an autoimmune response resulting in 
a profound inflammatory response against the pancreatic β cells leading to insulin deficiency.  
 
In addition to autoimmunity to the pancreatic β cells, Type 1 diabetic subjects are often 
associated with other autoimmune conditions as determined by the presence of specific 
antibodies. Data from the Belgian Diabetes Registry showed that the prevalence of thyroid 
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peroxidase auto-antibodies is 22% in patients with Type 1 diabetes. In addition, 
transglutaminase IgA auto-antibodies are detected in approximately 1 in 10 patients with Type 
1 diabetes. More than half of these patients have coeliac disease on intestinal biopsy. 
Approximately 1 in 50 people with Type 1 diabetes have 21-hydroxylase autoantibodies, and 
approximately 25% of these patients progress to Addison's disease (see Review by Devendra 
et al. 2004).  
 
3.4 CONSEQUENCES OF DIABETES MELLITUS 
The chronic hyperglycemia of diabetes mellitus is associated with long-term damage, and 
failure of various organs, especially the eyes, kidneys, nerves, heart, and blood vessels. 
Vascular complications are the leading causes of morbidity and mortality in diabetic patients 
and diabetes is regarded as a significant risk factor for macro- and micro-vascular events. The 
macrovascular complications include coronary artery disease, atherosclerosis and peripheral 
vascular disease whereas the microvascular complications include retinopathy, nephropathy 
and neurovascular abnormalities associated with autonomic neuropathy (see Review by 
Schuster & Duvuuri, 2002). The increased risk of vascular complications in diabetes may be 
related to inflammation, increased generation of AGEs and arachidonic acid metabolism. 
 
3.4.1 INFLAMMATION AND DIABETES MELLITUS 
Inflammation, a part immune response, involves a series of events in response to infection or 
irritation, which results in removal of the irritants, limitation on tissue damage and the 
initiation of tissue repair. The process involves a variety of blood and tissue derived mediators 
including cytokines, growth factors and other agents including prostanoids (for more details 
for the effects of prostanoids in the vasculature, see Section 1.3.2). At the cellular level, 
inflammation is initiated when injured tissues release histamine, bradykinin and serotonin, 
which leads to vasodilatation and increased permeability. The blood vessel wall then becomes 
coarse, which slows down the blood flow and allows the leukocytes to move out of the blood 
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vessels and into the injured tissue. These leukocytes act as phagocytes surrounding, engulfing, 
destroying foreign substances and preventing the spread of an infection while cleaning away 
cellular debris. In the case of chronic inflammation, cytokines such as IL-1 and TNF-α 
released by macrophages at the site of injury will act on endothelial cells leading to 
up-regulation vascular cell adhesion molecule-1 and intercellular adhesion molecule-1, which 
are capable of binding to leukocytes, subsequently resulting in further recruitment of 
neutrophils and monocytes, activation of T and B cells and adherence of leukocyte to the 
endothelium (see Review by Frijns & Kappelle 2002).  
 
Inflammation is though to be involved in the development of diabetes based on four lines of 
evidence. First, non-obese individuals without previous history of glucose abnormalities who 
rapidly develop diabetes often have islet cell antibodies and antibodies to glutamic acid 
decarboxylase, both of which are autoimmune responses against the pancreatic β cell (Tuomi 
et al. 1993; Tuomilehto et al. 1994; Pietropaolo et al. 2000). Second, inflammatory markers 
such IL-6 have been found to be increased in Type 2 diabetic individuals compared with those 
without diabetes (Pickup et al. 1997). Further, in response to increased cytokine 
concentrations, the liver can produce acute phase protein such as C-reactive protein (CRP), an 
indicator of the presence of low-grade inflammation. Indeed, elevated levels of sialic acid, a 
measure of CRP were detected in Type 2 diabetic individuals (Pickup et al. 1997). Third, 
inflammation mediators can interfere with insulin signaling pathways. For instance, 
inflammatory cytokines such as TNF-α have been shown to increase insulin resistance and 
impair insulin signaling pathways in cells (Uysal et al. 1997; Cheung et al. 1998). Last, 
inflammation as measured by an enhanced CRP level has been associated with the insulin 
resistance syndrome, and metabolic dysfunction in lipid and carbohydrate metabolism, 
sedentary life style, hypertension as well as other genetic factors, which contribute to the 
development of diabetes (Festa et al. 2000; Frohlich et al. 2000). Evidence suggests that 
enhanced inflammatory activity in diabetes is implicated in the development of chronic 
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diabetic complications and may be associated with hyperactivity in platelets, which is 
discussed below in Section 3.4.1.2. 
 
3.4.1.1 Atherosclerosis and diabetes mellitus  
Atherosclerosis involves the formation of atheroma or atherosclerotic plaques and hardening 
of arterial blood vessels resulting in tissue damage due to restriction of blood flow. The exact 
cause of atherosclerosis is unclear, however, evidence suggests that deposition of lipids in the 
arterial intima initiates the development of atherosclerotic plaque. Small lipid deposits at 
sub-endothelial layer triggers an inflammatory response, attracting monocytes from the 
bloodstream to the arterial wall. Monocyte-derived macrophages then ingest oxidized 
cholesterol forming large foam cells. Lipid-laden foam cells eventually die and further 
propagate the inflammatory response. Low density lipoproteins continuously deliver oxidized 
cholesterol into the blood vessel wall, a process that also sustains inflammatory process and 
attracts more macrophages. Fatty deposits accumulate underneath the intima forming a plaque, 
which has a protective fibrous cap over it. The presence of atherosclerotic plaques can narrow 
the blood vessel, damage the endothelium, compromise the activity of the vessel to 
dilate/constrict and disrupt blood flow to vital organs such as the brain and heart causing 
stroke and ischemic heart disease (see Review by Stary et al. 1994).  
 
The number, size and complexity of atherosclerotic plaques increases in diabetes indicated by 
increased lipids in the core region and increased infiltration of macrophages and lymphocytes 
present in plaque region (Jander et al. 1998; King et al. 1998). This may have important 
consequences. Matrix metalloproteinases (MMPs), proteolytic enzymes capable of degrading 
extracellular matrix components are up-regulated by cytokines released from peripheral blood 
monocytes and monocyte-derived macrophages (Moreau et al. 1999; Xu et al. 1999) and may 
decrease plaque stability (Galis et al. 1994). Enhanced MMP-9 activity in unstable carotid 
plaques (Loftus et al. 2000) and increased expression of active MMP-2 and MMP-9 has also 
 73
been reported in vulnerable regions of human carotid plaques in association with macrophages 
(Galis et al. 1994). The secretion of MMP-2 and MMP-9 by macrophages in human 
atherosclerotic plaques has been shown to occur through a PGE2/cAMP–dependent pathway 
(Corcoran et al. 1994), possibly via COX enzymes and PGE2 synthases associated with 
NFk-B activation (Cipollone et al. 2001). Thus macrophage COX may have a role in plaque 
stability and given enhanced numbers of macrophages in diabetes, plaques may predispose 
diabetic patients to increased cardiovascular risks. 
 
3.4.1.2 Platelet hyperactivity and diabetes mellitus 
Platelets are small anucleate discoid cells found in the circulation with their main function 
being to limit leaks through blood vessel walls by forming a thrombus. In response to injury, 
von Willebrand factor, a clotting factor attaches to sub-endothelium exposing multiple 
intrinsic binding sites for the platelet specific membrane Glycoprotein (GP) Ib. Once von 
Willebrand factor-GPIb binding takes place, it stimulates platelet shape changes and 
disintegration exposing GP IIb-IIIa binding sites for further attachment of von Willebrand 
factor and fibrinogen. Platelets then undergo a series of events to form a thrombus. First, 
dense granules in the platelets release ADP, a substance that promotes platelet aggregation and 
disintegration. TXA2, serotonin, phospholipids and lipoproteins are also released by the 
platelets to sustain platelet activation and promote the coagulation cascade. Second, 
translocation of P-selectin from the membrane of α-granules to the plasma membrane takes 
place (Stenberg et al. 1985) and α-granules release the coagulation proteins including 
fibrinogen, thrombospondin, fibronectin, factor V and factor VIII. The phospholipid 
phosphatidylserine, also known as platelet factor 3, is found on the surface of the 
disintegrating platelet, serving as an essential base for the initiation of soluble proteins in the 
coagulation pathway. When tissue factors form a complex with factor VII in the presence of 
Ca2+, factors IX and X are activated resulting in the conversion of thrombin from prothrombin. 
Fibrin is released from fibrinogen, a process initiated by thrombin. Fibrin then polymerises to 
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form the fibrin clot. Factor XIII, activated by thrombin and Ca2+, stabilizes this clot by 
forming covalent bonds between the fibrin molecules (see Review by Ashby et al. 1990). 
 
Platelet activity can be measured by platelet activation markers such as CD31, CD36, CD49b, 
CD62P and CD63. In diabetes, an increase in the expression of these activation markers on 
the surface of the platelets has been detected. These platelet activation markers were reduced 
in the platelets of Type 2 diabetic subjects with a good glycemic control regime (Eibl et al. 
2004). Several mechanisms have been proposed to explain platelet hyperactivity. First, 
chronic hyperglycemia has been identified as a causal factor of in vivo platelet activation and 
hypereactivity in diabetes (Bridges et al. 1965; Davì et al. 1997; Davì et al. 1999). Second, 
hyperglycemia promotes non-enzymatic glycation of platelet membrane proteins leading to 
structural changes in proteins, as well as alterations of membrane lipid dynamics (see Review 
by Winocour 1992). Consequently, platelet receptor expression increases due to altered 
dynamics of platelet membrane (Tschoepe et al. 1995), potentially affecting receptor 
accessibility to ligands (Watala et al. 1996). Third, hyperglycemia can induce oxidative stress 
and thus increase peroxidation of arachidonic acid to form biologically active isoprostanes 
without the action of COX, creating a feedback loop sustaining platelet activation (Davì et al. 
1999). Furthermore, increased oxidative stress promotes the endothelium towards a 
pro-thrombotic state by inhibiting endothelial thrombomodulin, a cofactor for a potent 
anticoagulant called protein C (Glaser et al. 1992). Therefore, the implications of hyperactive 
platelets in diabetes can be serious. With enhanced platelet activation, platelets are prone to 
aggregation and adhesion, which promote thrombosis development and increases the risk of 
ischemic heart diseases.  
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3.4.2 ADVANCED GLYCATION END PRODUCTS (AGES) AND DIABETES 
MELLITUS 
AGEs are formed from the non-enzymatic reaction of reducing sugars with free amino groups 
of proteins, lipids, and nucleic acids. Precursor AGEs form covalent crosslinks with these 
macro molecules changing their structure thus affecting the functioning of cellular matrix, 
basement membranes, and vessel-wall (see Review by Raj et al. 2000). AGEs also interact 
with a variety of cell-surface AGE-binding proteins, resulting in either cell degradation or 
cellular activation and pro-oxidant, pro-inflammatory events (see Review by Peppa et al. 
2003). In diabetes, the hyperglycemic environment promotes the formation of AGEs, which is 
evident in elevated serum AGE level in diabetic children and adolescents with or without 
vascular complications (Jakus & Rietbrock 2004). 
 
The formation of AGEs is linked to chemical modification of proteins by glucose and is 
thought to play a part in the pathogenesis of diabetic complications including atherosclerosis, 
nephropathy, neuropathy and retinopathy (see Review by Jakus & Rietbrock 2004). For 
instance, glycation of platelet membrane proteins has been associated with a change in the 
structure of platelet membrane resulting in decreased ligand-membrane interactions in 
diabetic patients (Watala et al. 1996). More details on the roles of AGE in diabetes are 
discussed in Chapter 6. 
 
3.4.3 ARACHIDONIC ACID METABOLISM AND DIABETES MELLITUS 
Arachidonic acid signaling pathway involves the production of prostanoids by PLA2, COX 
and prostanoid synthases. Prostanoids produced by this pathway mediate numerous 
physiological processes including vasoconstriction and vasodilatation, platelet aggregation 
and renal re-absorption (for more details see Section 1.3).  
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In diabetes, increasing evidence suggests that arachidonic acid metabolism is involved in the 
promotion of diabetic vascular complication development. PGE2 and TXA2 production 
increased in human mesangial cells and aortic endothelial cells, respectively after glucose 
incubation (Cosentino et al. 2003; Kiritoshi et al. 2003), whilst a decrease in PGI2 production 
was observed in HUVECs in response to glucose incubation (Cosentino et al. 2003). 
Furthermore, a study by Shanmugam et al. (2004) found that treating THP-1 monocytes with 
high concentrations of glucose led to a significant 3 to 5 fold induction of COX-2 mRNA and 
protein expression but not COX-1 mRNA. Enhanced levels of COX-2 mRNA were also found 
in isolated peripheral blood monocytes from Type 1 and Type 2 diabetic patients. In contrast, 
there was no COX-2 mRNA expression detected from normal subjects. These studies suggest 
that high levels of glucose can alter the prostanoid profile through the arachidonic acid 
pathway. Potentially, changes in the arachidonic acid pathway and prostanoid profile can 
result in a series of downstream events including alteration in vascular tone (see Section 1.3.2 
for the effects of prostanoids in the vasculature), platelet and monocyte activity, all of which 
promote diabetic vascular complication development (see Section 3.4 for more details). 
 
Given that diabetic subjects are at risk of vascular complications, however, the underlying 
mechanisms involved in the development of diabetic vascular complications are not clear, 
although AGE- and COX-mediated signaling pathways may be involved with inflammation as 
a common theme. The following three chapters discussed possible changes in these pathways 
in both Type 1 and Type 2 diabetes.   
 
 
 
 
 
 
 
 
 
CHAPTER 4 
ROLES OF COX IN TYPE 2 DIABETES  
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4.1 TYPE 2 DIABETES MELLITUS 
Type 2 diabetes is characterized by a high level of glucose in the circulation, which is caused 
by insufficient insulin secretion by the pancreatic β cells, increased insulin resistance in the 
tissue or both (for more details, see Section 3.2 and Reviews by Efendic & Luft 1986; Zimmet 
1992; Gerich 1998).The chronic diabetic complications in Type 2 diabetes include retinopathy, 
nephropathy, neuropathy, diseases of blood vessels and ischemic heart conditions (for more 
details, see Section 3.4). 
 
4.1.1 COX-MEDIATED PATHWAYS IN TYPE 2 DIABETES 
Increasing evidence suggests that insulin resistance and progressive pancreatic β cell failure, 
key events in the development of Type 2 diabetes is associated with persistent inflammatory 
activity indicated by elevated inflammatory markers such as TNF-α, CRP and IL-6 (Yudkin et 
al. 1999). Further animal studies found that these inflammatory markers interfered with 
insulin signaling pathways. For instance, IL-6 was capable of modifying glucose-stimulated 
insulin release from isolated pancreatic β cells in rodents (Sandler et al. 1990) and decreased 
insulin-stimulated glycogen synthesis in cultured hepatocytes (Kanemaki et al. 1998). TNF-α 
has also been shown to induce insulin resistance through mechanisms such as direct inhibitory 
effects on the glucose transporter protein GLUT4, the insulin receptor, and insulin receptor 
substrates (Hotamisligil & Spiegelman 1994). One of the consequences of Type 2 diabetes is 
the development of chronic diabetic complications including atherosclerosis. Data derives 
from experimental and epidemiological studies have shown that low-grade inflammation 
plays an important role in the initiation and progression of atherosclerotic plaque development. 
For example, CRP, an acute phase reactant produced by the liver has been found to induce 
monocyte chemoattractant protein and cellular adhesion molecule expression in human 
endothelial cells (Pasceri et al. 2001), and mediate low density lipoprotein uptake by 
macrophages (Zwaka et al. 2001). It is clear that both Type 2 diabetes and its complications 
may share a common link, namely inflammation. 
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COX expression, particularly COX-2, can be elevated by inflammatory cytokines (see Section 
1.2.3.2). COX isoforms are rate-limiting enzymes that catalyze arachidonic acid leading to the 
eventual production of various prostanoids, which can alter vascular reactivity, platelet 
aggregation and atherosclerotic plaque formation and stability. COX-1, expressed at constant 
levels throughout the cell cycle, is termed a constitutive isoform and has a “house-keeping” 
role (see Review by DeWitt & Meade 1993). In contrast, inducible COX-2, whose expression 
under normal physiological conditions is not usually detected, is up-regulated in response to a 
variety of agents such as hormones, growth factors, pro-inflammatory stimuli and 
inflammation (see Reviews by Herschman 1996; Smith et al. 1996; Garavito & DeWitt 1999). 
Prostanoids produced by COX pathways are crucial to numerous physiological processes 
including platelet aggregation, vasoconstriction and vasodilatation (for more details, see 
Section 1.3). TXA2 released by platelet and PGE2 released by monocytes due to the action of 
COX-1 and COX-2, respectively are important prostanoids involved in thrombosis and 
atherosclerosis development (for more details, see Section 3.4). Given that inflammation is 
elevated in Type 2 diabetes and the ability of COX-mediated prostanoids to be involved in 
thrombosis and atherosclerosis, it was of interest to investigate if COX-mediated pathways 
were altered in platelets and monocytes of Type 2 diabetes.  
 
In animal studies, COX-mediated pathways have been found to change in Zucker rats, an 
insulin resistant animal model that resembles the characteristics of Type 2 diabetes. For 
example, both COX-1 and COX-2 expression in platelets was increased significantly in obese 
Zucker rats compared with the lean controls (Raju et al. 2006). Renal COX-2, but not COX-1 
expression was also up-regulated in obese Zucker rats (Komers et al. 2005). Less data are 
available in humans, however, the limited available data have indicated that COX-mediated 
pathways may be altered in human Type 2 diabetic subjects. For instance, enhanced levels of 
COX-2 mRNA were found in isolated peripheral blood monocytes from Type 2 diabetic 
patients whereas COX-2 mRNA expression was not detected in human non-diabetic subjects 
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(Shanmugam et al. 2004). High glucose treatment of human THP-1 monocytes resulted in 
NF-κB activation (Miao et al. 2004), which is known to stimulate COX-2 expression. This 
appeared to be linked to enhanced histone acetylation as increased histone acetylation was 
observed near the promoter region of COX-2 in monocytes extracted from human Type 2 
diabetic subjects compared with non-diabetic controls (Miao et al. 2004). These animal and 
human studies suggest that in Type 2 diabetes COX-mediated pathways are altered. Altered 
COX-mediated activities may affect the production of prostanoids, potentially influencing 
vascular tone, platelet and monocyte activity, all of which play important roles in the 
development of diabetic vascular complications. 
 
4.2 AIMS 
There is some evidence that COX-mediated pathways are involved in the development and 
progression of Type 2 diabetes and its complications, but the data is not conclusive. The aim 
of this study was to investigate possible changes of COX-mediated pathways in Type 2 
diabetes. The specific aims were: 
1) to measure changes in COX expression in the platelets and monocytes isolated from 
female Zucker diabetic rats of 25 weeks of age, 
2) to investigate COX-mediated pathways in the platelets and monocytes isolated from 
human subjects by assessing COX protein and plasma COX metabolite levels, 
3) to determine whether COX expression in Type 2 diabetes is associated with histone H4 
hyperacetylation in monocytes. 
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4.3 METHODS 
4.3.1 COX LEVELS IN PLATELETS AND MONOCYTES IN ZUCKER RATS 
4.3.1.1 Collection of blood sample (Zucker rats) 
The present study involved the use of animals. Samples were collected from female Zucker 
rats and kindly given by Professor Julianne Reid and her research unit at RMIT University, 
Melbourne. Female Zucker rats, 25 weeks old, were anesthetized with carbon dioxide 
followed by decapitation. Whole blood (approximately 10 mL) was collected by draining the 
blood from the neck of the rats into a centrifuge tube containing citrate buffer (129 mM 
sodium citrate, pH 7.4) as anticoagulant (1 part citrate buffer: 9 parts blood). The collected 
blood sample was divided equally for platelet or monocyte isolation. 
 
4.3.1.2 Isolation of platelets and monocytes (Zucker rats) 
The collected blood sample (see Section 4.3.1.1) was centrifuged at 150 g for 10 minutes at 
4°C to isolate the platelet-rich plasma. The platelet-rich plasma was collected into an 
eppendorf tube followed by centrifugation at 200 g for 15 minutes at 4°C using a 
microcentrifuge to sediment platelets. The supernatant was then removed at the end of the 
spin and sedimented platelets were washed with excess Tris-citrate buffer (50 mM Tris-HCl, 
137 mM NaCl, 5.4 mM KCl, 1 mM dextrose, pH 7.4, with added citrate buffer; see Section 
4.3.1.1) then centrifuged at 200 g for 10 minutes at 4°C. The washing procedure was repeated 
before re-suspending the platelet pellet in PBS-based lysis buffer (1 mM KH2PO4, 154 mM 
NaCl, and 5.7 mM Na2HPO4, 0.5% Nonidet P-40, 0.01% EDTA, pH 7.4), with added protease 
inhibitors (1 mM PMSF , 0.2 mM leupeptin and 50 μM pepstatin A). Each sample was 
aliquoted into individual eppendorf tubes and stored at -80°C.  
 
The rat monocytes were isolated from the collected blood sample (see Section 4.3.1.1) with 
the mixer flotation technique. In a 50 mL centrifuge tube, 5 mL of whole blood sample was 
mixed with 0.625 mL of a density gradient medium, OptiPrepTM (Nycomed Pharma, Oslo, 
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Norway). To facilitate monocytes flowing to the surface, 0.5 mL of TBS-buffered saline (10 
mM Tricine-NaOH, 0.85% NaCl (w/v), pH 7.4) was layered onto the top of the blood mixture. 
The mixture was centrifuged at 1,300 g for 30 minutes at 4°C. Monocytes were then collected 
from the meniscus downwards to about 0.5 cm from the cell pellet and were transferred into 
another centrifuge tube. To completely remove platelets, the collected materials were diluted 
with an equal volume of TBS-buffered saline, which was layered over an equal volume of 
diluted OptiPrepTM solution (5 volume OptiPrepTM and 22 volume TBS-buffered saline). 
Samples were centrifuged at 350 g for 15 minutes at 4°C. The platelets form a wide band just 
below the interface; the entire liquid phase was aspirated and the monocyte pellet was then 
re-suspended in lysis buffer and protease inhibitors as described in platelet sample preparation 
above. Each sample was aliquoted into individual eppendorf tubes and stored at -80°C. 
 
4.3.1.3 Protein assay (Zucker rats) 
The total protein concentration of the isolated platelet and monocyte samples were determined 
by using the micro bicinchoninic acid (micro BCA) assay system from the Pierce micro BCA 
kit (Pierce, Rockford, IL, USA). The re-suspended samples were diluted 400X with lysis 
buffer (see Section 2.3.3.1). According to the manufacturer’s protocol, the micro BCA 
reagents were mixed and added to protein samples, standards and blanks followed by 
incubation at 60°C for 1 hour before determination of total protein content with a micro plate 
reader at 562 nm absorbance wavelength. Protein standard concentrations ranging from 5 to 
20 μg/mL were prepared from the stock of 2 mg/mL bovine serum albumin protein (Pierce, 
Rockford, IL, USA) and diluted with lysis buffer. Blanks were prepared with lysis buffer 
without any protein content. 
 
4.3.1.4 Western blot: COX protein (Zucker rats) 
The samples were diluted with lysis buffer and reducing buffer (1 mg/mL bromophenol blue, 
20% glycerol, 100 mM dithiothreitol, 2% sodium dodecyl sulphate, pH 6.8) to produce 
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equivalent protein concentrations (usually 40 μg/mL). Samples and molecular weight markers 
(Sigma, St Louis, USA) were placed in eppendorf tubes and denatured at 100°C for 3 minutes 
on a heating block. Samples were loaded in duplicate onto a 10% polyacrylamide gel with a 
final total protein concentration of 10 μg per well. The protein samples and molecular weight 
markers were electrophoresed, transferred onto nitrocellulose membranes and incubated with 
selective COX-1 and COX-2 antibodies using the same Western blot protocol for the 
detection of COX protein expression as in Section 2.3.3. The density of all Western blot bands 
was analyzed using the ChemiDoc™ XRS system (Biorad, CA, USA).  
 
4.3.2 COX LEVELS IN PLATELETS AND MONOCYTES IN TYPE 2 DIABETES 
4.3.2.1 Human subjects (Type 2 diabetes) 
Twenty five (25) non-diabetic control (14 males, 11 females) and 52 Type 2 diabetic (28 
males, 24 females) human subjects were recruited at St. Vincent’s Hospital (Melbourne, 
Australia). The diagnosis of diabetes was made based on plasma glucose levels of venous 
plasma using the diagnostic guideline provided by the Australian Diabetes Society (a single 
fasting plasma glucose level of ≥ 7 mmol/L or 2 hour post-glucose or casual postprandial 
plasma glucose level of ≥ 11.1 mmol/L; Colman et al. 1999). All participants were informed 
of the study by an endocrinologist, Dr. Alicia Jenkins, who was a collaborator of this study. 
Human subjects were required to sign an approved written informed consent prepared by St 
Vincent’s Hospital, Melbourne (HREC-A 024/00 Glycoxidation, HDL and diabetes 
angiopathy). The plain language statement that details the study of the human subjects is 
attached in Appendix. In addition, 14 non-diabetic samples from healthy male human subjects 
collected during a previous project at RMIT University (HREC 15/01 Majewski: 
Age-dependent alterations in cyclooxygenase in platelets and human monocytes) and stored 
away at -80°C were also included in this study. In my role I had no data, which linked any 
results to individual patients by name. 
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4.3.2.2 Collection of human blood samples (Type 2 diabetes) 
The volunteer recruitment and blood sample collection was performed by the endocrinologist, 
Dr. Alicia Jenkins at St Vincent’s Hospital (Melbourne, Australia). Human subjects were 
asked to donate approximately 50 mL of whole blood where possible by a single 
venepuncture. In some cases, human subjects were only asked to donate 37 mL of blood 
sample based on Dr. Jenkins’ professional opinion. For each sample, approximately 5 mL of 
blood were sent to the Pathology Department of the Hospital for the determination of 
hemoglobin A1C, cholesterol and triglyceride levels if the human subjects did not already 
have their blood profile measured. The remaining blood sample was mixed with citrate buffer 
as anticoagulant (see Section 4.3.1.1) and was divided equally for the isolation of platelets and 
monocytes. In some cases, plasma sample was available for collection and was stored at 
-80°C for COX metabolite study. 
 
4.3.2.3 Isolation of human platelets and monocytes (Type 2 diabetes) 
The isolation of human platelets and monocytes was performed using OptiPrepTM solution 
according to the manufacturer’s standard protocol. To isolate platelets, in a centrifuge tube a 
10 mL blood sample was layered over 10 mL density barrier (5 volume OptiPrepTM and 22 
volume of Solution B: 0.85% (w/v) NaCl, 20 mM HEPES-NaOH, pH 7.4, 1 mM EDTA). The 
sample was centrifuged at 350 g for 15 min at 4°C in a swinging-bucket rotor and the rotor 
was allowed to decelerate without the brake. The autologous plasma and the 
platelet-containing band were harvested from the broad turbid band below the interface. The 
collected material was then centrifuged at 400 g for 10 minutes at 4°C before re-suspending 
the pellet in lysis buffer (see Section 4.3.1.2 for lysis buffer recipe) and being processed and 
stored at -80°C as detailed in Section 4.3.1.2. To isolate human monocytes, a 10 mL blood 
sample was mixed gently but thoroughly (by repeated inversion) with 1.25 mL OptiPrepTM in 
a 50 mL centrifuge tube. To facilitate monocyte isolation, 0.5 mL of TBS (0.85% (w/v) NaCl, 
10 mM Tricine-NaOH, pH 7.4) was layered on top and the whole preparation was centrifuged 
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at 1,500 g for 30 min at 4°C. Human monocytes were then purified, collected and processed 
as outlined in Section 4.3.1.2 for further analysis. 
 
4.3.2.4 Protein assay (Type 2 diabetes) 
Determination of human sample protein concentration was performed using the Biorad 
microBCA system as outlined in Section 4.3.1.3. 
 
4.3.2.5 Western blot: COX protein (Type 2 diabetes) 
Human samples were loaded in duplicate with a final total protein concentration of 10 μg per 
well. The protein samples and molecular weight markers were electrophoresed, transferred 
onto nitrocellulose membranes and incubated with selective COX-1 and COX-2 antibodies 
using the same Western blot protocol for the detection of COX protein expressions as in 
Section 4.3.1.4. The density of all Western blot bands was analyzed using the ChemiDoc™ 
XRS system (Biorad, CA, USA).  
 
4.3.3 PLASMA COX METABOLITE STUDY IN TYPE 2 DIABETES 
The Biotrak EIA system (Amersham Bioscience, UK) was chosen to measure plasma TXB2 
and PGE2. Plasma samples contain interfering compounds, which make the already low 
quantity of TXB2 metabolite that is difficult to measure directly by the EIA method. To avoid 
this, plasma TXB2 metabolite had to be extracted from plasma sample prior to measurement 
whereas the level of plasma PGE2 was directly determined by the Biotrak EIA kit. 
 
4.3.3.1 Solid phase extraction of COX metabolites (Type 2 diabetes) 
COX metabolites can be extracted from plasma samples using Solid phase extraction 
procedures with Amprep C2 ethyl minicolumn (100 mg, Amersham Bioscience, UK).  
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4.3.3.1.1 Plasma TXB2 extraction (Type 2 diabetes) 
Extraction of plasma TXB2 was performed according to the manufacturer’s protocol using 
Amprep C2 minicolumn (Amersham Bioscience, UK). Briefly, Amprep C2 minicolumn was 
conditioned and activated by 2 mL methanol and 2 mL milliQ water followed by 1 mL 
acidified plasma sample (2M HCl, pH 3). The minicolumn was then washed in sequence with 
5 mL of milliQ water, 10% ethanol and hexane to elute away interference. Analyte was then 
collected with 500 μL elution solvent, methyl formate, which was evaporated under nitrogen. 
The extracted TXB2 was determined with the Biotrak EIA system (see Section 4.3.3.2 for 
details). 
 
4.3.3.1.2 Solid phase extraction validation (Type 2 diabetes) 
In order to verify the solid phase extraction procedure and analyte recovery, a known amount 
of PGE standard (PGE2, 1 ng/mL; Sigma, St Louis, USA) was passed through a conditioned 
minicolumn in place of the acidified plasma sample as described in Section 4.3.3.1.1. PGE2 
standard was collected with the elution solvent, methyl formate in four different volumes (500 
μL, 1, 1.5 and 2 mL). Extracts were then dried under nitrogen followed by the determination 
of PGE2 recovery by the Biotrak EIA system.  
 
4.3.3.2 Amersham Biotrak EIA system (Type 2 diabetes) 
The PGE2 EIA Biotrak System allows a direct determination of plasma PGE2 levels without 
the need for PGE2 extraction. The measurement of extracted TXB2 metabolites and plasma 
PGE2 were performed using the TXB2 and PGE2 EIA Biotrak System, respectively 
(Amersham Bioscience, UK). Briefly, the Biotrak EIA system is based on the competition 
between unlabelled TXB2 or PGE2 and a known quantity of peroxidase-labeled TXB2 or PGE2 
for a given number of binding sites on a TXB2 or PGE2 specific antibody. The amount of 
peroxidase-labeled ligand bound by the antibody is inversely proportional to the concentration 
of added unlabelled ligand. Peroxidase-labeled TXBB2 or PGE2 bound to the antibody is 
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immobilized by the secondary antibody which was pre-coated to the wells of the EIA system. 
The addition of a tetramethylbenzidine/hydrogen peroxide single pot substrate allows the 
determination of the amount of peroxidase-labeled TXB2 or PGE2. The reaction is then 
terminated by the addition of sulphuric acid (1 M, 100 μL/well, Sigma, St Louis, USA). The 
optical density was read at 450 nm immediately.  
 
4.3.4 ACETYLATED HISTONE H4 LEVELS IN TYPE 2 DIABETES 
4.3.4.1 Isolation of histones from human monocytes (Type 2 diabetes) 
Histones were isolated from human monocytes as previously described in Section 2.3.2 
 
4.3.4.2 Western blot: acetylated histone H4 protein (Type 2 diabetes) 
Histone samples extracted in Section 4.3.4.1 were electrophoresed on a 15% SDS-PAGE gel 
and labelled with anti-rabbit polyclonal anti-acetyl histone H4 antibody (Upstate, NY, USA) 
according to standard Western blot procedures outlined in Section 2.3.3.2. 
 
4.3.5 DRUGS AND CHEMICALS 
Dextrose, HCl, methyl formate, Nonidet P-40, sodium citrate, Tricine-NaOH; BDH Chemical 
(Kilsyth, Victoria, Australia). PGE2, sulphuric acid; Sigma (St Louis, USA). OptiPrepTM; 
Nycomed Pharma (Oslo, Norway). Other drugs and chemicals used in the preparation of 
buffers/solutions and present Western blot experiments were the same as that used in Chapter 
2 and thus, were obtained from the same sources (see Section 2.3.4). 
 
4.3.6 STATISTICAL ANALYSES 
All values are given as the mean ± standard error of mean (S.E.) and n indicates the number 
of observations. Differences in the percentage densities of Western blot bands were analyzed 
using Student’s t-test (unpaired and paired), Mann-Whitney test, 1-way ANOVA and post-hoc 
tests (Tukey’s, Games-Howell and Dunn’s multiple tests), Pearson Chi-Square and Fisher’s 
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exact test whenever applicable. SPSS (SPSS Inc., IL, USA) and Prism (GraphPad Software, 
Inc., CA, USA) statistical packages were used in statistical analyses.  
 
4.3.7 ANIMAL AND HUMAN ETHICS APPROVAL 
All procedures used for animal blood/tissue collection were approved by the Animal Ethics 
Committee of RMIT University (Melbourne, Australia) and the investigation conforms to the 
Australian code of practice for the care and use of animals for scientific purposes published 
by the National Health and Medical research Council of Australia. All procedures used for 
human blood collection were approved by the Human Research Ethics Committee of St. 
Vincent’s Hospital (Melbourne, Australia; HREC-A 024/00 Glycoxidation, HDL and diabetes 
angiopathy) in accordance with the National Statement on Ethical Conduct in Research 
Involving Humans (June 1999) produced by the National Health and Medical Research 
Council of Australia. A separate set of human samples from another study was included in the 
present study. The collection of these samples was approved by the Human Research Ethics 
Committee of RMIT University (Melbourne, Australia; HREC 15/01 Majewski: 
Age-dependent alterations in cyclooxygenase in platelets and human monocytes).  
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4.4 RESULTS 
4.4.1 COX LEVELS IN PLATELETS AND MONOCYTES IN ZUCKER RATS 
4.4.1.1 Western blotting method validation (Zucker rats) 
4.4.1.1.1 Specificity of COX primary antibodies (Zucker rats) 
The specificity of the COX primary antibodies (murine anti-ovine COX-1 monoclonal 
antibody, Cayman, MI, USA and mouse anti-COX-2 monoclonal antibody, BD Biosciences, 
CA, USA) was tested by incubating samples with the secondary antibody only. The absence 
of COX bands confirmed the specificity of the antibodies to targeted COX proteins (Figure 
4-1). 
 
4.4.1.1.2 COX expression at correct molecular weight (Zucker rats) 
In order to verify that the bands on the gels were corresponding to COX-1 and COX-2 
proteins, molecular weight standards were run parallel to all samples (Figure 4-1). Detected 
protein bands were compared with the manufacturer’s values of molecular weight standards 
corresponding to approximately 70 kD (69 kD for COX-1 and 72 kD for COX-2; see Davidge 
2001), which is the established molecular weight for both COX-1 and COX-2 proteins (see 
Reviews by Smith et al. 1996; Golden & Abramson 1999). 
 
4.4.1.1.3 Sample loading determination (Zucker rats) 
A series of protein concentrations (5 to 20 μg/lane) was performed in selected samples to 
determine the most suitable sample loading concentration. It was found that 10 μg of total 
protein from platelet and monocyte samples produced one clear 69 kD band of COX-1 and 72 
kD band of COX-2 protein expression, respectively (Figure 4-1).  
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4.4.1.1.4 Internal standard (Zucker rats) 
On every gel, a COX standard prepared from 8 week-old, male Sprague-Dawley rats was run 
parallel with all samples. To normalize possible density differences between gels, the densities 
of all COX-1 and COX-2 bands were expressed as a percentage of the respective platelet or 
monocyte standard band, which was standardized at 100%. 
 
4.4.1.2 Western blot: COX levels in platelets and monocytes in Zucker rats 
Immunoblotting studies shown in Figure 4-2 summarize COX-1 and COX-2 protein levels in 
the respective platelet and monocyte samples isolated from lean and obese female Zucker rats. 
It was observed that the platelets and monocytes isolated from obese Zucker rats expressed 
higher platelet COX-1 and monocyte COX-2 protein levels compared to lean Zucker rats 
(Figure 4-2). 
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A.  COX-1 Zucker rats
Figure 4-1
B.  COX-1 negative control Zucker rats
C.  COX-2 Zucker rats
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Figure 4-1
Western blot validation: COX protein levels in platelets and monocytes (Zucker rats)
Western blot validation for platelet COX-1 and monocyte COX-2 in female Zucker rat. Panels A 
and C: A signal for COX-1 and COX-2, respectively, was evident at 70 kD according to molecular 
weight markers. Panels B and D: COX-1 and COX-2 immuno-reactivity was verified by negative 
controls, which were performed with omission of the COX primary antibodies but in the presence of 
the secondary antibodies. Lane a: internal standard, lanes b + c: duplicate samples from lean Zucker 
rats, lanes d + e: duplicates samples from obese Zucker rats. A series of sample loading 
concentrations was performed to determine the final protein loading for COX-1 (Panels E and F) 
and COX-2 (Panels G and H). Lanes f to i represent 5, 10, 15 and 20 μg protein loading. A final 
protein loading of 10 μg per lane was chosen, because this was the concentration at which the 
minimal amount of sample was required to produce a reliable and clear band. Higher protein 
loading resulted in the risk of signal saturation.
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Figure 4-2
 
Figure 4-2 
Quantitative densitometry of COX proteins in Zucker rats 
Panel A: Platelet COX-1 protein expression was measured in lean and obese Zucker rats. Panel B: Monocyte 
COX-2 protein expression was measured in lean and obese Zucker rats. A rat platelet or monocyte standard 
control was run with each Western blot and the density of all sample bands were expressed as a percentage of the 
corresponding standard control. In all cases, 10 μg of total protein of platelet or monocyte samples was used. 
Values represent the mean, S.E. and number of Zucker rats. * significant difference from lean values, p<0.001, 
unpaired Student’s t-test; # significant difference from lean values, p<0.05, Mann Whitney test. 
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4.4.2 COX-MEDIATED PATHWAYS IN TYPE 2 DIABETES 
4.4.2.1 Basis parameters of human Type 2 diabetic subjects 
Human subject selection was made by Dr. Alicia Jenkins at St. Vincent’s Hospital, Melbourne, 
Victoria for another research project, which had broad selection criteria. The present study did 
not exclude any samples collected including samples from smokers and hypertensive human 
subjects in control groups. The goal of this was to have a sample population that resembled 
the characteristics of the general population. One exception was COX inhibition. Human 
subjects on non-steroidal anti-inflammatory drugs were separated from the rest of the sample 
population and treated separately. Thus the three groups in the present study were: 39 human 
control subjects (28 males, 11 females), 28 human Type 2 diabetic subjects (13 males, 15 
females) and 23 human Type 2 diabetic subjects on NSAIDs (14 males, 9 females). A 
summary of the physiological parameters, blood examination and pharmacological 
interventions of these human subjects is detailed in Table 4-1 and Table 4-2. Human Type 2 
diabetic subjects were older than human control subjects and were characterized by greater 
weight, BMI, serum glucose and hemoglobin A1C levels. White blood cell counts were 
significantly greater in human Type 2 diabetic subjects who were not on NSAIDs compared 
with human control subjects. Human Type 2 diabetic subjects taking NSAIDs had lower 
levels of high density lipoprotein and hemoglobin compared with the control group, although 
the readings were within normal ranges. The incidence of vascular complications, 
hypertension and hyperlipidemia was higher in human Type 2 diabetic subjects, particularly 
human subjects taking NSAIDs compared with human non-diabetic subjects (Table 4-2). 
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* p<0.05, significant difference from the control group (1-way ANOVA, Tukey's or Games-Howell multiple comparison). 
n indicates the number of subjects. Some subjects did not have a full blood examination.
<0.20±00±00±0Basophils (x109/L)
<0.60.2±00.2±00.2±0Eosinophils (x109/L)
<1.00.6±0.10.5±0.10.5±0Monocytes (x109/L)
1.0-4.02.2±0.32.3±0.31.8±0.1Lymphocytes (x109/L)
2.0-8.04.0±0.55.0±0.63.6±0.3Neutrophils (x109/L)
4.0-11.07±0.77.9±0.6*6.2±0.4White cell count (x109/L)
27-3229.6±0.830.8±0.730.5±0.4Mean corpuscular hemoglobin (pg)
80-9888.9±2.192.2±1.991±1.1Mean corpuscular volume (fL)
0.4-0.540.4±00.4±00.4±0Packed cell volume
4.6-6.24.5±0.24.6±0.24.8±0.1Red blood cells (x 1012/L)
130-180130.9±4*140.2±3.5145.5±2Hemoglobin (g/L)
150-400214±23261±20245±12Platelets (x109/L)
<3.52.3±0.22.9±0.22.8±0.2Low density lipoprotein (mmol/L)
>1.01.1±0.1*1.3±0.11.4±0.1High density lipoprotein (mmol/L)
<2.02.3±0.32.2±0.31.8±0.3Triglyceride (mmol/L)
<5.54.5±0.25.0±0.24.9±0.2Cholesterol (mmol/L)
4.0-6.08.0±0.3*8.2±0.3*5.2±0.3Hemoglobin A1C (%)
3.0-7.711.5±1.1*12.1±1.2*4.9±1Serum glucose (mmol/L)
18.5-24.940.3±2.2*32±2.124.5±1BMI (kg/m2)
-94.3±4.3*91.7±3.9*74.5±3.7Weight (kg)
-162.8±3.6*166.9±3.6174±1.7Height (cm)
-67±2.8*60.5±2.6*37.9±2.2Age (years)
-14/913/1528/11Gender (male/female)
n=23n=28n=39
Normal rangeType 2 diabetes with NSAIDsType 2 diabetesControl 
Table 4-1
Physiological parameters of human subjects in Type 2 diabetic study
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Table 4-2
Clinical characteristics of human subjects in Type 2 diabetic study
control Type 2 diabetes Type 2 diabeteswith NSAIDs
n =39 n =28 n =23 Acrossgroup
Between Type
2 diabetes
Gender (male/female) 28/11 13/15 14/9
Smokers 2 7 3
Micro-vascular complication 0 8 12 p <0.05
  Retinopathy 0 3 6 p <0.05
  Nephropathy 0 4 7 p <0.05
  Neuropathy 0 4 2
Macro-vascular complication 0 4 13 p <0.05 p <0.05
  Ischemic heart diseases 0 4 13 p <0.05 p <0.05
Medication
  Insulin 0 13 14 p <0.05
  Metformin 0 15 12 p <0.05
  Sulfonylurea 0 6 6 p <0.05
  Fibrate 0 1 2
  Statin 0 10 12 p <0.05
  Anti-coagulants 0 2 3
  Nitrate 0 0 0
  Diuretics 0 4 5 p <0.05
  Aspirin 0 0 19 p <0.05 p <0.05
  COX-2 selective inhibitors 0 0 2
  Other NSAIDs 0 0 17 p <0.05 p <0.05
  Other medications 0 14 14 p <0.05
Disease
  Hypertension 2 16 23 p <0.05 p <0.05
  Hyperlipidemia 8 16 20 p <0.05 p <0.05
  Depression/schizophrenia 0 1 2
  Asthma 0 2 1
  Other conditions 0 18 14 p <0.05
Chi-square/Fisher's
exact test
n  indicates the number of subjects. Some subjects did not have a full blood examination.
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4.4.2.2 Experimental protocol validations 
4.4.2.2.1 Specificity of Western blot: COX (humans) 
COX-1 and COX-2 protein bands were determined and verified against their corresponding 
molecular weight at approximately 70 kD. The specificity of the COX primary antibodies was 
further assessed by incubating samples with the secondary antibodies only. The absence of 
COX bands at 70 kD in this case confirmed the specificity of the primary antibodies to COX 
proteins (Figure 4-3). A series of sample protein concentration was performed to determine 
the suitable loading concentrations. Density analysis indicated that 10 μg of total protein was 
the loading requirement for detecting a clear COX protein band that was not over saturated 
(Figure 4-3).  
 
4.4.2.2.2 Western blot data reproducibility: COX (humans) 
Type 2 diabetic study was done concurrently with Type 1 diabetic study. Data for Type 1 
diabetes will be the subject of Chapter 5. All validation studies for both studies were 
performed using samples collected from Type 1 diabetes. COX protein levels were measured 
in two samples collected from 6 human Type 1 diabetic subjects at separate occasions 
(Section 5.3.1.2). The values obtained were very consistent indicating both assay accuracy 
and reproducibility after time of COX levels in the same human subjects (Figure 4-4).  
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A. COX-1
Figure 4-3
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Figure 4-3
Western blot validation: COX protein levels in platelets and monocytes (humans)
Western blot validation for platelet COX-1 and monocyte COX-2 in humans. Panels A and C: A 
signal for COX-1 and COX-2, respectively, was evident at 70 kD according to molecular weight 
markers. Panels B and D: COX-1 and COX-2 immuno-reactivity was verified by negative controls, 
which were performed with omission of the COX primary antibodies but in the presence of the 
secondary antibodies. Lane a: internal standard, lanes b + c: duplicate samples from human control 
subjects, lanes d + e: duplicates samples from Type 2 diabetic human subjects. A series of sample 
loading concentrations was performed to determine the final protein loading for COX-1 (Panel E and 
F) and COX-2 (Panels G and H). Lanes f to i represent 5, 10, 15 and 20 μg protein loading. A final 
protein loading of 10 μg per lane was chosen, because this was the concentration at which the 
minimal amount of sample was required to produce a reliable and clear band. Higher protein loading 
resulted in the risk of signal saturation.
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Figure 4-4
A.  COX-1 (repeated sample) B.  COX-2 (repeated sample)
 
 
Figure 4-4 
Reproducibility of COX protein expression in human Type 1 diabetic subjects  
COX expression in human platelets and monocytes from individual human Type 1 diabetic subjects taken on 
separate occasions (sets A and B). Panel A: Platelet COX-1 protein expression measured in repeated samples 
from 6 human Type 1 diabetic subjects. Panel B: Monocyte COX-2 protein expression measured in repeated 
samples from 6 human Type 1 diabetic subjects. A rat platelet or monocyte standard control was run with each 
Western blot and the density of all sample bands was expressed as a percentage of the corresponding standard 
control. p>0.05, paired Student’s t-test. 
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4.4.2.2.3 Solid phase extraction of COX metabolite validation: recovery of analyte 
(humans) 
Figure 4-5A summarizes the validation of the metabolite extraction method. Eluting analyte 
with 500 μL methyl formate produced 87.7% metabolite recovery whereas larger eluting 
solvent volumes (1.5 and 2 mL methyl formate) produced a slightly better metabolite recovery 
(90.6 and 90.7%, respectively). The time required to evaporate methyl formate more than 500 
μL, however, was longer than 30 minutes per sample. This extended drying time was not 
practical and may also have affected the integrity of extracted metabolites. Given this 
consideration, an eluting volume of 500 μL methyl formate was satisfactory. No correction for 
recovery was performed, but the variability was very minimal and repeat analyses were 
reproducible (Figure 4-5B). 
 
4.4.2.2.4 EIA method: Data reproducibility (humans) 
Plasma levels of TXB2 and PGE2 were measured in repeated samples collected from 6 human 
Type 1 diabetic subjects at separate occasions (see Section 5.3.1.2). The values obtained were 
very consistent indicating both EIA assay accuracy and reproducibility after time of plasma 
TXB2 and PGE2 levels in the same human subjects (Figure 4-5B).
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B.  Plasma TXB2 (repeated sample) C.  Plasma PGE2 (repeated sample)
A.  Plasma COX metabolite extraction
 
Figure 4-5 
Method validation and reproducibility of plasma COX metabolites 
COX metabolite extraction method was studied using a known standard to assess the recovery of the extraction 
method. Data accuracy and reproducibility was further studied by measuring COX metabolites at plasma level 
from individual human Type 1 diabetic subjects taken on separate occasions (sets A and B). Panel A: A PGE2 
standard (1 ng/mL) was used to estimate the recovery of the extraction method. The standard was applied to a 
conditioned C2 minicolumn followed by washing away interference and eluting analyte with various volumes of 
methyl formate. Values represent the mean, S.E. and number of independent experiments. * represents 
significant difference from 0.5 mL; 1-way ANOVA (Tukey’s multiple comparison test). Panel B: Plasma TXB2 
was measured in repeated samples obtained from 6 human Type 1 diabetic subjects. Panel C: PGE2 was 
measured in repeated samples obtained from 6 human Type 1 diabetic subjects. p>0.05, paired Student’s t-test. 
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4.4.2.3 Influence of ages on sample population (Type 2 diabetes) 
There was a difference in age between control and Type 2 diabetic groups (37.9±2.2 and 
60.5±2.6 years old, respectively. p<0.001, unpaired Student’s t-test, Table 4-1). Correlation 
analyses were performed to analyze the relationship between COX expression and age of the 
human subjects. Platelet COX-1 was not correlated with age. Monocyte COX-2, in contrast, 
was correlated with advancing age (Figure 4-6). 
 
4.4.2.3.1 Age-matching procedures 
To correct for age-dependent effects on COX expression, ages for both groups was matched 
so that control and Type 2 diabetic age ranges were the same. This meant that older human 
diabetic subjects (>66 years old) were excluded as were younger human control subjects (<29 
years old). Then each human control subject was age-matched with the closest human Type 2 
diabetic subject and both human subjects then eliminated from the matching pool. This 
age-matching process continued until all human control subjects were matched with an 
individual Type 2 diabetic subject. The result of this process was closely matched mean ages 
of 50.0±2.4 and 53.0±2.6 years old, which were not significantly different (Table 4-3). The 
process, however, eliminated 29 human subjects from the original pool.  
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Figure 4-6
A.  Platelet COX-1 B.  Monocyte COX-2
 
Figure 4-6  
Correlation analysis on COX expression and age of human subjects (Type 2 diabetes) 
The relationship between COX expression and age of the human subjects was investigated. Panel A: Scatter plot 
of the densities of COX-1 human platelet samples in relation to age. Panel B: Scatter plot of the densities of 
COX-2 human monocyte samples in relation to age. R2 represents correlation coefficient. * represent significant 
correlation, p<0.05, Pearson test. 
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* p<0.05, significant difference from  control group (unpaired Student's t-test). 
n indicates the number of subjects.  Some subjects did not have a full blood examination.
<0.20±00±0Basophils (x109/L)
<0.60.2±00.2±0Eosinophils (x109/L)
<1.00.5±00.4±0Monocytes (x109/L)
1.0-4.02.4±0.2*1.8±0.2Lymphocytes (x109/L)
2.0-8.05.2±0.84±0.4Neutrophils (x109/L)
4.0-11.08.3±1*6.5±0.5White cell count (x109/L)
27-3230±0.731±0.3Mean corpuscular hemoglobin (pg)
80-9891±293±1Mean corpuscular volume (fL)
0.4-0.540.4±00.4±0Packed cell volume
4.6-6.24.7±0.24.6±0.1Red blood cells (x 1012/L)
130-180140±3142±0.1Hemoglobin (g/L)
150-400278±23257±18Platelets (x109/L)
<3.53±0.33.1±0.3Low density lipoprotein (mmol/L)
>1.01.2±0.11.5±0.1High density lipoprotein (mmol/L)
<2.02.3±0.42.2±0.5Triglyceride (mmol/L)
<5.55±0.35.3±0.2Cholesterol (mmol/L)
4.0-6.08.2±0.4*5.2±0.1Hemoglobin A1c (%)
3.0-7.713±3.1*5.1±0.3Serum glucose (mmol/L)
18.5-24.933±3.7*26±1.2BMI
-95±6.2*76±23.7Weight (kg)
-170±7.3171±1.5Height (cm)
-53±2.650±2.4Age (years)
-9/1011/8Gender (male/female)
n=19n=19
Normal rangeType 2 diabetesControl 
Table 4-3
Physiological parameters of human subjects in Type 2 diabetic study (age-matched)
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Table 4-4
Clinical characteristics of human subjects in Type 2 diabetic study (age-matched)
control Type 2 diabetes Fisher's exact test
n =19 n =19
Gender (male/female) 11/8 9/10
Smokers 1 6
Micro-vascular complication 0 6 p <0.05
  Retinopathy 0 2
  Nephropathy 0 3
  Neuropathy 0 3
Macro-vascular complication 0 1
  Ischemic heart diseases 0 1
Medication
  Insulin 0 10 p <0.05
  Metformin 0 12 p <0.05
  Sulfonylurea 0 3
  Fibrate 0 1
  Statin 0 7 p <0.05
  Anti-coagulants 0 1
  Nitrate 0 0
  Diuretics 0 3
  Aspirin 0 0
  COX-2 selective inhibitors 0 0
  Other NSAIDs 0 0
  Other medications 0 8 p <0.05
Disease
  Hypertension 2 8
  Hyperlipidemia 6 10
  Depression/schizophrenia 0 1
  Asthma 0 2
  Other conditions 0 11 p <0.05
n  indicates the number of subjects. Some subjects did not have a full blood examination.
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4.4.2.4 COX levels in Type 2 diabetes 
Initial analyses on non age-matched human subjects revealed a significant increase in 
monocyte COX-2 expression in human Type 2 diabetic subjects compared with human control 
subjects while platelet COX-1 protein expression remained unchanged (Figure 4-7). In 
age-matched sub-analyses, previously increased monocyte COX-2 expression disappeared 
and there were no differences and in age-matched human subjects platelet COX-1 levels were 
not significantly different (Figure 4-8). Further analysis on physiological parameters showed 
that platelet COX-1 expression was elevated in human subjects with hyperlipidemia (Figure 
4-9). COX-1 levels in platelets were significantly higher in human non-diabetic subjects with 
hyperlipidemia whereas COX-1 levels were not affected by hyperlipidemia in Type 2 diabetes 
(Figure 4-9). 
 
4.4.2.5 Plasma COX metabolites in Type 2 diabetes  
The level of COX metabolites, TXB2 and PGE2 was measured in the plasma. It was found that 
plasma PGE2 level, but not TXB2 level was significantly higher in human Type 2 diabetic 
subjects compared with human control subjects in non age-matched groups (Figure 4-7). This 
elevation in plasma PGE2 level in human Type 2 diabetic subjects appeared to be 
age-independent as shown in age-matched analyses where PGE2 levels were still elevated 
(Figure 4-8).  
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Figure 4-7
A.  COX-1 (non age-matched) B. COX-2 (non age-matched)
C.  TXB2 (non age-matched) D.  PGE2 (non age-matched)
 
Figure 4-7 
Quantitative densitometry of COX protein expression and plasma metabolites in human subjects  
(Type 2 diabetes, non age-matched) 
Non age-matched analysis of COX expression in human platelets and monocytes and plasma COX metabolites. 
Panel A: Platelet COX-1 protein expression was measured in control and human Type 2 diabetic subjects. Panel 
B: Monocyte COX-2 protein expression measured in control and human Type 2 diabetic subjects. A rat platelet 
or monocyte standard control was run with each Western blot and the density of all sample bands was expressed 
as a percentage of the corresponding standard control. Panel C and Panel D: Plasma level of TXB2 and PGE2 
were measured using EIA. Values represent the mean, S.E. and number of human subjects. * significant 
difference from human control subjects, p<0.01, Mann Whitney test; N.S. represents not significant, p>0.05, 
unpaired Student’s t-test or Mann Whitney test. 
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Figure 4-8
A.  COX-1 (age-matched) B.  COX-2 (age-matched)
C.  TXB2 (age-matched) D.  PGE2 (age-matched)
 
 
Figure 4-8 
Quantitative densitometry of COX protein expression and plasma metabolites in human subjects  
(Type 2 diabetes, age-matched) 
Age-matched analysis of COX expression in human platelets and monocytes and plasma COX metabolites. 
Panel A: Platelet COX-1 protein expression was measured in control and human Type 2 diabetic subjects. Panel 
B: Monocyte COX-2 protein expression measured in control and human Type 2 diabetic subjects. A rat platelet 
or monocyte standard control was run with each Western blot and the density of all sample bands was expressed 
as a percentage of the corresponding standard control. Panel C and Panel D: Plasma level of TXB2 and PGE2 
were measured using EIA. Values represent the mean, S.E. and number of human subjects. * significant 
difference from human control subjects, p<0.01, Mann Whitney test; N.S. represents not significant, p>0.05, 
unpaired Student’s t-test or Mann Whitney test. 
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Figure 4-9 
Quantitative densitometry of platelet COX-1 protein expression in human subjects  
(Type 2 diabetes, hyperlipidemia, non age-matched) 
Non age-matched analysis of COX-1 expression in human platelets. Panel A: Platelet COX-1 protein expression 
was measured in human subjects with and without hyperlipidemia. Panel B: Sub-analysis of platelet COX-1 
protein expression was measured in human subjects with and without hyperlipidemia. A rat platelet standard 
control was run with each Western blot and the density of all sample bands was expressed as a percentage of the 
corresponding standard control. Values represent the mean, S.E. and number of human subjects. * significant 
difference from human subjects without hyperlipidemia, p<0.05, unpaired Student’s t-test; # significant 
difference from human control subjects without hyperlipidemia, p<0.05, 1-way ANOVA (Tukey’s multiple 
comparison test).  
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4.4.3 ACETYLATED HISTONE H4 LEVELS IN MONOCYTES IN TYPE 2 
DIABETES 
4.4.3.1 Method validations 
A series of method validations was performed to ensure the data produced by Western blot 
were accurate and reproducible.  
 
Acetylated histone H4 bands were determined and verified against the molecular weight at 10 
kD. The specificity of the primary histone antibody was further assessed by incubating 
samples with the secondary antibody only. The absence of histone H4 bands at 10 kD 
confirmed the specificity of the primary antibody to histone H4 proteins (Figure 4-10). A 
series of loadings was performed with selected samples to ensure the accuracy of target 
protein detected (Figure 4-10).   
 
Histone H4 protein expression measured in two samples collected from 6 human Type 1 
diabetic subjects at separate occasions (see Section 5.3.1.2 for the recruitment of human Type 
1 diabetic subjects). The values obtained were very consistent suggesting both Western blot 
procedure accuracy and reproducibility over time of acetylated histone H4 in samples 
collected from the same human subjects (Figure 4-11). 
 
4.4.3.2 Acetylated histone H4 levels in Type 2 diabetes 
Initial analyses on non age-matched human subjects did not reveal any significant change in 
monocyte acetylated histone expression in human Type 2 diabetic subjects compared with 
human control subjects (Figure 4-12). Furthermore, histone H4 acetylation in monocytes 
isolated from human Type 2 diabetic subjects remained unchanged compared with 
age-matched human control subjects (Figure 4-12).  
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A.  Acetylated histone H4
Figure 4-10
B.  Acetylated histone H4 negative control
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Figure 4-10
Western blot validation: acetylated histone H4 protein levels in monocytes (humans)
Western blot validation for monocyte acetylated histone H4 in humans. Panel A: A signal for 
acetylated histone H4 was evident at 10 kD according to molecular weight markers. Panel B: 
Acetylated histone H4 immuno-reactivity was verified by negative controls, which was 
performed with omission of the acetylated histone H4 primary antibody but in the presence of 
the secondary antibody. Lane a: internal standard, lanes b + c: duplicate samples from human 
control subjects, lanes d + e: duplicates samples from Type 2 diabetic human subjects. Panels 
C and D: A series of sample loading concentrations was performed to determine the final 
protein loading for acetylated histone H4. Lanes f to i represent 5, 10, 15 and 20 μg protein 
loading. A final protein loading of 10 μg per lane was chosen, because this was the 
concentration at which the minimal amount of sample was required to produce a reliable and 
clear band. Higher protein loading resulted in the risk of signal saturation.
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Figure 4-11
 
ken on 
s (sets A and B). A rat histone standard control was run with each Western blot and the density 
of all sample bands was expressed as a percentage of the corresponding standard control. p>0.05, paired 
Student’s t-test. 
 
Figure 4-11 
Reproducibility of histone H4 acetylation in human Type 1 diabetic subjects  
Monocyte histone H4 acetylation levels were measured from individual human Type 1 diabetic subjects ta
separate occasion
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Figure 4-12 
Quantitative densitometry of histone H4 acetylation in human subjects (Type 2 diabetes) 
Level of histone H4 acetylation in human monocytes. Panel A: Non age-matched analysis of acetylated histone 
H4 in human monocytes. Panel B: Age-matched analysis of acetylated histone H4 in human monocytes. A rat 
histone H4 standard control was run with each Western blot and the density of all sample bands was expressed as 
a percentage of the corresponding standard control. Values represent the mean, S.E. and number of human 
subjects. N.S. represents not significant, p>0.05, Mann Whitney test or unpaired Student’s t-test. 
0
100
200
300
19      19
B Acetylated histone H4
 (age-matched)
M
on
oc
yt
e 
ac
et
yl
at
ed
 h
is
to
ne
 H
4
(%
 o
f i
nt
er
na
l s
ta
nd
ar
d)
control    T2 diabetes
N.S.
0
100
200
300
control   T2 diabetes
39 28M
on
oc
yt
e 
ac
et
yl
at
ed
 h
is
to
ne
 H
4
(%
 o
f i
nt
er
na
l s
ta
nd
ar
d)
A.  Acetylated histone H4
     (non age-matched)
Figure 4-12
N.S.
  
113 
4.4.4 EFFECT OF NSAIDS ON TYPE 2 DIABETES 
4.4.4.1 Effect of NSAIDs on COX, TXB2, PGE2 and acetylated histone H4 levels in Type 
2 diabetes 
Human Type 2 diabetic subjects with NSAID treatment regime showed a significant reduction 
in platelet COX-1 and monocyte COX-2 expression compared to human Type 2 diabetic 
subjects without NSAIDs (Figure 4-13). There was a decrease in plasma TXB2 and PGE2 
levels in human Type 2 diabetic subjects taking NSAIDs compared to human Type 2 diabetic 
subjects not taking NSAIDs (Figure 4-13). Monocytes of human Type 2 diabetic subjects 
taking NSAIDs expressed markedly lower acetylated histone H4 proteins compared to non 
age-matched human Type 2 diabetic subjects not taking NSAIDs (Figure 4-14). 
  
114 
0
100
200
300
*
Pl
at
el
et
  C
O
X-
1
(%
 o
f i
nt
er
na
l s
ta
nd
ar
d)
39            28  23
control
    T2
diabetes
T2 diabetes
+ NSAIDs
0
100
200
300
#
39            28  22
control
    T2
diabetes
T2 diabetes
+ NSAIDs
M
on
oc
yt
e 
C
O
X-
2
(%
 o
f i
nt
er
na
l s
ta
nd
ar
d)
#
0
1
2
3
4
5
6
*
19            17  14
control
    T2
diabetes
T2 diabetes
+ NSAIDs
Pl
as
m
a 
TX
B
2
(p
g/
m
L) N.S.
0
10
20
30
40
50
60
70
^
19            20  18
control
    T2
diabetes
T2 diabetes
+ NSAIDs
Pl
as
m
a 
PG
E
2
(p
g/
m
L)
^
Figure 4-13
A.  COX-1 B.  COX-2
C.  Plasma TXB2 D.  Plasma PGE2
 
Figure 4-13 
Quantitative densitometry of COX protein expression and plasma metabolites in the presence of NSAIDs 
in human subjects (Type 2 diabetes, non age-matched) 
Non age-matched analysis of COX expression in human platelets and monocytes and plasma COX metabolites 
in the presence of NSAIDs. Panel A: Platelet COX-1 protein expression was measured in human Type 2 diabetic 
subjects with and without NSAIDs. Panel B: Monocyte COX-2 protein expression measured in human Type 2 
diabetic subjects with and without NSAIDs. A rat platelet or monocyte standard control was run with each 
Western blot and the density of all sample bands was expressed as a percentage of the corresponding standard 
control. Panel C and Panel D: Plasma level of TXBB2 and PGE2 were measured using EIA. Values represent the 
mean, S.E. and number of human subjects. * and ^ significant difference from Type 2 diabetes not taking 
NSAIDs, p<0.05, 1-way ANOVA (Dunn’s multiple comparison test); # significant difference from Type 2 
diabetes not taking NSAIDs, p<0.05, 1-way ANOVA (Tukey’s multiple comparison test); N.S. represents not 
significant from Type 2 diabetes not taking NSAIDs, p>0.05, 1-way ANOVA (Dunn’s multiple comparison test). 
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Figure 4-14 
Quantitative densitometry of histone H4 acetylation in human subjects in the presence of NSAIDs in 
human subjects (Type 2 diabetes, non age-matched) 
The level of histone H4 acetylation in monocytes was measured in non age-matched human Type 2 diabetic 
subjects with and without NSAIDs. A rat histone H4 standard control was run with each Western blot and the 
density of all sample bands was expressed as a percentage of the corresponding standard control. Values 
represent the mean, S.E. and number of human subjects. * significant difference from Type 2 diabetes without 
NSAIDs, p<0.001, 1-way ANOVA (Dunn’s multiple comparison test).  
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4.5 DISCUSSION  
The two questions of this current study were whether COX-1 and COX-2 expression was 
altered in Type 2 diabetes and if so, could this be associated with altered histone acetylation? 
The animal model used was obese Zucker rats, which has several of the elements of Type 2 
diabetes including hyperglycemia, obesity, dyslipidemia and hypertension (see Review by 
Kasiske et al. 1992). The human subjects were Type 2 diabetic patients from a hospital clinic. 
The two cell types studied were platelets and monocytes. 
 
4.5.1 COX LEVELS IN PLATELETS AND MONOCYTES IN ZUCKER RATS  
4.5.1.1 COX-1-mediated pathway in platelets in Zucker rats  
Obese Zucker rats have been extensively used as a model of Type 2 diabetes as they exhibit 
several characteristics of Type 2 diabetes including hyperglycemia, obesity, dyslipidemia and 
hypertension. In the present study, COX-1 levels in platelets were measured in obese Zucker 
rats and found to be elevated compared to lean Zucker rats (Figure 4-2). Similar finding has 
also been reported by Raju et al. (2006) in the platelets of obese Zuker rats. Hyperactive 
platelets have been reported by Schafer et al. (2004) in the young Zucker rats with impaired 
glucose tolerance and increased COX-1 levels in platelets may potentially result in enhanced 
production of prostanoids such as TXA2 and platelet aggregation (Liu et al. 2004). Potentially, 
changes in prostanoid production may result in an increased risk in thrombosis due to 
enhanced platelet activation and aggregation, a phenomenon that was not observed in COX-1 
knock-out mice (Yu et al. 2005).  
 
4.5.1.2 COX-2-mediated pathway in monocytes in Zucker rats 
COX-2 is the rate-limiting enzyme in prostanoid production in monocytes. In diabetes, 
COX-2 up-regulation in monocytes is often associated with enhanced monocyte infiltration 
into the intima and macrophage-induced inflammation processes (Martin-Ventura et al. 2005). 
In the present study, monocyte COX-2 levels were measured and found to be elevated in 
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obese Zucker rats compared with the lean rats (Figure 4-2). In obese Zucker rats, enhanced 
COX-2 expression in the renal cortex and micro-vessels was found to contribute to renal 
damage (Komers et al. 2005; Dey et al 2004; Dey et al. 2004a). Increased monocyte COX-2 
levels observed in the current study may further exacerbate the renal injury often seen in 
obese Zucker rats. In monocytes, elevated COX-2 levels can also lead to increased PGE2 
production. COX-2-mediated release of PGE2 plays a role in inflammatory processes. For 
instance, PGE2 increases blood flow to inflamed area by dilating blood vessels and stimulates 
the migration of leukocytes through capillary walls. Furthermore, COX-2-mediated release of 
PGE2 has been suggested to play a role in destabilizing atherosclerotic plaque via MMP 
pathways (for more details, see Section 3.4.1.1). Therefore, an up-regulation of COX-2 in 
monocyte in obese Zucker rats indicates an elevated inflammatory activity and could account 
for the more severe degree of atherosclerosis in obese Zucker rats compared to lean Zucker 
rats (see Review by Kasiske et al. 1992).  
 
4.5.2 COX-MEDIATED PATHWAYS IN TYPE 2 DIABETES 
4.5.2.1 Effect of age on COX-mediated pathways in Type 2 diabetes  
Studies in humans are less controlled than animal studies and in the present study, because the 
blood samples were being obtained from an open-ended study with few exclusion criteria, 
post-hoc analyses were performed to try and refine the population. One important factor is age, 
which in animal studies had been shown to increase COX-1 and COX-2 with advancing age 
(Heymes et al. 2000; Armstead et al. 2003; Siironen et al. 2004). In the present study, an 
important finding was that COX-2 levels in monocytes increased with age in human Type 2 
diabetic subjects (Figure 4-6). Therefore, sub-analysis was done using an age-matched 
procedure to take this into account.  
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4.5.2.2 COX-1-mediated pathway in platelets in Type 2 diabetes 
The present study showed that platelet COX-1 levels were unaltered in Type 2 diabetes with 
and without age-matching (Figures 4-7 and 4-8). To the best of our knowledge, platelets COX 
levels in human Type 2 diabetic subjects were not previously measured, although an early 
study by Abbate et al. (1988) reporting enhanced TXA2 synthesis by platelets in human Type 
2 diabetic subjects after thrombin stimulation. The animal study reported in Section 4.5.1.1 
showed that COX-1 in platelets was increased in female diabetic Zucker rats, data from this 
current human study did not agree with data from the animal model. This suggests that 
changes in platelet COX-1 may be species-dependent.  
 
Several studies indicated that platelets are more hyperactive in diabetes (see Section 3.4.1.2 
for more details) and a good glycemic control has been shown to reduce platelet activation 
markers in human Type 2 diabetic subjects (Eibl et al. 2004). Hyperglycemia has been 
proposed to be a causal factor for in vivo platelet activation. For instance, excess glucose 
contributes to non-enzymatic glycation of platelet lipid membrane, which may affect the 
activation of receptors on the surface of platelet lipid membrane (for more details, see Chapter 
6). High levels of glucose can also increase oxidative stress via polyol pathway (see Section 
6.1.3), which may be responsible for enhanced peroxidation of arachidonic acid and increased 
isoprostane production, which is known to cause persistent platelet activation (see Review by 
Ferroni et al. 2004). The current study, however, suggests that changes in platelet COX-1 is 
most likely not involved in hyperactivity of platelets in Type 2 diabetes. 
 
The current data were also sub-analyzed according to disease and age. Hyperlipidemia is a 
condition characterized by an elevated lipid level including cholesterol, phospholipids and 
triglycerides in the bloodstream. The present study found that human subjects with 
hyperlipidemia had a significantly higher level of platelet COX-1 compared with human 
control subjects (Figure 4-9). Further sub-analysis showed that increased platelet COX-1 
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levels were clearly elevated with hyperlipidemia in control and diabetic groups, although this 
was not significant in human Type 2 diabetic subjects presumably due to the low numbers 
(Figure 4-9). A study by Davi et al. (1997) found enhanced COX-1-mediated activity in 
platelets as indicated by an increased TXA2 synthesis in hypercholesterolemic subjects. Belton 
et al. (2003) further reported elevated COX-1 expression in the vascular lesions during 
atherosclerosis development was reported in apolipoprotein E-deficient mice. Changes in lipid 
levels are known to promote thrombosis by affecting the activity of platelets (Di Minno et al. 
1986), fibrinolytic factors (Lowe et al. 1991; Levin et al. 1994) and coagulation proteins 
(Drake et al. 1991; Hoffman et al. 1994). Indeed, increased cholesterol levels increase the risk 
of arterial thrombotic events in patients with atherosclerosis (Pitt et al. 1995). Potentially, 
alteration in COX-1 levels due to hyperlipidemia, a condition commonly observed in Type 2 
diabetes may contribute to the development of macro-vascular complications. The present 
results for the first time show a link between hyperlipidemia and COX-1, a factor which could 
promote platelet aggregation. It may also be an indication for the use of COX inhibitors in 
hyperlipidemia.  
 
The present study measured plasma TXB2. In Type 2 diabetes, plasma TXB2 was unaltered 
with and without age-matching, although a trend of increased plasma TXB2 was observed in 
human Type 2 diabetic subjects (Figures 4-7 and 4-8). Plasma TXB2 level, however, is not 
always indicative of platelet COX-1 level and activity, because plasma TXB2 can derive from 
various sources. These sources include endothelial cells (Kobayashi et al. 2005), Kupffer cells 
(Xu et al. 2005), lung epithelial cells (Khan et al. 2002), mast cells (Mita et al. 1999), 
monocytes and macrophages (Yamazaki et al. 2002; Eligini et al. 2006). When platelet 
COX-1 activity was measured, Vericel et al. (2004) demonstrated that basal TXB2 
significantly increased in resting platelets from human Type 2 diabetic subjects. When 
stimulated with thrombin, platelets isolated from human Type 2 diabetic subjects were 
capable of producing high level of TXA2 (Abbate et al. 1988), suggesting hyperactivity in 
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platelets in Type 2 diabetes. The present study would suggest that this is not due to increased 
platelet COX-1 levels.   
 
4.5.2.3 COX-2-mediated pathway in monocytes in Type 2 diabetes 
Very little is known about COX-2 in Type 2 diabetes. Increasing evidence has revealed 
increased inflammation in Type 2 diabetes and inflammation may be an important component 
in diabetic complication development (Bluher et al. 2005; Lee et al. 2005), our study hence 
investigated if COX-2 expression in monocytes was elevated in Type 2 diabetes as elevated 
COX-2 occurs in inflammation (see Section 1.2.3.2).  
 
Initial analyses on non age-matched data indicate that monocyte COX-2 expression was 
significantly increased in human Type 2 diabetic subjects (Figure 4-7). This increased in 
COX-2 expression appeared age-dependent and subsequent analyses in age-matched human 
subjects failed to detect any changes in COX-2 level in human Type 2 diabetic subjects 
compared with age-matched human control subjects (Figure 4-8). In contrast, COX-2 mRNA 
levels were increased in peripheral blood monocytes from human Type 2 diabetic subjects 
(Shanmugam et al. 2004). This non age-matched study, however, did not measure the actual 
expression of COX-2 protein and only had a very small sample size (four human control and 
two human Type 2 diabetic subjects, respectively). Therefore, it is difficult to interpret the 
results and establish the relationship between increased COX-2 mRNA and actual functional 
protein expression. In another study involved age-matched human subjects, COX-2 
up-regulation was observed in monocyte-derived macrophages at the site of atherosclerotic 
plaques in Type 2 diabetes (Cipollone et al. 2003). Potentially, changes in COX-2 expression 
in these cells can lead to an activation of numerous signalling transduction pathways. For 
example, through PGE2-mediated EP4 signaling pathway, enhanced COX-2 is associated with 
the induction of MMPs, proteases that digest extracellular matrix and destabilize 
atherosclerotic plaques (Cipollone et al. 2005; Lu & Wahl 2005). The age-dependence of 
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COX-2 expression in monocytes, which the present study observed is worth noting as it has 
been reported previously (Kang et al. 2003) and may be a potential factor in cardiovascular 
complications of aging. 
 
The present study found that plasma PGE2 increased significantly in Type 2 diabetes in 
age-matched analysis (Figure 4-8). This increase in plasma PGE2 level in Type 2 diabetes 
suggests that inflammatory activity is elevated in Type 2 diabetes. The exact source of 
enhanced plasma PGE2 production is unclear as several sources of plasma PGE2 have been 
identified. These sources include endothelial cells (Uracz et al. 2002), platelets (Abbate et al. 
1988), lung epithelial cells (N'guessan et al. 2006), alveolar macrophages (Kuhn et al. 1995) 
and monocyte-derived macrophages at the site of atherosclerotic plaques (Zhou & von 
Eckardstein 2002). It has also been reported that stromal pre-adipocytes expressed high level 
of COX-2 protein and released PGE2 after stimulation by adiponectin, a hormone secreted by 
adipocytes that regulates glucose and lipid metabolism (Yokota et al. 2002). Obesity is a 
common problem among human Type 2 diabetic subjects, it is possible that pre-adipocytes via 
adiponectin may be the alternative source of plasma PGE2 production in Type 2 diabetes.  
 
Regardless the source of the elevated plasma PGE2, PGE2 production has been associated 
with destabilizing atherosclerotic plaques (Martin-Ventura et al. 2005; Gomez-Hernandez et 
al. 2006), diabetic retinopathy (Sennlaub et al. 2003) and nephropathy (Kiritoshi et al. 2003) 
possibly through increased MMP activity (Cipollone et al. 2005; Lu & Wahl 2005) and 
increased oxidative stress (Tabatabaie et al. 2003). Therefore, this may be an important factor 
in diabetic complications. 
  
4.5.3 HISTONE H4 ACETYLATION IN TYPE 2 DIABETES 
We have demonstrated previously in Section 2.4.4 that both COX-1 and COX-2 proteins were 
up-regulated in endothelial cells treated with TSA, a histone de-acetylase inhibitor, suggesting 
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COX expression may be associated with histone hyperacetylation (see Section 2.4.3). In this 
section, we studied whether acetylated histone H4 expression changed in monocytes of human 
Type 2 diabetic subjects and if such a change was associated with monocyte COX-2 
expression.  
 
4.5.3.1 Histone H4 acetylation in monocytes in Type 2 diabetes 
Histones are small proteins that are subject to extensive post-translational modifications on 
the N-terminus. Hyperacetylation of the core histones, which loosens DNA strands and allows 
transcription factors better access to DNA is commonly associated with transcriptionally 
active regions within the genome, while histone de-acetylation is believed to be involved in 
the repression of genes (see Reviews by Pazin & Kadonaga 1997; Imhof & Wolffe 1998).  
 
The current study found that in age-matched human subjects, monocyte acetylated histone H4 
expression was not altered in Type 2 diabetes compared with the control group (Figure 4-12). 
The lack of changes in acetylated histone H4 is consistent with lack of changes in monocyte 
COX-2 (see Section 4.4.2.4). The current result, however, differed from that of a study by 
Miao et al. (2004), which showed that in cultured THP-1 monocytes and human blood 
monocytes isolated from Type 2 diabetic, increased COX-2 levels was associated with histone 
H3 and H4 hyperacetylation at the promoter of COX-2 genes. It is, however, important to note 
that this particular study only recruited two controls and two human Type 2 diabetic subjects 
following the initial cell culture work. With such a limited n number, a valid conclusion 
cannot be made. In the present study, the age-matched analysis in the present study contained 
19 subjects per control and Type 2 diabetic groups.  
 
Enhanced histone acetyltransferase activity and histone acetylation, however, have also been 
observed in diabetes in various other experimental conditions and cell types. For example, 
treatment of high level of glucose in mouse insulinoma 6 cells, an islet tumor cell line that 
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produces excessive insulin led to histone H4 hyperacetylation at the insulin gene and glucose 
transporter-2 gene promoter (Mosley & Ozacn 2003). In isolated islets, transcription factors 
including β-2/NeuroD1 and Pdx-1, which are involved in glucose-stimulated insulin gene 
expression, have also been shown to interact with the histone acetyltransferase p300 (Mosley 
at al. 2004). To the best of our knowledge, the present work was the first with a reasonable 
sample size investigating monocyte histone acetylation status in Type 2 diabetes and the 
results were negative.  
 
It is important to note that we failed to observe an age-depend increase in monocyte histone 
H4 acetylation in human Type 2 diabetes (Figure 4-12) despite an age-dependent increase in 
monocyte COX-2 expression (Figure 4-7). Although previous studies suggest a link between 
increased COX levels and histone hyperacetylation in aging (see Chapter 2), it is possible that 
this relationship may be cell/tissue-dependent. Hence modulation of COX expression via 
histone acetylation requires further investigation.  
  
4.5.4 EFFECT OF NSAIDS ON TYPE 2 DIABETES 
NSAIDs have long been used clinically to reduce pain and inflammation. Most NSAIDs 
except for aspirin block COX active site preventing the binding of the enzyme to the substrate, 
arachidonic acid (Vane 1996). Aspirin inhibits COX enzymatic activity permanently by 
covalently binding to a serine residue (Ser529 and Ser516 for human COX-1 and COX-2, 
respectively) located in the COX channel of the enzyme (Roth & Majerus 1975; Lecomte et al. 
1994). By inhibiting COX activity, NSAIDs are able to reduce platelet aggregation and have 
been used commonly to prevent ischemic heart diseases (see Review by Patrono et al. 2005). 
NSAIDs can be divided into three categories: traditional NSAIDs that inhibiting both COX-1 
and COX-2 activities, salicylates with aspirin being the most well-known and COX-2 
selective NSAIDs. In the case of aspirin, inhibition of platelet COX-1 activity prevents 
platelet aggregation, reduces the occurrences of thrombosis and hence decreases myocardial 
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infarction (see Review by Patrono et al. 2005). Type 2 diabetes is a strong risk factor for 
cardiovascular disease and is associated with the development of atherosclerosis and 
significant death through stroke and myocardial infarction (see Review by Garber 2000). This 
present study aimed to investigate if the use of NSAIDs in human Type 2 diabetic subjects 
would affect COX-1 and COX-2 protein levels.  
 
4.5.4.1 Effect of NSAIDs on COX-mediated pathways in Type 2 diabetes 
The current study reported that the use of NSAIDs significantly reduced platelet COX-1 and 
monocyte COX-2 protein expression in Type 2 diabetes (Figure 4-13). No work has been 
reported in regards to COX levels in platelets or monocytes in Type 2 diabetes, although the 
effect of NSAIDs on COX in other cell types has been observed. For example, in endothelial 
cells, IL-stimulated COX expression was down-regulated by non-selective COX inhibitor, 
naproxen and COX-1 selective inhibitor, aspirin (Wu et al. 1991; Zyglewska et al. 1992). 
These studies, however, did not specify which COX isoform was down-regulated by NSAIDs. 
To the best of our knowledge, the present finding that platelet COX-1 levels were reduced by 
NSAIDs in human Type 2 diabetic subjects was a novel finding and it may contribute to these 
anti-COX effects of these drugs. 
 
Platelets play a crucial role in atherosclerotic plaque formation and human Type 2 diabetic 
subjects have higher basal platelet activity (see Review by Ferroni et al. 2004). Consequently, 
this increases the chance of developing thrombosis and other cardiovascular diseases in Type 
2 diabetes. Low dose NSAIDs, particularly aspirin has long been used to lower and prevent 
ischemic heart diseases (see Review by Patrono et al. 2005). The ability of NSAIDs not 
merely to inhibit COX activity, which was reflected by decreased plasma TXB2, but also to 
lower platelet COX-1 expression in human Type 2 diabetic subjects suggests an additional 
regulatory mechanism for COX-1 by NSAIDs, which may be important in delaying or 
preventing the macro-vascular complication in Type 2 diabetes. 
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Increased COX-2 expression has been associated with increased inflammation and 
atherosclerosis development (Martin-Ventura et al. 2005; Gomez-Hernandez et al. 2006), 
conditions that are common in human Type 2 diabetic subjects. NSAIDs have been used to 
reduce inflammation and prevent thrombosis by inhibiting COX activity. The present study 
found that monocyte COX-2 expression was reduced significantly in human Type 2 diabetic 
subjects taking low dose NSAIDs compared with human Type 2 diabetic subjects not taking 
NSAIDs.  
 
The use of NSAIDs has been shown to affect COX-2 expression in various experimental 
settings. NSAIDs such as indomethacin, piroxicam and flurbuprofen partially inhibit 
serum-induced COX-2 mRNA in murine osteoblastic cells (Pilbeam et al. 1995). Sodium 
salicylate also down-regulated COX-2 expression in human endothelial cells (Xu et al. 1999a). 
In contrast, Meade et al. (1999) reported increased COX-2 transcription in mammary 
epithelial cells by NSAIDs and suggested that this up-regulation occurred via a peroxisome 
proliferator response element, a defined nucleotide sequence crucial to gene transcription, 
which is found at the sites of COX-2 promoter region. Furthermore, Gao et al. (2004) 
reported COX-2 expression up-regulation by aspirin and indomethacin in endometrial cancer 
cell lines. It is unclear why conflicting data have been reported. Factors such as differences in 
cell line and type of NSAIDs used may account for the different results.  
 
In addition to changes in COX levels, the present study also reported a reduction in both 
plasma TXB2 and plasma PGE2 by NSAIDs in Type 2 diabetes (Figure 4-13). A small study 
by Capone et al. (2004) found that COX-1 and COX-2 had a different response to NSAIDs 
when aspirin and naproxen were tested in nine healthy human subjects for six days. Aspirin 
and naproxen reduced platelet COX-1 activity, indicated by both plasma TXB2 and urinary 
excretion of TXB2 level, in a similar fashion. In contrast to low-dose aspirin, naproxen 
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significantly lowered LPS-induced PGE2 in the plasma, an index of monocyte COX-2 
expression and activity. This confirms again that the use of different type of NSAIDs affects 
COX-mediated pathways differently. As previously explained, plasma TXB2 and PGE2 can 
come from various cellular sources (see Sections 4.5.2.2. and 4.5.2.3 for more details), a 
reduction in COX metabolites by NSAIDs in the current finding suggests a global decrease in 
COX expression and activity.  
 
The ability of NSAIDs to affect COX-1- and COX-2-mediated pathways levels may be of 
clinical significance in management of Type 2 diabetes, because both platelets and monocytes 
play a crucial role in the development of vascular complications such as thrombosis, 
atherosclerosis and ischemic heart diseases in Type 2 diabetes (for more details, see Section 
3.4). Cipollone et al. (2001) has shown that enhanced COX-2 expression in macrophages 
located at the site of human atherosclerotic plaques is associated with reduced in plaque 
stability via MMP induction. A similar finding was reported in plaque-derived macrophages in 
Type 2 diabetes (Cipollone et al. 2003). Furthermore, compared with human control subjects, 
inflammation, oxidative stress and platelet hyperactivity was significantly elevated in human 
Type 2 diabetic subjects as indicated by increased levels of plasma CRP, urinary isoprostane 
and platelet-mediated release of TXB2, respectively (Santilli et al. 2006). Enhanced platelet 
activity in Type 2 diabetes was re-affirmed with increased expression of soluble CD40 ligand 
(Santilli et al. 2006), which is a transmembrane protein structurally similar to TNF-α and is 
expressed on the surface of activated platelets. Soluble CD40 ligand promotes the secretion of 
chemokines and expression of adhesion molecules by endothelial cells, thereby facilitating the 
binding of leukocytes to activated platelets and endothelium and contributing to thrombus 
formation (Henn et al. 1998). Both platelet-mediated released TXB2 and soluble CD40 ligand 
were reduced in human Type 2 diabetic subjects after a week of aspirin use, with slow 
recovery over 10 days after aspirin withdrawal (Santilli et al. 2006). Therefore, the present 
study suggests that the use of NSAIDs in Type 2 diabetes may be beneficial.
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4.5.4.2 Effect of NSAIDs on histone H4 acetylation in Type 2 diabetes 
Histone acetylation in general is associated with active gene transcription. Core histone 
acetylation loosens DNA strands and allows the better access of transcription factors to the 
DNA resulting in gene up-regulation (see Review by Ng & Bird 2000). This section of the 
study investigated if the use of NSAIDs affected monocyte histone acetylation in Type 2 
diabetes. It was found that the use of NSAIDs lowered monocyte acetylated histone H4 
expression in Type 2 diabetes (Figure 4-14). This is consistent with reduced monocyte COX-2 
level in human Type 2 diabetic subjects taking NSAIDs (see Section 4.5.4.1) supporting the 
hypothesis that COX expression was regulated by histone hyperacetylation (see Chapter 2 for 
more details). Human COX-2 promoter region, which are responsible for the induction of 
human COX-2 gene, contains multiple regulatory elements including NF-κB, 
CCAAT/enhancer-binding protein binding sites and cAMP-response element (Tazawa et al. 
1994). It has been found that human COX-2 gene induction by NF-IL-6β was regulated by 
p300, a coactivator and an integrator for gene transcription with histone acetyltransferase 
activity (Wang et al. 2006). Our finding suggests that changes in the level of the core histone 
acetylation may be associated with down-regulation of monocyte COX-2 in human Type 2 
diabetic subjects taking NSAIDs. This novel finding may potentially be a new mechanism by 
which NSAIDs regulate COX expression.   
 
4.6 CONCLUSIONS 
The current study reported that COX levels were up-regulated in platelets and monocytes of 
Zucker rats, an observation that was not found in human Type 2 diabetic study. This suggests 
that changes in COX levels in these inflammatory cells may be species-dependent. In addition 
to unaltered platelet COX-1 and monocyte COX-2 levels in Type 2 diabetes, the human study 
also reported elevated plasma PGE2, but not plasma TXB2 in Type 2 diabetes, suggesting an 
overall increase in inflammatory activity in Type 2 diabetes. Treatment with NSAIDs in Type 
2 diabetes reduced both platelet COX-1 and monocyte COX-2 levels. Plasma TXB2 and PGE2 
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levels were also decreased in human Type 2 diabetic subjects taking NSAIDs. This re-affirms 
the previous observation that inflammation was increased in human Type 2 diabetic subjects. 
 
Further analysis showed acetylated histone H4 expression in monocytes in Type 2 diabetes 
was unaltered, which was concurrent with lack of changes in monocyte COX-2 levels 
suggesting COX expression may be associated with hyperacetylation of the core histones in 
Type 2 diabetes. The use of NSAIDs resulted in a reduction in monocyte acetylated histone 
H4 levels in Type 2 diabetes. To the best of our knowledge, this is a novel finding suggesting 
potentially COX regulation by NSAIDs may involve post-translational modification of the 
core histones. Further studies are required to better understand the relationship between 
histone modifications and COX expression. 
 
 
 
 
 
 
 
 
CHAPTER 5 
ROLES OF COX IN TYPE 1 DIABETES  
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5.1 TYPE 1 DIABETES MELLITUS 
Type 1 diabetes, also known as insulin-dependent diabetes mellitus or juvenile-onset diabetes, 
accounts for approximately 10-15% of the diabetic population. Type 1 diabetes appears at any 
age, although most Type 1 diabetic patients are diagnosed before 40 years of age. It is a 
chronic disease of carbohydrate, fat and protein metabolism due to the inability of the 
pancreas to produce insulin, a hormone that regulates blood glucose levels by promoting 
glucose uptake into cells. In Type 1 diabetes, the body's immune system destroys the 
insulin-producing β cells in the pancreas during an inflammatory process with an infiltration 
of inflammatory cell types such as T lymphocytes, B lymphocytes and macrophages and it is 
classified as an auto-immune disease (Imagawa et al. 1999; Tabatabaie et al. 2000). Human 
Type 1 diabetic subjects require daily insulin injections to manage their blood glucose levels.  
 
5.1.1 COX-MEDIATED PATHWAYS IN TYPE 1 DIABETES 
COX-mediated pathways involve the release of arachidonic acid from the lipid membrane by 
the action of PLA2, production of prostanoids via COX and tissue prostanoid synthases (for 
more details see Section 1.2). Evidence suggests that COX-mediated pathways are involved in 
the development of Type 1 diabetes. To create a diabetic animal model that has similar 
characteristics of Type 1 diabetes, streptozotocin (STZ), a glucosamine-nitrosourea compound 
that causes DNA damage and toxic to the pancreatic β cell, is commonly used to induce injury 
of the pancreas. In the STZ-treated diabetic rats, Takahashi et al. (2004) reported that 
LPS-induced COX-2 expression decreased in the aortas compared with the control rats and 
this was accompanied by a reduction in PGI2 production. COX-1 levels remained stable in 
aortas isolated from both diabetic and control rats. In contrast to these reports, Nasrallah (et al. 
2003) found both COX-1 and COX-2 isoforms were up-regulated in kidney cells in a 
STZ-induced diabetic rat model. Western blotting revealed a 4-fold increase in both COX 
isoforms at 4 to 6 week of diabetes with a 6-fold increase in PGE2 synthase expression noted 
in the outer medullary region of kidney of 6-week old diabetic rats. Culturing cells from rat 
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inner medullary collecting duct with high levels of glucose for 4 days also resulted in 
up-regulation of both COX isoforms. Although PGE2 synthase expression did not alter, 
increased PGE2 production was found in the culture (Nasrallah et al. 2003). In another study 
using cultured monocytes, COX-2 mRNA and protein expression, but not COX-1 was 
up-regulated in response to glucose treatment (Shanmugam et al. 2004). Although conflicting 
data have been reported, it is clear that COX-mediated pathways are altered in Type 1 diabetes, 
particularly with changes in COX-2 expression, which can be induced by inflammatory 
stimuli (For details of the inflammatory processes, see Section 3.4.1). Increased inflammation 
is indicated by the presence of inflammatory markers such as TNF-α, IL-6 and CRP, which 
are elevated in human Type 1 diabetic subjects with a history of cardiovascular diseases (Jager 
et al. 1999; Schalkwijk et al. 1999; Kilpatrick et al. 2000; Lechleitner et al. 2000). Alterations 
in COX-mediated pathways potentially upset the balance of prostanoid production such as 
TXA2 and PGI2, which are known to regulate blood vessel tone and platelet activity and 
participate in the development of thrombosis and atherosclerosis (for more details see Section 
3.4). 
 
5.2 AIMS 
Accumulating evidence suggests the involvement of COX-mediated pathways in the 
development and progression of Type 1 diabetes and its complications. The aim of this study 
was to investigate the changes in COX-mediated pathways in Type 1 diabetes. The specific 
aims were: 
1) to measure possible changes in COX-mediated pathways in the platelets and monocytes 
isolated from human subjects by assessing COX protein and plasma COX metabolite 
levels and 
2) to determine whether COX expression in Type 1 diabetes is associated with histone H4 
hyperacetylation in monocytes. 
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5.3 METHODS 
5.3.1 COX LEVELS IN PLATELETS AND MONOCYTES IN TYPE 1 DIABETES  
5.3.1.1 Subjects (Type 1 diabetes) 
Twenty five (25) non-diabetic Control (14 males, 11 females) and 19 Type 1 diabetic (10 
males, 9 females) subjects were recruited at St. Vincent’s Hospital (Melbourne, Australia). All 
participants were informed about the details of the study by an endocrinologist, Dr. Alicia 
Jenkins, who was an external collaborator of this study. Subjects were required to sign an 
approved written informed consent prepared by St Vincent’s Hospital, Melbourne (HREC-A 
024/00 Glycoxidation, HDL and diabetes angiopathy). The plain language statement that 
details the study to the subjects is attached in Appendix. In addition, 14 non-diabetic samples 
from healthy male subjects collected during previous project at RMIT University (HREC 
15/01 Majewski: Age-dependent alterations in cyclooxygenase in platelets and human 
monocytes) and stored away at -80°C were also included in this study. In my role I had no 
data, which linked any results to individual patients by name. 
 
5.3.1.2 Collection of human blood samples (Type 1 diabetes) 
The volunteer recruitment and blood sample collection was performed by the endocrinologist, 
Dr. Alicia Jenkins at St Vincent’s Hospital (Melbourne, Australia). For more details see 
Section 4.3.2.2. 
 
5.3.1.3 Isolation of human platelets and monocytes (Type 1 diabetes) 
The isolation of human platelets and monocytes was performed using OptiPrepTM solution 
according to the manufacturer’s protocol, which was described in Section 4.3.2.3.  
 
5.3.1.4 Protein assay (Type 1 diabetes) 
Determination of human sample protein concentration was performed using the Biorad 
microBCA system as outlined in Section 4.3.2.4. 
  
133
5.3.1.5 Western blot: COX protein (Type 1 diabetes) 
Samples were loaded in duplicate with a final total protein concentration of 10 μg per well. 
The protein samples and molecular weight markers were electrophoresed, transferred onto 
nitrocellulose membranes and incubated with selective COX-1 and COX-2 antibodies using 
the same Western blot protocol for the detection of COX protein levels as in Section 4.3.5.5. 
The density of all Western blot bands was analyzed using the ChemiDoc™ XRS system 
(Biorad, CA, USA).  
 
5.3.2 PLASMA COX METABOLITE STUDY IN TYPE 1 DIABETES 
The Biotrak EIA system (Amersham Bioscience, UK) was chosen to measure plasma TXB2 
and PGE2. For more details see Section 4.3.3. 
 
5.3.2.1 Solid phase extraction of COX metabolites (Type 1 diabetes) 
COX metabolites were extracted from plasma samples using Solid phase extraction 
procedures with Amprep C2 ethyl minicolumn (100 mg, Amersham Bioscience, UK). Prior to 
plasma TXB2 extraction, the solid phase extraction method was validated with a known 
amount of amount of PGE standard (PGE2, 1 ng/mL; Sigma, St Louis, USA). The extraction 
validation and extraction method for plasma TXB2 was detailed in Section 4.3.3.1. 
 
5.3.2.2 Amersham Biotrak EIA system (Type 1 diabetes) 
The PGE2 EIA Biotrak System allows a direct determination of plasma PGE2 levels without 
the need for PGE2 extraction. The measurement of extracted TXB2 metabolites and plasma 
PGE2 were performed using the TXB2 and PGE2 EIA Biotrak System, respectively 
(Amersham Bioscience, UK). See Section 4.3.3.2 for more details on the EIA Biotrak System. 
 
  
134
5.3.2.2.1 EIA method: Data reproducibility (humans) 
Reproducibility of the Biotrak EIA system assessed by measuring repeated samples obtained 
from 6 human Type 1 diabetic subjects. 
 
5.3.3 ACETYLATED HISTONE H4 LEVELS IN TYPE 1 DIABETES 
5.3.3.1 Isolation of histones from human monocytes (Type 1 diabetes) 
Histones were isolated from human monocytes as previously described in Section 2.3.2. 
 
5.3.3.2 Western blot: acetylated histone H4 protein (Type 1 diabetes) 
Histone samples extracted in Section 5.3.3.1 were electrophoresed on a 15% SDS-PAGE gel 
and labelled with anti-rabbit polyclonal anti-acetyl histone H4 (Upstate, NY, USA) according 
to standard Western blot procedures outlined in Section 2.3.3.2. 
 
5.3.4 DRUGS AND CHEMICALS 
Drugs and chemicals used in the present experiments were the same as those used in Chapters 
2 and 4 and thus, were obtained from the same sources (see Sections 2.3.4 and 4.3.5).  
 
5.3.5 STATISTICAL ANALYSES 
All values are given as the mean ± standard error of mean (S.E.) and n indicates the number 
of observations. Differences in the percentage densities of Western blot bands were analyzed 
using unpaired Student’s t-test, Mann-Whitney test, 1-way ANOVA and post-hoc tests 
(Tukey’s, Games-Howell and Dunn’s multiple tests), Pearson Chi-Square and Fisher’s exact 
test whenever applicable. SPSS (SPSS Inc., IL, USA) and Prism (GraphPad Software, Inc., 
CA, USA) statistical packages were used in statistical analyses.  
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5.3.6 HUMAN ETHICS APPROVAL 
All procedures used for human blood collection were approved by the Human Research 
Ethics Committee of St. Vincent’s Hospital (Melbourne, Australia; HREC-A 024/00 
Glycoxidation, HDL and diabetes angiopathy) in accordance with the National Statement on 
Ethical Conduct in Research Involving Humans (June 1999) produced by the National Health 
and Medical Research Council of Australia. A separate set of human samples from another 
study was included in the present study. The collection of these samples was approved by the 
Human Research Ethics Committee of RMIT University (Melbourne, Australia; HREC 15/01 
Majewski: Age-dependent alterations in cyclooxygenase in platelets and human monocytes).  
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5.4 RESULTS 
5.4.1 COX-MEDIATED PATHWAYS IN TYPE 1 DIABETES  
5.4.1.1 Basis parameters of human Type 1 diabetic subjects 
Subject selection was made by Dr. Alicia Jenkins at St. Vincent’s Hospital, Melbourne, 
Victoria for another research project, which had broad selection criteria. The present study did 
not exclude any samples collected including samples from smokers and hypertensive subjects 
in the control group. The goal of this was to have a sample population that resembled the 
characteristics of the general population. The exception was subjects on non-steroidal 
anti-inflammatory drugs (NSAIDs). Thus the four groups in the present study were: 39 human 
control subjects (28 males, 11 females), 19 human Type 1 diabetic subjects (10 males, 9 
females), 6 human Type 1 diabetic subjects on NSAIDs (2 males, 4 females). Six human Type 
1 diabetic subjects had a second sample taken and this was used for assay validation. A 
summary of the physiological parameters, blood examination and pharmacological 
interventions of these subjects is detailed in Table 5-1 and Table 5-2. Human Type 1 diabetic 
subjects were of similar age as human control subjects and were characterized by elevated 
serum glucose and hemoglobin A1C levels. All human subjects with Type 1 diabetes were 
treated with insulin. Hemoglobin levels were significantly lower in human Type 1 diabetic 
subjects not taking NSAIDs compared with human control subjects, although the readings 
were within normal ranges. The incidence of vascular complications, hypertension and 
depression/schizophrenia was higher in human Type 1 diabetic subjects compared with human 
non-diabetic subjects (Table 5-2). 
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* p<0.05, significant difference from the control group (1-way ANOVA, Tukey's or Games-Howell multiple comparison). 
n indicates the number of subjects. Some subjects did not have a full blood examination.
<0.20.1±00±00±0Basophils (x109/L)
<0.60.2±0.10.2±00.2±0Eosinophils (x109/L)
<1.00.4±0.10.5±00.5±0Monocytes (x109/L)
1.0-4.02.1±0.32±0.21.8±0.1Lymphocytes (x109/L)
2.0-8.04.9±0.74.7±0.33.6±0.2Neutrophils (x109/L)
4.0-11.07.6±1.27.4±0.46.2±0.3White cell count (x109/L)
27-3227±130±0.530.5±0.4Mean corpuscular hemoglobin(pg)
80-9881±2.989.1±1.591.4±1.1Mean corpuscular volume (fL)
0.4-0.540.4±00.4±00.4±0Packed cell volume
4.6-6.25±0.34.5±0.14.8±0.1Red blood cells (x 1012/L)
130-180133.8±6.4133.8±3.3*145.5±2.3Hemoglobin (g/L)
150-400308±32276±16245±12Platelets (x109/L)
<3.52.6±0.42.1±0.22.8±0.2Low density lipoprotein (mmol/L)
>1.01.3±0.21.5±0.11.4±0.1High density lipoprotein (mmol/L)
<2.01.4±0.51.5±0.31.8±0.3Triglyceride (mmol/L)
<5.54.6±0.44.3±0.24.9±0.2Cholesterol (mmol/L)
4.0-6.08±0.4*8.9±0.2*5.2±0.2Hemoglobin A1C (%)
3.0-7.710.4±3*12.7±1.5*4.9±1.1Serum glucose (mmol/L)
18.5-24.924.6±2.625.5±1.424.5±0.9BMI (kg/m2)
-80.4±6.477.4±3.774.5±23Weight (kg)
-169.7±15.7154.5±8.2174±5.2Height (cm)
-42.5±634.6±3.437.9±2.4Age (years)
-2/410/928/11Gender (male/female)
n=6n=19n=39
Normal rangeType 1 diabetes with NSAIDs
Type 1 
diabetesControl 
Table 5-1
Physiological parameters of human subjects in Type 1 diabetic study
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Table 5-2
Clinical characteristics of human subjects in Type 1 diabetic study
Control Type 1diabetes
Type 1 diabetes
with NSAIDs
n =39 n =19 n =6 Across group Between Type 1diabetes
Gender (male/female) 28/11 10/9 2/4
Smokers 2 2 0
Micro-vascular complication 0 5 3 p <0.05
  Retinopathy 0 4 3 p <0.05
  Nephropathy 0 5 3 p <0.05
  Neuropathy 0 5 2 p <0.05
Macro-vascular complication 0 1 2 p <0.05
  Ischemic heart diseases 0 1 2 p <0.05
Medication
  Insulin 0 19 6 p <0.05
  Metformin 0 0 0
  Sulfonylurea 0 0 0
  Fibrate 0 0 0
  Statin 0 4 2 p <0.05
  Anti-coagulants 0 1 0
  Nitrate 0 1 0
  Diuretics 0 2 0
  Aspirin 0 0 5 p <0.05 p <0.05
  COX-2 selective inhibitors 0 0 2 p <0.05
  Other NSAIDs 0 0 6 p <0.05 p <0.05
  Other medications 0 5 3 p <0.05
Disease
  Hypertension 2 5 4 p <0.05
  Hyperlipidemia 8 5 3
  Depression/schizophrenia 0 3 1 p <0.05
  Asthma 0 0 0
  Other conditions 0 3 3 p <0.05
Chi-square/Fisher's exact test
n  indicates the number of subjects. Some subjects did not have a full blood examination.
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5.4.1.2 Experimental protocol validations 
5.4.1.2.1 Western blot validation: COX (humans) 
Several validation procedures were in place to verify COX-1 and COX-2 protein bands 
detected. These validations included (for more details on Western blot validation, see Section 
4.4.2.2): 
i) establishing COX proteins at correct molecular weight with the use of molecular 
weight standard (Figure 4-3), 
ii) COX primary antibody specificity testing by incubating target proteins with secondary 
antibodies only (Figure 4-3), 
iii) establishing the suitable sample loading concentration (Figure 4-3), 
iv) normalizing densitometry readings between blots with inclusion of an internal 
standard on every gel and 
v) data reproducibility was also assessed in repeated samples from 6 human Type 1 
diabetic subjects (Figure 4-4). 
 
5.4.1.2.2 COX metabolite validation: recovery of analyte and EIA method data 
reproducibility (humans) 
A solid phase extraction method was used to extract TXB2 from plasma samples. Extracted 
plasma was then measured with the Biotrak EIA system. Validation procedures for both the 
extraction procedure and EIA system are summarized in Figure 4-5. 
 
5.4.1.3 Influence of ages on sample population (Type 1 diabetes) 
There was no significant difference in age between control and Type 1 diabetic groups 
(37.9±2.4 and 34.6±3.4 years old, respectively), although monocyte COX-2 was weakly 
correlated with age (Figure 5-1). 
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Figure 5-1
A.  Platelet COX-1
B.  Monocyte COX-2
 
 
Figure 5-1  
Correlation analysis on COX expression and age of human subjects (Type 1 diabetes) 
The relationship between COX levels and age of the subjects was investigated. Panel A: Scatter plot of the 
densities of all COX-1 human platelet samples in relation to age. Panel B: Scatter plot of the densities of all 
COX-2 human monocyte samples in relation to age. R2 represents correlation coefficient. * represent significant 
correlation, p<0.05, Pearson R2 test. 
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5.4.1.4 COX levels in Type 1 diabetes 
Monocyte COX-2 levels, but not platelet COX-1 levels were significantly increased in human 
Type 1 diabetic subjects compared with human control subjects (Figure 5-2). Further 
sub-analyses according to physiological parameters of the subjects showed that COX-1 levels 
were altered in subjects with hypertension and hyperlipidemia.  
 
In human subjects with hypertension, platelet COX-1 was significantly elevated compared 
with human subjects without hypertension (Figure 5-3A). Insufficient sample size, however, 
prevented further conclusive analyses after sub-grouping, although there was a trend showing 
increased platelet COX-1 levels in human Type 1 diabetic subjects with hypertension 
compared with human Type 1 diabetic subjects without hypertension (Figure 5-3B).  
 
COX-1 levels were also significantly enhanced in subjects with hyperlipidemia (Figure 5-4A) 
and further analyses on sub-groups showed that platelet COX-1 levels were elevated in human 
control subjects with hyperlipidemia compared with human control subjects without 
hyperlipidemia (Figure 5-4B).   
 
5.4.1.5 Plasma COX metabolites in Type 1 diabetes 
The level of COX metabolites, TXB2 and PGE2 was measured in the plasma. It was found that 
plasma PGE2, but not TXBB2 was significantly higher in human Type 1 diabetic subjects 
compared with the human control subjects (Figure 5-2).  
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A.  COX-1 B.  COX-2
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Figure 5-2 
Quantitative densitometry of COX protein levels and plasma metabolites in human subjects  
(Type 1 diabetes) 
Analysis of COX levels in human platelets and monocytes and plasma COX metabolites. Panel A: Platelet 
COX-1 protein levels were measured in human control and human Type 1 diabetic subjects. Panel B: Monocyte 
COX-2 protein levels were measured in human control and human Type 1 diabetic subjects. A rat platelet or 
monocyte standard control was run with each Western blot and the density of all sample bands was expressed as 
a percentage of the corresponding standard control. Panel C and Panel D: Plasma levels of TXB2 and PGE2 were 
measured using EIA. Values represent the mean, S.E. and number of subjects. * significant difference from 
human control subjects, p<0.05, unpaired Student’s t-test; # significant difference from human control subjects, 
p<0.05, Mann Whitney test; N.S. not significant difference from human control subjects, p>0.05, unpaired 
Student’s t-test or Mann Whitney test. 
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A.  Hypertension
B.  Hypertension
 
 
Figure 5-3 
Quantitative densitometry of platelet COX-1 protein levels in human subjects  
(Type 1 diabetes, hypertension) 
Analysis of COX-1 levels in human platelets. Panel A: Platelet COX-1 protein levels were measured in subjects 
with and without hypertension. Panel B: Sub-analysis of platelet COX-1 protein levels was performed in subjects 
with and without hyperlipidemia. A rat platelet standard control was run with each Western blot and the density 
of all sample bands was expressed as a percentage of the corresponding standard control. Values represent the 
mean, S.E. and number of subjects. * significant difference from subjects without hypertension, p<0.01, unpaired 
Student’s t-test; N.S. not significant difference from Type 1 diabetes without hypertension, p>0.05, 1-way 
ANOVA (Tukey’s multiple comparison test).
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Figure 5-4 
Quantitative densitometry of platelet COX-1 protein levels in human subjects  
(Type 1 diabetes, hyperlipidemia) 
Analysis of COX-1 levels in human platelets. Panel A: Platelet COX-1 protein levels were measured in subjects 
with and without hyperlipidemia. Panel B: Sub-analysis of platelet COX-1 protein levels was performed in 
subjects with and without hyperlipidemia. A rat platelet standard control was run with each Western blot and the 
density of all sample bands was expressed as a percentage of the corresponding standard control. Values 
represent the mean, S.E. and number of subjects. * significant difference from subjects without hyperlipidemia, 
p<0.01, unpaired Student’s t-test; # significant difference from Type 1 diabetes without hyperlipidemia, p<0.05, 
1-way ANOVA (Tukey’s multiple comparison test). 
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5.4.2 ACETYLATED HISTONE H4 LEVELS IN MONOCYTES IN TYPE 1 
DIABETES 
5.4.2.1 Western blot validation: acetylated histone H4 (humans) 
Several validation procedures were in place to verify acetylated histone H4 protein bands 
detected. These validations included (more details on Western blot validation, see Section 
4.4.3.1): 
vi) establishing acetylated histone H4 protein at correct molecular weight with the use of 
molecular weight standard (Figure 4-10), 
vii) histone H4 primary antibody specificity testing by incubating target proteins with 
secondary antibodies only (Figure 4-10), 
viii) establishing the suitable sample loading concentration (Figure 4-10), 
ix) normalizing densitometry readings between blots with inclusion of an internal 
standard on every gel and 
x) data reproducibility was also assessed in repeated samples from 6 human Type 1 
diabetic subjects (Figure 4-11). 
 
5.4.2.2 Acetylated histone H4 levels in Type 1 diabetes 
In Type 1 diabetes, acetylated histone H4 levels were significantly increased in monocyte 
compared with those of the human control subjects (Figure 5-5).  
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Figure 5-5 
Quantitative densitometry of histone H4 acetylation in human subjects (Type 1 diabetes) 
Analysis of acetylated histone H4 levels in human monocytes. A rat histone H4 standard control was run with 
each Western blot and the density of all sample bands was expressed as a percentage of the corresponding 
standard control. Values represent the mean, S.E. and number of subjects. * significant difference from human 
control subjects, p<0.001, Mann Whitney test. 
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5.4.3 EFFECT OF NSAIDS ON TYPE 1 DIABETES 
5.4.3.1 Effect of NSAIDs on COX, TXB2, PGE2 and acetylated histone H4 levels in Type 
1 diabetes 
Human Type 1 diabetic subjects with NSAID treatment regime showed a significant reduction 
in platelet COX-1 and monocyte COX-2 levels compared to human Type 1 diabetic subjects 
without NSAIDs (Figure 5-6).  
 
There was a significant reduction in PGE2, but not plasma TXB2 levels in human Type 1 
diabetic subjects taking NSAIDs compared to human Type 1 diabetic subjects not taking 
NSAIDs (Figure 5-6). 
 
Monocytes of human Type 1 diabetic subjects taking NSAIDs expressed markedly lower 
acetylated histone H4 proteins compared to human Type 1 diabetic subjects not taking 
NSAIDs (Figure 5-7). 
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Figure 5-6 
Quantitative densitometry of COX protein levels and plasma metabolites in human subjects in the 
presence of NSAIDs (Type 1 diabetes) 
Analysis of COX levels in human platelets and monocytes and plasma COX metabolites in the presence of 
NSAIDs. Panel A: Platelet COX-1 levels were measured in human control, human Type 1 diabetic subjects with 
and without NSAIDs. Panel B: Monocyte COX-2 levels were measured in human control, human Type 1 
diabetic subjects with and without NSAIDs. A rat platelet or monocyte standard control was run with each 
Western blot and the density of all sample bands was expressed as a percentage of the corresponding standard 
control. Panel C and Panel D: Plasma levels of TXB2 and PGE2 were measured using EIA. Values represent the 
mean, S.E. and number of subjects. * significant difference from Type 1 diabetes not taking NSAIDs, p<0.05, 
1-way ANOVA (Dunn’s comparison test); N.S. not significant difference from Type 1 diabetes not taking 
NSAIDs, p>0.05; # significant difference from control; ^ significant difference from Type 1 diabetes not taking 
NSAIDs significant difference from Type 1 diabetes not taking NSAIDs, p<0.001, 1-way ANOVA (Tukey’s 
multiple comparison test).  
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Fig 5-7 
Quantitative densitometry of histone H4 acetylation in human subjects in the presence of NSAIDs  
(Type 1 diabetes) 
Acetylated histone H4 expression was measured in human control, human Type 1 diabetic subjects with and 
without NSAIDs. A histone H4 standard control was run with each Western blot and the density of all sample 
bands was expressed as a percentage of the corresponding standard control. Values represent the mean, S.E. and 
number of subjects. * significant difference from human control subjects, p<0.01; # significant difference from 
Type 1 diabetes not taking NSAIDs, p<0.001, 1-way ANOVA (Dunn’s multiple comparison test). 
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5.5 DISCUSSION  
The purpose of the current study was to investigate whether COX-1 and COX-2 levels were 
altered in platelets and monocytes of Type 1 diabetes and if so, could this be associated with 
altered histone acetylation?  
 
5.5.1 COX-MEDIATED PATHWAYS IN TYPE 1 DIABETES 
5.5.1.1 Effect of age on COX-mediated pathways in Type 1 diabetes  
Human subjects in the present study were recruited from a hospital clinic with few exclusion 
criteria. Post-hoc analyses were performed to try and refine the population. One important 
factor is age, which in animal studies had shown that COX-1 and COX-2 increase with 
advancing age (Heymes et al. 2000; Armstead 2003). In the present study, COX protein levels 
did not change with aging in either platelets or monocytes isolated, although monocyte 
COX-2 expression was weakly correlated with age (Figure 5-1).  
 
5.5.1.2 COX-1-mediated pathway in platelets in Type 1 diabetes 
The present study revealed that COX-1 levels in platelets were unaltered in Type 1 diabetes 
(Figure 5-2). Platelet COX-1 levels in human Type 1 diabetic subjects have not been 
measured previously. Further, there are no animal studies indicating changes in COX-1 in 
platelets in Type 1 diabetes, although kidney COX-1 is elevated in STZ diabetic rats 
(Nasrallah et al. 2003). Several studies showed that platelets of Type 1 diabetes are more 
reactive (Davi et al. 2003; Hu et al 2004), but if this is the case elevated COX-1 expression is 
not involved.  
 
The current data were also sub-analyzed according to disease and age. It was found that 
COX-1 protein levels in platelets was up-regulated in hypertensive human subjects compared 
with non-hypertensive human subjects (Figure 5-3A). An in vivo study by Davi et al. (1997) 
found that hypertension was associated with platelet activation as indicated by enhanced 
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TXA2 synthesis suggesting enhanced COX-1-mediated pathway in platelets. Further 
conclusive analyses after sub-grouping in the present study, however, could not be made due 
to insufficient sample size, although there was a trend showing increased platelet COX-1 
levels in human Type 1 diabetic subjects with hypertension compared with human Type 1 
diabetic subjects without hypertension (Figure 5-3B). 
 
It was also found that subjects with hyperlipidemia had significantly higher levels of platelet 
COX-1 compared with human control subjects (Figure 5-4A). Further sub-analysis on 
non-diabetic subjects showed increased platelet COX-1 levels were associated with 
hyperlipidemia, although this was not observed in human Type 1 diabetic subjects (Figure 
5-4B). The precise effect of hyperlipidemia-dependent increase in COX-1 levels is not clear, 
but changes in lipid levels are known affect the activity of platelets (Di Minno et al. 1986). A 
study by Davi et al. (997) found enhanced COX-1-mediated activity in platelets indicated by 
increased TXA2 synthesis was associated with hypercholesterolemia. Therefore, potentially, 
alteration in COX-1 levels in subjects with hyperlipidemia may promote thrombosis 
development (Pitt et al. 1995). 
 
In addition to platelet COX-1 levels, the present study also measured plasma TXB2. Plasma 
TXB2 was unaltered in Type 1 diabetes and was not correlated with COX-1 levels in platelets 
(Figure 5-2). Similar findings were reported previously in that no difference in the plasma 
levels of TXB2 was found between Type 1 diabetic and human control subjects (Arisaka et al. 
1986; Mourits-Andersen et al. 1986). Plasma TXB2 levels, however, is not always indicative 
of COX-1 levels and activity in platelets as plasma TXB2 can come from various sources as 
described in Section 4.5.2.2. Unaltered plasma TXB2 levels in Type 1 diabetes in this case 
suggests overall COX-1 levels were not changed. This, however, does not mean that the 
COX-1-mediated pathway is unaltered in platelets in Type 1 diabetes as a direct functional 
assessment of platelet COX-1 enzymatic activity is required to determine this. In the literature, 
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several reports found platelets were more hyperactive in Type 1 diabetes. Early studies by 
Udvardy et al. (1987) and Abbate et al. (1988) showed that platelets isolated from human 
Type 1 diabetic subjects produced more TXB2 when stimulated with thrombin compared with 
those of human control subjects. Similar findings were also reported in resting platelets in 
Type 1 diabetes (Vericel et al. 2004). Platelet hyperactivity contributes to the development of 
thrombosis and may in this case increase the risk of cardiovascular complications in Type 1 
diabetes.  
 
5.5.1.3 COX-2-mediated pathway in platelets in Type 1 diabetes 
The COX-2 isoform is up-regulated in inflammation and is implicated in Type 1 diabetes, 
which was re-affirmed by increased COX-2 expression in mouse islet-infiltrated macrophages 
(Luo et al. 2002). The present study investigated changes in human monocyte COX-2 
expression in Type 1 diabetes and reported that monocyte COX-2 levels were increased in 
Type 1 diabetes (Figure 5-2). A similar finding was reported in human monocyte (Litherland 
et al. 1999; Litherland et al. 2003). Furthermore, COX-2 mRNA was also found to be induced 
by glucose in cultured THP-1 monocyte cells and in peripheral blood monocytes from human 
Type 1 diabetic subjects, although only four control and three human Type 1 diabetic subjects 
were involved in this investigation (Shanmugam et al. 2004).  
 
The current study reported that in Type 1 diabetes, plasma PGE2 levels were elevated 
compared with the control group (Figure 5-2). This is supported by early studies by Chase et 
al. (1979) and Arisaka et al. (1986) who reported increased plasma PGE2 in children with 
diabetes, although no difference in the plasma levels of PGE2 between Type 1 diabetic and 
human control subjects has also been reported (Mourits-Andersen et al. 1986). The exact 
source of this increased plasma PGE2 levels is unknown as plasma PGE2 can come from 
various sources (see Section 4.5.2.3 for more details). Enhanced plasma PGE2 production may 
affect renal functions as PGE2 is a major prostanoid in the kidney. In the kidney, PGE2 
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selectively activates at least three distinct EP receptors with each EP receptor preferentially 
couples to different signal transduction pathways (for more details on EP receptors, see 
Section 1.2.2.2). Activation of these EP receptors leads to changes in the regulation of 
vascular smooth muscle tone, glomerular filtration, renin release and tubular salt and water 
transport in kidney (see Review by Breyer et al. 1996).  
 
Although the exact source was unknown, elevated plasma PGE2 in the current study 
suggested an overall alteration on COX-2-mediated activity and possibly an elevated 
inflammatory activity in Type 1 diabetes. The potential biological effects associated with 
these changes can be profound and are discussed in Section 4.5.2.3.  
 
5.5.2 HISTONE H4 ACETYLATION IN TYPE 1 DIABETES  
We have demonstrated previously in Section 2.4.3 that up-regulation of both COX-1 and 
COX-2 protein expression in endothelial cells was associated with histone H4 
hyperacetylation. The current study investigated whether histone H4 acetylation changed in 
monocytes isolated from human Type 1 diabetic subjects and if the levels of histone H4 
acetylation were associated with monocyte COX-2 expression.  
 
5.5.2.1 Histone H4 acetylation in monocytes in Type 1 diabetes 
Histone hyperacetylation, a post-translational modification of histones, is associated with 
active gene transcription. Histone acetylation loosens histone structure and DNA strands 
making DNA more accessible to transcription factors (see Reviews by Pazin & Kadonaga 
1997; Imhof & Wolffe 1998). The current study found that in monocytes acetylated histone 
H4 expression was increased in Type 1 diabetes compared with the control group (Figure 5-5). 
This increased acetylated histone H4 is associated with increased COX-2 levels in monocytes 
in Type 1 diabetes, suggesting the possibility that COX expression in human Type 1 diabetes 
is modulated through histone modifications (see Chapter 2 for more details). In support of the 
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current finding, enhanced histone acetyltransferase activity and histone acetylation in islets 
cells (Mosley & Ozacn 2003; Mosley at al. 2004) and in cultured THP-1 monocytes (Miao et 
al. 2004) have been reported. To the best of our knowledge, the current study was the first 
with a meaningful sample size to investigate monocyte histone H4 acetylation status in Type 1 
diabetes.  
 
5.5.3 EFFECT OF NSAIDS ON TYPE 1 DIABETES  
NSAIDs have long been used clinically to reduce pain and inflammation by inhibiting COX 
activity (for more details on the action of NSAIDs on COX enzymes, see Section 4.5.4). By 
inhibiting COX activity, NSAIDs are able to reduce platelet function and prevent ischemic 
heart diseases (see Review by Vane 1971; Patrono et al. 2005). Type 1 diabetes is associated 
with micro- and macro-vascular complications with tissue damage in eyes, kidneys, blood 
vessels and nerves. These chronic diabetic vascular complications may involve mechanisms 
mediated by COX enzymes (see Section 3.4). The present study aimed to investigate whether 
the use of NSAIDs in human Type 1 diabetic subjects would change COX-1 and COX-2 
protein levels and if so, was this regulated through histone acetylation modification. This 
preliminary study did not include human non-diabetic subjects on NSAIDs. Further 
recruitment of these subjects is required to accurately analyze and interpret the data collected.  
 
5.5.3.1 Effect of NSAIDs on COX-mediated pathways in Type 1 diabetes  
The current study reported that the use of NSAIDs significantly lowered platelet COX-1 and 
monocyte COX-2 in Type 1 diabetes (Figure 5-6). COX down-regulation by NSAIDs has 
been previously reported. Wu et al. (1991) and Zyglewska et al. (1992) found that COX levels 
were reduced by naproxen and aspirin in human endothelial cells. In the case of monocyte 
COX-2, Pilbeam et al. (1995) showed that indomethacin, piroxicam and flurbuprofen were 
able to partially down-regulate mRNA COX-2 expression in murine osteoblastic cells. A 
decrease in COX-2 expression by sodium salicylate was also found in human endothelial cells 
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(Xu et al. 1999). In contrast, COX-2 expression was up-regulated by NSAIDs in mammary 
epithelial cells (Meade et al. 1999) and endometrial cancer cell lines (Gao et al. 2004). 
Factors such as differences in cell line and type of NSAIDs studied may account for the 
different results.  
 
The present study also found that NSAID use decreased plasma TXB2 and PGE2, but in the 
case of TXB2 this was not statistically significant, presumably due to low sample numbers 
(Figure 5-6). A small study by Capone et al. (2004) found that COX-1 and COX-2 had a 
different response to NSAIDs when aspirin and naproxen were tested in nine healthy human 
subjects for six days. Aspirin and naproxen reduced platelet COX-1 activity, indicated by both 
plasma TXB2 and urinary excretion of TXB2 levels, in a similar fashion. In contrast to 
low-dose aspirin, naproxen significantly lowered LPS-induced PGE2 in the plasma, an index 
of monocyte COX-2 activity. This confirms again that the use of different types of NSAIDs 
affects COX-mediated pathways differently.   
 
Platelets and monocytes play an important role in the development of vascular complications 
such as thrombosis and atherosclerosis. In diabetes, platelets are more hyperactive (Li et al. 
2001) and particularly platelets of human Type 1 diabetic subjects with micro complications 
expressed higher levels of P-selectin and soluble CD40 ligand (Yngen et al. 2004). P-selectin, 
an adhesion molecule, is located in membranes of α-granules in resting platelets and 
redistributed to the cell surface upon platelet activation (Stenberg et al. 1985; Berman et al. 
1986; see Review by Hogg 1992). Soluble CD40 ligand, a transmembrane protein structurally 
similar to TNF-α, is expressed on the surface of activated platelets CD40 ligand. Both 
P-selectin and soluble CD40 ligand promote the secretion of chemokines and expression of 
adhesion molecules by endothelial cells, thereby facilitating the binding of leukocytes to 
activated platelets and endothelium and contributing to thrombus formation (Henn et al. 1998; 
see Review by Hogg 1992). Anti-thrombotic therapy such as aspirin may be able to prevent 
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over-expression of these platelet surface proteins by reducing the activation of platelets 
through blocking platelet COX-1 activity. Consequently, the use of NSAIDs clinically may 
lower the occurrences of thrombosis and ischemic heart diseases in Type 1 diabetes. 
 
The COX-2-mediated pathway is implicated in Type 1 diabetes with increased COX-2 
expression found in the monocytes of human Type 1 diabetic subjects (Litherland et al. 1999). 
Most NSAIDs currently available are non-selective COX inhibitors and they are effective 
anti-inflammatory agents. COX-2 selective inhibitors in particular, however, play a crucial 
role in the inflammatory process. NSAIDs may reduce vascular and leukocyte inflammatory 
components and therefore interfere with the development of atherothrombotic disease, a 
condition that may involve increased COX-2 expression (Luo et al. 2002; Martin-Ventura et 
al. 2005; Gomez-Hernandez et al. 2006). The present study showed the ability of NSAIDs to 
down-regulate COX-2 levels in monocytes, possibly through inhibition of NF-κB (Yoneda et 
al. 2003) in Type 1 diabetes. This suggests the importance of NSAIDs in management of Type 
1 diabetes. 
 
5.5.3.2 Effect of NSAIDs on histone H4 acetylation in Type 1 diabetes 
The core histones are subjected to extensive post-translational modifications, which result in 
changes in DNA structure. Histone acetylation, a process that loosens DNA strands and 
allows the access of transcription factors to the DNA, is commonly associated with active 
gene transcription (Allfrey et al. 1964; see Review by Wade et al. 1997). This section of the 
study investigated whether the use of NSAIDs affected monocyte histone acetylation in Type 
1 diabetes. It was found that the use of NSAIDs lowered monocyte acetylated histone H4 
expression in Type 1 diabetes (Figure 5-7). This is consistent with reduced monocyte COX-2 
levels in human Type 1 diabetic subjects taking NSAIDs (see Section 5.5.3.1), supporting the 
hypothesis that COX expression was regulated by histone hyperacetylation (see Chapter 2 for 
more details). This is further supported by Wang et al. (2006) who reported that in cultured 
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cells, histone acetyltransferase, p300, up-regulated COX-2 gene by acetylating NF-IL6β, a 
transcription factor that activates COX-2 promoter region. To the best of our knowledge, the 
down-regulation of acetylated histone H4 expression in monocytes by NSAIDs in Type 1 
diabetes is a novel finding. This may potentially be an important mechanism by which 
NSAIDs regulate COX expression.   
 
5.6 CONCLUSIONS 
This human study reported monocyte COX-2, but not platelet COX-1 increased in Type 1 
diabetes compared with the control group. Elevated plasma PGE2, but not plasma TXB2 was 
also observed in Type 1 diabetes, suggesting an overall increase in inflammatory activity in 
Type 1 diabetes. Treatment with NSAIDs in Type 1 diabetes reduced both platelet COX-1 and 
monocyte COX-2 levels. Plasma TXB2 and PGE2 levels were also decreased in human Type 1 
diabetic subjects taking NSAIDs. This re-affirms the previous observation that inflammation 
was increased in human Type 1 diabetic subjects. 
 
Further analysis showed increased acetylated histone H4 expression in monocytes in Type 1 
diabetes, which was concurrent with enhanced COX-2 expression in monocytes, suggesting 
hyperacetylation of the core histones is associated with COX up-regulation. The use of 
NSAIDs down-regulate monocyte acetylated histone H4 levels in Type 1 diabetes. To the best 
of our knowledge, this is a novel finding suggesting potentially NSAIDs may down-regulate 
COX expression via histone acetylation/de-acetylation. 
 
 
 
 
 
 
 
 
CHAPTER 6 
CHANGES OF RECEPTORS FOR 
ADVANCED GLYCATION END 
PRODUCTS (RAGE) IN DIABETES  
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6.1 INTRODUCTION 
The strong association between hyperglycemia in diabetes mellitus and the development of 
chronic diabetic complications including both micro and macro vascular dysfunction has been 
shown in the results of an intervention study in both Type 1 (Diabetes Control and 
Complications Trial Research Group 1993) and Type 2 (UKPDS 1998) diabetic patients. 
Despite much research, the mechanisms by which chronic hyperglycemia results in functional 
changes and tissue injury are yet to be clarified, although several mechanisms have been 
proposed. These include enhanced glucose metabolism through the polyol pathway, activation 
of PKC by hyperglycemia, increased oxidative stress, enhanced inflammation and increased 
formation of AGEs. These mechanisms have some overlapping links and are discussed below 
(for details of enhanced inflammation in diabetes, see Section 3.4.1). 
 
6.1.1. POLYOL PATHWAY  
Most cells require the action of insulin for glucose entry into the intracellular compartments; 
the few exceptions are vascular endothelial cells of the retina, kidney, and nervous tissue. 
These insulin-independent cells allow a free interchange of glucose between the extracellular 
and intracellular spaces regardless of insulin’s action. The insulin-independent diffusion of 
glucose ensures normal physiologic cellular functions to proceed during the euglycemic state, 
and the homeostasis is then maintained by the enzyme aldose reductase, which metabolizes 
excess glucose into sorbitol via the polyol pathway (see Review by Swidan & Montgomery 
1998). Under normal circumstances, the amount of glucose metabolized by aldose reductase 
is minimal as the enzyme has a low affinity for glucose. Sorbitol production in the 
insulin-independent cells, however, increases dramatically when excess glucose enters the 
polyol pathway during hyperglycemic states (Figure 6-1). When this happens there is a 
concomitant decrease in nicotinamide–adenine dinucleotide phosphate (NADPH). Sorbitol is 
then oxidized by sorbitol dehydrogenase to fructose, coupled with the reduction of oxidized 
nicotinamide–adenine dinucleotide (NAD+) to the reduced form nicotinamide–adenine 
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dinucleotide (NADH) (Figure 6-1 and see Reviews by Swidan & Montgomery 1998; 
Brownlee 2001). Changes in the polyol pathway may impact on various metabolic reactions. 
For instance, NADPH is important in keeping glutathione in its reduced form. Reduced 
glutathione together with glutathione peroxidase converts dangerous reactive oxygen species 
such hydrogen peroxide to water (for more details on oxidative stress, see Section 6.1.3). 
Subjects who could not make adequate NADPH were found to be at an increased risk of 
oxidative damage from glutathione insufficiency (Cathcart 1985). Excess glucose can also 
result in an increased production of sorbitol, which cannot diffusible through cell membranes 
easily. The accumulation of sorbitol causes osmosis stress leading to imbalances in 
intracellular homeostasis. Together with enhanced glycation of macromolecules (for more 
details, see Section 6.1.4), increased sorbitol may contribute to the development of diabetic 
complications (see Reviews by Kinoshita 1986; Chung et al. 2003). 
 
This series of biochemical activities provides a ground for metabolic disturbances resulting 
from altered enzyme activity due to a decreased availability of unbound cytosolic NADPH or 
an increased availability of NADH (see Reviews by Brownlee 2001; Sheetz & King 2002). 
Accumulation of sorbitol, fructose and unbound cytosolic NADH potentially can result in 
microvascular injury via mechanisms such as sorbitol-induced osmotic stress, increased AGE 
and prostaglandin production, and alterations in PKC activity (see Reviews by Brownlee 2001; 
Tilton 2002).  
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Figure 6-1 
Polyol Pathway 
Aldose reductase metabolizes excess glucose, resulting in an increase in sorbitol production. This 
process takes place with a concomitant decrease in nicotinamide–adenine dinucleotide phosphate 
(NADPH) before sorbitol is oxidized by sorbitol dehydrogenase to fructose. This action results in a 
decrease in glutathione, an important molecule in the defence of oxidative stress. Oxidized 
nicotinamide–adenine dinucleotide (NAD+) is then reduced to nicotinamide–adenine dinucleotide 
(NADH), subsequently producing advanced glycation end product (AGE) precursors such as 
methylglyoxal. AGE precursors are then further re-arranged and consequently become irreversible 
AGEs. 
Figure 6-1 
aldose reductase 
triose phosphate
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If the polyol pathway is important, selective inhibitors should prevent some of the 
consequences of high glucose. In vivo studies involving polyol pathway inhibitors have been, 
for the most part, disappointing. In diabetic rats, inhibition of aldose reductase, an enzyme 
that converts glucose to sorbitol has been shown to prevent diabetes-induced nephropathy 
(Mauer et al. 1989), neuropathy (Cameron et al. 1986) and retinopathy (Robinson et al. 1989). 
Zenarestat, a potent aldose reductase inhibitor was studied in a fifty two-week, randomized, 
placebo-controlled, double-blind clinical trial by Greene et al. (1999). Nerve conduction 
velocity and small-diameter sural nerve density were assessed in patients with mild to 
moderate diabetic peripheral neuropathy. It was found that zenarestat decreased diabetic 
peripheral neuropathy in these patients (Greene et al. 1999). Long term studies involving 
aldose reductase inhibition, however, have shown contradictory results. Engerman et al. (1994) 
conducted a five-year study in dogs and found aldose reductase inhibition did not prevent 
diabetic retinopathy or thickening of the capillary basement membrane in the retina or kidney, 
respectively. While some clinical trials showed the effectiveness of aldose reductase inhibitors 
in improving diabetic complications, results from most other clinical trials of aldose reductase 
inhibition have been less impressive due to inadequate efficacy and/or safety concerns 
(Sorbinil Retinopathy Trial Research Group 1990; Oates et al. 1999). In short, while 
experimental data provide support to the notion that sorbitol production may contribute to 
micro-vascular dysfunction observed in diabetes, most human studies to date have failed to 
demonstrate a clinical benefit of reducing sorbitol levels. 
 
6.1.2 PKC AND ITS ISOFORMS 
PKC is a large family of at least 12 isoforms of the serine and threonine kinase family. In the 
vasculature, several PKC isoforms are present, however, in a diabetic rat model there is a 
preferential activation of PKC β2 in the aorta, heart, and retina, and PKC β1 in the glomeruli 
(Inoguchi et al. 1992; Koya et al. 1997). Phospholipases C and D, produce diacylglycerol 
(DAG) from phosphatidylinositides and phosphatidylcholine, respectively. Elevated DAG 
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levels then leads to activation of PKC, a process which is known to maintain important 
functions in vascular cells including regulating permeability, contractility, extracellular matrix 
integrity, cell growth, angiogenesis, cytokine actions, and leukocyte adhesions, all of which 
are abnormal in diabetes (see Reviews by Nishizuka 1992; Nishizuka 1995). Excess glucose 
can be transported intracellularly, mainly by the glucose transporter GLUT-1, and lead to 
increased DAG production and PKC activation (Kaiser et al. 1993 and see Reviews by 
Greene et al. 1987; Baynes 1991; Williamson et al. 1993; Derubertis & Craven 1994; Sharma 
& Ziyadeh 1995; King et al. 1997).  
 
Hyperglycemia-induced PKC activation has been shown to increase platelet-derived growth 
factor-β receptor expression in smooth muscle cells, endothelial cells and 
monocyte/macrophages (Kawno et al. 1993; Inaba et al. 1996). PKC activation can also 
increase the expression of transforming growth factor-β (TGF-β), which has been implicated 
in the development of mesangial expansion and basement membrane thickening in diabetes 
(MacKay et al. 1989; Nakamura et al. 1992; Suzuki et al. 1993; Yamamoto et al. 1993; 
Pankewycz et al. 1994; Sharma et al. 1994). TGF-β activates gene expression of 
proteoglycans and collagen and decreases the synthesis of proteolytic enzymes that degrade 
matrix proteins and therefore, is one of the most important growth factors regulating 
extracellular matrix production (Nabel et al. 1993). Up-regulation of TGF-β has been linked 
to thickening of the capillary basement membrane, one of the early structural abnormalities 
observed in almost all tissues in diabetes (Williamson et al. 1984). These structural alterations, 
however, were slowed down when TGF-β antibodies were applied to the renal tissue of 
diabetic rats and in cultured mesangial cells exposed to high glucose levels (Ziyadeh et al. 
1994; Sharma et al. 1996). LY333531, a PKC β selective inhibitor has been shown to reduce 
expression of TGF-β and extracellular matrix proteins such as fibronectin and type IV 
collagen in renal glomeruli of diabetic rats (Koya et al. 1997; Koya et al. 2000), biochemical 
and molecular changes associated with early renal dysfunctions in nephropathy in diabetic 
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models. Stringent assessment of PKC inhibition, however, is required as to date, long-term 
studies involving PKC inhibitors have not been possible due to their non specificity for other 
kinases resulting in serious toxic effects. 
 
6.1.3 OXIDATIVE STRESS 
Another hypothesis, which has been proposed to explain the development of diabetic 
complications, involves oxidative stress, a persistent imbalance between the production of 
highly reactive molecular species and antioxidant defences (see Review by Rosen et al. 2001). 
Oxidative stress can result from increased production of reactive oxygen species (ROS) 
and/or reactive nitrogen species (RNS), decreased anti-oxidative defence and failure to repair 
oxidative damage. ROS or RNS can either be free radicals, reactive anions containing oxygen 
or nitrogen atoms, or molecules containing oxygen or nitrogen atoms that can either produce 
free radicals or are chemically activated by them.  
 
The precise sources of or the mechanisms involving enhanced oxidative stress in diabetes are 
unclear, although polyol and PKC pathways may be involved. Satoh et al. (2005) showed that 
increased NADH was associated with enhanced ROS production in the kidneys of 
STZ-induced diabetic rats. The use of specific PKC and NADPH inhibitors successfully 
lowered systemic oxidative stress in vivo in both Zucker and STZ-induced diabetic rats (Sonta 
et al. 2004). Under normal circumstances, increased free radical production is neutralized by 
the action of superoxide dismutase, catalase or glutathione peroxidase, which form the 
anti-oxidant defence mechanisms (see Reviews by Fiers et al. 1999; Hayes & McLellan 1999; 
Nicholls & Budd 2000). In diabetes, these mechanisms may be impaired (Weidig et al. 2004) 
and favor the action of reactive molecular species, which have the ability to directly cause 
macromolecular damage by oxidizing and damaging DNA, proteins and lipids (see Reviews 
by Nishikawa et al. 2000; Rosen et al. 2001). The oxidative stress hypothesis, therefore, may 
be the common link between proposed mechanisms of diabetic complications (i.e. sorbitol 
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formation and PKC activation), resulting in vasculopathy in diabetes.  
 
In the vasculature, ROS can alter the production of cytokines and growth factors regulating 
the vascular endothelium, affect lipid oxidation status and enhance platelet hyperreactivity. 
For example, ROS-induced activation of PKC isoforms results in the generation of TGF-β, 
endothelin, and vascular endothelial growth factor from the vascular endothelium. PKC 
activation in this instance also alters the expression of fibronectin, hence affecting the 
integrity of the basement membrane (Williams & Schrier 1992 and see Review by King et al. 
1996). By activating the NF-κB pathway, inducing gene transcription, ROS are also able to 
increase cytokine production such as TNF-α and adhesion molecules and potentiate the 
formation of atherosclerotic lesions (see Reviews by Thurberg BL, Collins 1998; Christman et 
al. 2000). Signaling pathways such as NH2-terminal Jun kinases/stress activated protein 
kinases (JNK/SAPK), p38 mitogen-activated protein (MAP) kinase and hexosamine are also 
reported to be modulated by ROS (see Reviews by Marshall et al. 1991; Kyriakis & Avruch 
1996; Barnes & Karin 1997). Therefore, in addition to directly oxidizing macromolecules, 
ROS also acts through numerous intracellular signaling pathways hence, affecting gene 
expression and consequently cellular damage results. Oxidative stress thus, plays a critical 
role in the etiology of diabetic complications. 
 
6.1.4 FORMATION OF AGES 
The formation of AGEs, as detailed in Figure 6-2, is the result of non-enzymatic glycosylation 
of proteins or lipids when a high level of glucose is present, a “browning” effect observed 
made by Maillard almost a century ago, also known as a Schiff’s base (Maillard 1912). A 
Schiff’s base is further rearranged to form the more stable Amadori-type product and 
eventually the irreversible AGEs (Brownlee et al. 1988).  
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Figure 6-2 
 
Figure 6-2 
Formation of AGEs (diagram adapted from Sulochana et al. 2001) 
AGE formation begins with reversible condensation of the aldehyde group of glucose with a macromolecule 
such as a protein forming a Schiff’s base. A Schiff’s base is re-arranged to form a stable Amadori product and 
eventually irreversible AGEs such as carboxyl methyl lysine (CML). 
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AGEs can be found in plasma and various cell types including monocytes, red blood cell, 
vessel walls and kidney. Of the large number and complex family, carboxyl methyl lysine 
(CML) (Ikeda et al. 1996) and pentosidine (Sell & Monnier 1989) are the predominant AGEs 
found in human. Although a hyperglycemic environment favors the formation of AGEs, 
diabetes mellitus is not the pre-requisite for such a formation. Studies have shown that AGE 
cross-linking is a natural process in aging and can also take place in conditions such as 
Alzheimer’s disease (Picklo et al. 2002). Once formed, AGE cross-linking affects the 
biochemistry of proteins such as reducing enzyme activity (Facchiano et al. 2002), changing 
biophysical properties of proteins and affecting protein interactions with other enzymes 
(Verzijl 2002; Badenhorst 2003). AGEs can also bind to specific receptors including RAGE, 
AGE-R2, and AGE-R3. Hence, they play an important role in cell signaling processes. 
Increasing evidence suggests that the engagement of AGEs to their receptors, RAGE plays a 
pivotal role in the accelerated vascular dysfunction observed in diabetes.  
 
6.1.4.1 Cell surface AGE binding proteins 
Whilst glycation per se may alter protein activity in a general sense, there appears to be 
specific pathways, which are activated by glycated macromolecules. Using radio-labelled 
AGE proteins, proteins that bind to AGEs have been identified, isolated and purified from cell 
membranes of various cell types including monocytes, lymphocytes, erythrocytes and 
endothelial cells (see Review by Kim et al. 2005).  
 
AGE binding proteins appear to be very heterogenous, because they have different molecular 
weights depending on the cell type (see Review by Hudson et al. 2002). Further study by 
Schmidt et al. (1994) has resulted in the characterisation of AGE binding proteins from 
endothelial cells. The main component of the cellular binding site is an integral membrane 
protein belonging to an immunoglobulin superfamily known as RAGE. A second 
lactoferrin-like polypeptide, which is highly homologous with lactoferrin binds 
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non-covalently to RAGE forming the cellular AGE binding site (Schmidt et al.1994). More 
AGE receptors have been discovered and the list of AGE binding proteins now includes 
OST-48 (AGE-R1), 80K-H (AGE-R2), galectin-3 (AGE-R3), the macrophage scavenger 
receptor A (MSR-A), and lysozyme (see Review by Vlassara 1996). Despite the large number 
of AGE receptors, RAGE is the best characterized AGE receptor and appears to play a central 
role in AGE cell signaling pathways (see Review by Schmidt et al. 2001). 
 
6.1.4.1.1 Receptors for RAGE 
RAGE is a member of the immunoglobulin superfamily of cell surface molecules. 
Immunohistochemistry and in situ hybridization studies have shown that RAGE is expressed 
in endothelial cells, vascular smooth muscle cells, macrophage, T-lymphocytes, mesangial 
cells and astrocytes (Brett et al. 1993; Ritthaler et al. 1995). Cloned from bovine lung in 1992, 
RAGE has a molecular weight of 35 Kd in a truncated form (Neeper et al. 1992). The 
extracellular portion of the receptor consists of one V-type, two C-type domains and a short 
cytoplasmic tail. This highly charged cytoplasmic tail may be responsible for the recruitment 
of cellular effectors by binding to signal transduction molecules in the cytoplasm once the 
ligand occupies the receptor (Neeper et al. 1992; Schmidt et al. 1992; Schmidt et al. 1994). 
There is a high degree of RAGE homology in human, rat and cow. The slight differences in 
glycosylation sites and susceptibility to proteases may contribute to their different 
pharmacological parameters (Renard et al. 1997; Renard et al. 1999). There are also 
similarities in homology between RAGE and some other members of the immunoglobulin 
superfamily. For instance, the cytosolic tail of RAGE at the C terminus is the most 
homologous with CD20, a B cell activation marker. Its place in the immunoglobulin 
superfamily means RAGE may participate in the host response to environmental perturbation 
(Li & Schmidt 1997). 
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The signaling transduction pathways involving RAGE are complex. It has been shown that 
AGE-RAGE interactions can result in the generation of oxidative stress and activation of 
p21ras, erk 1/2 kinases and NF-κB in endothelial cells, monocytes, and vascular smooth 
muscle cells (Kislinger et al. 1999). Consequently, this series of events leads to expression of 
pro-inflammatory mediators. The role of RAGE in mediating inflammation was further 
demonstrated by the suppression of the effects of AGEs when RAGE was blocked with 
soluble RAGE, the extracellular ligand-binding domain of the receptor or by transient 
transfection of cDNA encoding cytosolic tail-deleted RAGE into RAGE-bearing cells (Neeper 
et al. 1992; Schmidt et al. 1992). More importantly, it was found that AGE-RAGE interaction 
itself can provide a positive feedback loop by enhancing RAGE expression, which further 
sustains RAGE up-regulation. (Soulis et al.1997). This positive feedback loop of AGE-RAGE 
interaction has been proposed to set the stage for chronic cellular activation and tissue damage 
(Schmidt et al. 1999). 
 
6.1.4.1.2 Cellular interaction of AGEs: central role of RAGE in diabetes 
In the presence of diabetes, cells and tissues are constantly exposed to AGEs from the 
circulating blood and consequently results in AGE accumulation. The cross-links between 
AGEs and proteins/tissues can lead to disturbances in vascular homeostasis. For example, in a 
diabetic rat model following AGE-RAGE engagement, endothelial cells reduce in size 
resulting in increased endothelial permeability (Wautier et al. 1996), which is an early sign of 
the development of diabetic vasculopathy (Viberti 1983). RAGE can be blocked by the 
soluble form of RAGE, which consists of only the extracellular ligand-binding domain of 
RAGE. Soluble RAGE can reverse previously observed endothelial impairment (Wautier et al. 
1996). The use of antioxidants further reduced AGE-mediated endothelial hyper-permeability, 
suggesting AGE-mediated vascular dysfunction was in part oxidative-stress related (Wautier 
et al. 1996). 
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The binding of AGEs to endothelial RAGE also results in the expression of vascular cell 
adhesion molecule-1 (VCAM-1) by endothelial cells stimulated by recruitment of monocytes 
to the vessel wall. Monocytes then infiltrate the blood vessel wall and release cytokines and 
growth factors when activated, setting the stage for the development of atherosclerosis 
(Schmidt et al. 1995). In fact, several studies have suggested that RAGE may be a key 
component in the progression of atherosclerosis and its acceleration observed in diabetic 
animal models (Park et al. 1998; Kislinger et al. 1999; Kislinger et al. 2001). In human 
studies, atherosclerotic plaques showed infiltration of RAGE-expressing cells in the expanded 
intima (Brett et al. 1993).  
 
Accumulating evidence strongly indicates a close relationship between RAGE and 
inflammation. Enhanced expression of monocyte RAGE has been shown to be involved in 
systemic inflammation during chronic kidney disease. In a study including 102 non-diabetic 
subjects with chronic kidney disease, Hou et al. (2004) found that monocyte RAGE 
expression increased with the severity of chronic kidney disease and RAGE expression was 
strongly correlated with plasma levels of pentosidine, a marker for AGE formation and 
various other substances including TNF-α, the monocyte activation marker, neopterin and 
CRP. When stimulated with AGEs, these monocytes showed an increase in the number and 
affinity of specific AGE binding sites together with a higher production of TNF-α. This was 
reduced by a RAGE antibody (Hou et al. 2004). Interestingly, Bucciarelli et al. (2002) has 
reported a link between RAGE and the COX-2 pathway, which is also known to play a role in 
the process of inflammation. It was found that COX-2 expression in plaque macrophages 
isolated from diabetic mice was up-regulated by RAGE. Potentially, it is possible that RAGE 
may augment and amplify COX-mediated matrix metalloproteinase release and worsen 
diabetic complications.  
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6.2 AIMS 
Given that AGE-RAGE interaction plays a critical role in diabetes, a better understanding of 
RAGE expression in platelets and monocytes may provide a better means to understand 
diabetic vasculopathy. The aims of the current study were to investigate the protein level of 
RAGE in platelets and monocytes isolated from both human Type 2 and Type 1 diabetic 
subjects. 
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6.3 METHODS 
6.3.1 RAGE LEVELS IN PLATELETS AND MONOCYTES IN HUMAN DIABETIC 
SUBJECTS 
6.3.1.1 Human subjects and blood sample collection (Type 2 diabetes) 
Twenty five (25) human non-diabetic control (14 males, 11 females) and 52 human Type 2 
diabetic (28 males, 24 females) subjects were recruited at St. Vincent’s Hospital (Melbourne, 
Australia). The volunteer recruitment and blood sample collection was performed by the 
endocrinologist, Dr. Alicia Jenkins (Melbourne, Australia; see Section 4.3.2.2). In addition, 14 
non-diabetic samples from healthy male subjects collected during previous project at RMIT 
University and stored away at -80°C were also included in this study.  
 
6.3.1.2 Human subjects and blood sample collection (Type 1 diabetes) 
Twenty five (25) human non-diabetic control (14 males, 11 females) and 19 Type 1 diabetic 
(10 males, 9 females) subjects were recruited by Dr. Alicia Jenkins at St. Vincent’s Hospital 
(Melbourne, Australia; see Section 4.3.2.2). In addition, 14 non-diabetic samples from healthy 
male subjects collected during previous project at RMIT University and stored away at -80°C 
were also included in this study. 
 
6.3.1.3 Isolation of human platelets and monocytes  
The isolation of human platelets and monocytes was performed using OptiPrepTM solution 
according to the manufacturer’s protocol, which was described in Section 4.3.2.3.  
 
6.3.1.4 Protein assay (humans) 
Determination of human sample protein concentrations was performed using the Biorad 
microBCA system as outlined in Section 4.3.1.3. 
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6.3.1.5 Western blot: RAGE protein (humans) 
Human samples were loaded in duplicate with a final total protein concentration of 10 μg per 
well. The protein samples and molecular weight markers were electrophoresed, transferred 
onto nitrocellulose membranes and incubated with anti-mouse monoclonal anti-RAGE 
antibody using the same Western blot protocol for the detection of COX protein expressions 
as in Section 4.3.1.4. The density of all Western blot bands was analyzed using the 
ChemiDoc™ XRS system (Biorad, CA, USA).  
 
6.3.2 DRUGS AND CHEMICALS 
Anti-mouse monoclonal anti-RAGE antibody, peroxidase conjugated goat anti-mouse 
immunoglobulins; Chemicon International (Temecula, CA, USA). All other drugs and 
chemicals used in the present experiments were the same as that used in Chapters 2 and 4 and 
thus, were obtained from the same sources (see Sections 2.3.4 and 4.4.5).  
 
6.3.3 STATISTICAL ANALYSES 
All values are given as the mean ± standard error of mean (S.E.) and n indicates the number 
of observations. Differences in the percentage densities of Western blot bands were analyzed 
using unpaired Student’s t-test, Mann-Whitney test, 1-way ANOVA and post-hoc tests 
(Tukey’s, Games-Howell and Dunn’s multiple tests), Pearson Chi-Square and Fisher’s exact 
test whenever applicable. SPSS (SPSS Inc., IL, USA) and Prism (GraphPad Software, Inc., 
CA, USA) statistical packages were used in statistical analyses.  
 
6.3.4 HUMAN ETHICS APPROVAL 
All procedures used for human blood collection were approved by the Human Research 
Ethics Committee of St. Vincent’s Hospital (Melbourne, Australia; HREC-A 024/00 
Glycoxidation, HDL and diabetes angiopathy) in accordance with the National Statement on 
Ethical Conduct in Research Involving Humans (June 1999) produced by the National Health 
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and Medical Research Council of Australia. A separate set of human samples from another 
study was included in the present study. The collection of these samples was approved by the 
Human Research Ethics Committee of RMIT University (Melbourne, Australia; HREC 15/01 
Majewski: Age-dependent alterations in cyclooxygenase in platelets and human monocytes).  
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6.4 RESULTS 
6.4.1 RAGE LEVELS IN PLATELETS AND MONOCYTES IN TYPE 2 DIABETES  
6.4.1.1 Basis parameters of human Type 2 diabetic subjects 
Human subject selection was made by Dr. Alicia Jenkins at St. Vincent’s Hospital, Melbourne 
(Section 4.3.2.2). The present study did not exclude any samples collected in order to have a 
sample population that resembled the characteristics of the general population. One exception 
was COX inhibition. Human subjects on non-steroidal anti-inflammatory drugs (NSAIDs) 
were separated from the rest of the sample population and treated separately. Thus the three 
groups in the present study were: 39 human control subjects (28 males, 11 females), 29 
human Type 2 diabetic subjects (13 males, 15 females) and 23 hHuman Type 2 diabetic 
subjects on NSAIDs (14 males, 9 females). A summary of the physiological parameters, blood 
examination and pharmacological interventions of these subjects is detailed in Table 4-1 and 
Table 4-2 (Section 4.4.2.1).  
 
6.4.1.2 Western blot validations (humans) 
6.4.1.2.1 Specificity of Western blot: RAGE (humans)  
RAGE protein bands were determined and verified against their corresponding molecular 
weight at approximately 48 kD. The specificity of the primary RAGE antibody was further 
assessed by incubating samples with the secondary antibody only. The absence of RAGE 
bands at 48 kD in this case confirmed the specificity of the primary antibody to RAGE 
proteins (Figure 6-3). A series of sample protein concentrations was performed to determine 
the suitable loading concentration. Density analysis indicated that 10 μg of total protein was 
the minimum loading requirement for detecting a clear RAGE protein band that was not over 
saturated (Figure 6-3).  
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A.  Platelet RAGE kD
Figure 6-3
B.  Platelet RAGE negative control
C.  Monocyte RAGE
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Lane         
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G.  Monocyte RAGE sample loading
Figure 6-3
Western blot validation: RAGE protein levels in platelets and monocytes (humans)
Western blot validation for platelet and monocyte RAGE in human subjects. Panels A and C: A 
signal for platelet RAGE and monocyte RAGE, respectively, was evident at 48 kD according to 
molecular weight markers. Panels B and D: RAGE immuno-reactivity was verified by negative 
controls, which were performed with omission of the RAGE primary antibody but in the presence of 
the secondary antibody. Lanes a + b, c + d: duplicate samples from human Type 2 diabetic subjects, 
lanes e + f, g + h: duplicates samples from human control subjects, lane i: internal standard. A series 
of sample loading concentrations was performed to determine the final protein loading for platelet 
RAGE (Panels E and F) and monocyte RAGE (Panels G and H). Lanes j to m represent 5, 10, 15 
and 20 μg protein loading. A final protein loading of 10 μg per lane was chosen, because this was 
the concentration at which the minimal amount of sample was required to produce a reliable and 
clear band. Higher protein loading resulted in the risk of signal saturation.
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6.4.1.2.2 Western blot data reproducibility: RAGE (humans) 
RAGE protein expression was measured in two samples collected from 6 human Type 1 
diabetic subjects on separate occasions (Section 5.3.1.2). The values obtained were very 
consistent indicating both assay accuracy and stability of RAGE levels in the same subjects 
(Figure 6-4).  
 
6.4.1.3 Influence of age on sample population (Type 2 diabetes) 
There was a difference in age between human control and Type 2 diabetic groups (37.9±2.2 
and 60.5±2.6 years old, respectively. Table 4-1, Section 4.4.2.1). Correlation analyses were 
performed to analyze the relationship between RAGE expression and age of human Type 2 
diabetic subjects. There was no significant correlation between platelet RAGE or monocyte 
RAGE expression and advancing age (Figure 6-5). 
 
RAGE gene expression, however, has been shown to decrease (Casselmann et al. 2004; Simm 
et al. 2004) in aging human hearts. Simm et al. (2004) further assessed RAGE protein 
expression and found that it was increased with aging in human hearts. This inverse 
relationship suggested that RAGE may be regulated at the post-transcriptional rather than 
transcriptional level. In order to assess potential age-dependent effects on RAGE expression 
in the current study, age-matching was performed according to the procedure detailed in 
Section 4.4.2.3. This age-matching process continued until all human control subjects were 
matched with an individual Type 2 diabetic subject. The result of this process was closely 
matched mean ages of 50.0±2.4 for human controls (n=19) and 53.0±2.6 years old for Type 2 
diabetic patients (n=19), which were not significantly different. A summary of the 
physiological parameters, blood examination and pharmacological interventions of 
age-matched subjects is detailed in Table 4-3 and Table 4-4 (see Section 4.4.2.2.1).  
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Figure 6-4
A.  Platelet RAGE (repeated sample) B.  Monocyte RAGE (repeated sample)
 
 
Figure 6-4 
Reproducibility of RAGE protein expression in human Type 1 diabetic subjects  
RAGE expression in human platelets and monocytes from individual Type 1 diabetic subjects taken on separate 
occasions (sets A and B). Panel A: Platelet RAGE protein expression measured in repeated samples from 6 
human Type 1 diabetic subjects. Panel B: Monocyte RAGE protein expression measured in repeated samples 
from 6 human Type 1 diabetic subjects. A rat platelet or monocyte standard control was run with each Western 
blot and the density of all sample bands were expressed in the percentage of the corresponding standard control. 
p>0.05, paired Student’s t-test. 
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Figure 6-5
A.  Platelet RAGE B.  Monocyte RAGE
 
 
Figure 6-5  
Correlation analysis on RAGE expression and age of human subjects (Type 2 diabetes, non age-matched) 
The relationship between RAGE expression and age of the subjects was investigated. Panel A: Scatter plot of the 
densities of all platelet RAGE samples in relation to age. Panel B: Scatter plot of the densities of all monocyte 
RAGE samples in relation to age. R2 represents correlation coefficient. p>0.05, Pearson Correlation. 
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6.4.1.4 RAGE levels in Type 2 diabetes 
Initial analyses on non age-matched subjects revealed a significant increase in both platelet 
and monocyte RAGE expression in human Type 2 diabetic subjects compared with human 
control subjects. The increased RAGE level in platelets was, however, age-dependent as 
shown in age-matched analysis (Figure 6-6C) whereas monocyte RAGE levels remained to be 
significantly elevated in age-matched Type 2 diabetes (Figure 6-6D).  
 
RAGE expression was not correlated with COX expression in either platelets or monocytes 
(Figure 6-7) and RAGE was not significantly correlated with plasma hemoglobin A1C (Figure 
6-8).  
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Figure 6-6
A.  Platelet RAGE (non age-matched) B.  Monocyte RAGE (non age-matched)
0
100
200
300
19       19
control    T2 diabetes
N.S.
Pl
at
el
et
 R
AG
E
(%
 o
f i
nt
er
na
l s
ta
nd
ar
d)
0
100
200
300
*
M
on
oc
yt
e 
R
AG
E
(%
 o
f i
nt
er
na
l s
ta
nd
ar
d)
19       19
control    T2 diabetes
C.  Platelet RAGE (age-matched) D.  Monocyte RAGE (age-matched)
 
 
Figure 6-6 
Quantitative densitometry of RAGE protein expression in Type 2 diabetes 
Density analysis of RAGE expression in human platelets and monocytes. Panel A: Non age-matched analysis of 
platelet RAGE protein expression in human control and human Type 2 diabetic subjects. Panel B: Non 
age-matched analysis of monocyte RAGE protein expression in human control and human Type 2 diabetic 
subjects. A rat platelet or monocyte standard control was run with each Western blot and the density of all sample 
bands was expressed as a percentage of the corresponding standard control. Panel C: Age-matched analysis of 
platelet RAGE protein expression in control and human Type 2 diabetic subjects. Panel D: Age-matched analysis 
of monocyte RAGE protein expression in human control and human Type 2 diabetic subjects. Values represent 
the mean, S.E. and number of subjects. * significant difference from human control subjects, p<0.01, Mann 
Whitney test; N.S. not significant, unpaired Student’s t-test. 
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A.  Platelet RAGE vs. platelet COX-1 B.  Monocyte RAGE vs. monocyte COX-2
Figure 6-7
 
 
Figure 6-7 
Non-age matched correlation analysis on RAGE expression and COX expression of human subjects  
(Type 2 diabetes) 
The relationship between RAGE and COX expression in human control and human Type 2 diabetic subjects was 
investigated. Panel A: Scatter plot of the densities of all platelet RAGE samples in relation to platelet COX-1 
expression. Panel B: Scatter plot of the densities of all monocyte RAGE samples in relation to monocyte COX-2 
expression. R2 represents correlation coefficient. P>0.05, Pearson Correlation.  
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Figure 6-8
A.  Platelet RAGE v.s. hemoglobin A1c B.  Monocyte RAGE v.s. hemoglobin A1c
 
 
Figure 6-8 
Non-age matched correlation analysis on RAGE expression and hemoglobin A1C of human subjects  
(Type 2 diabetes) 
The relationship between RAGE and hemoglobin A1C in human control and human Type 2 diabetic subjects was 
investigated. Panel A: Scatter plot of the densities of all platelet RAGE samples in relation to hemoglobin A1C. 
Panel B: Scatter plot of the densities of all monocyte RAGE samples in relation to hemoglobin A1C. R2 
represents correlation coefficient. * significant correlation, p<0.05, Pearson Correlation. 
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6.4.2 RAGE LEVELS IN PLATELETS AND MONOCYTES IN TYPE 1 DIABETES 
6.4.2.1 Basis parameters of human Type 1 diabetic subjects 
Human subject selection of Type 1 diabetic study was based on broad selection criteria. Most 
human subjects were included in the study analyses with one exception that human subjects 
on NSAIDs were separated from the rest of the sample population and treated separately. 
Thus the three groups in the present study were: 39 human control subjects (28 males, 11 
females), 19 human Type 1 diabetic subjects (10 males, 9 females) and 6 human Type 1 
diabetic subjects on NSAIDs (2 males, 4 females). A summary of the physiological 
parameters, blood examination and pharmacological interventions of these subjects is detailed 
in Table 5-1 and Table 5-2 (see Section 5.4.1.1).  
 
6.4.2.2 Western blot validations (humans) 
Several validation procedures were in place to verify that bands detected corresponded to 
RAGE protein. These procedures have been discussed in details in previous Section 6.4.1. 2.  
 
6.4.2.3 Influence of ages on sample population (Type 1 diabetes) 
There was no significant difference in age between human control and human Type 1 diabetic 
subjects (37.9±2.4 and 34.6±3.4 years old, respectively. Table 5-1, Section 5.4.1), which was 
also shown in correlation analysis (Figure 6-9), although RAGE expression has been shown to 
alter in human heart with aging, as previously discussed (Casselmann et al. 2004; Simm et al. 
2004).  
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6.4.2.4 RAGE levels in Type 1 diabetes 
The present study showed a significant increase in both platelet and monocyte RAGE 
expression in human Type 1 diabetic subjects compared with human control subjects (Figure 
6-10). Correlation analyses showed a weak correlation between RAGE expression and plasma 
hemoglobin A1C (Figure 6-11). RAGE expression was not correlated with COX expression in 
either platelets or monocytes (Figure 6-12). COX levels were not correlated with hemoglobin 
A1C (Figure 6-13). 
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Figure 6-9
A.  Platelet RAGE B.  Monocyte RAGE
 
 
Figure 6-9 
Correlation analysis on RAGE expression and age of human subjects (Type 1 diabetes) 
The relationship between RAGE expression and age of the subjects was investigated. Panel A: Scatter plot of the 
densities of all platelet RAGE samples in relation to age. Panel B: Scatter plot of the densities of all monocyte 
RAGE samples in relation to age. R2 represents correlation coefficient. p>0.05, Pearson Correlation. 
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Figure 6-10
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Figure 6-10 
Quantitative densitometry of RAGE protein expression in Type 1 diabetes 
Density analysis of RAGE expression in human platelets and monocytes. Panel A: Platelet RAGE protein level 
in human control and human Type 1 diabetic subjects. Panel B: Monocyte RAGE protein expression in human 
control and human Type 1 diabetic subjects. A rat platelet or monocyte standard control was run with each 
Western blot and the density of all sample bands was expressed as a percentage of the corresponding standard 
control. Values represent the mean, S.E. and number of subjects. * significant difference from human control 
subjects, p<0.0001, Mann Whitney test; ** significant difference from human control subjects, p<0.0001, 
unpaired Student’s t-test. 
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Figure 6-11
A.  Platelet RAGE v.s. hemoglobin A1c B.  Monocyte RAGE v.s. hemoglobin A1c
 
 
Figure 6-11 
Correlation analysis on RAGE expression and plasma hemoglobin A1C of human subjects 
(Type 1 diabetes) 
The relationship between RAGE and plasma hemoglobin A1C in human control and human Type 1 diabetic 
subjects was investigated. Panel A: Scatter plot of the densities of all platelet RAGE samples in relation to 
platelet COX-1 expression. Panel B: Scatter plot of the densities of all monocyte RAGE samples in relation to 
monocyte COX-2 expression. R2 represents correlation coefficient. * significant correlation, p<0.05, Pearson 
Correlation.  
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Figure 6-12
A.  Platelet RAGE vs. platelet COX-1 B.  Monocyte RAGE vs. monocyte COX-2
 
 
Figure 6-12 
Correlation analysis on RAGE expression and COX expression of human subjects (Type 1 diabetes) 
The relationship between RAGE and COX expression in human control and human Type 1 diabetic subjects was 
investigated. Panel A: Scatter plot of the densities of all platelet RAGE samples in relation to platelet COX-1 
expression. Panel B: Scatter plot of the densities of all monocyte RAGE samples in relation to monocyte COX-2 
expression. R2 represents correlation coefficient. * significant correlation, p<0.05, Pearson Correlation.  
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Figure 6-13
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Figure 6-13 
Correlation analysis on monocyte COX-2 expression and plasma hemoglobin A1C of human subjects  
(non age-matched) 
The relationship between monocyte COX-2 expression and plasma hemoglobin A1C in human control and 
diabetic subjects was investigated. Panel A: Scatter plot of the densities of all monocyte COX-2 samples in 
relation to plasma hemoglobin A1C. Panel B: Scatter plot of the densities of all monocyte COX-2 samples in 
relation to plasma hemoglobin A1C. R2 represents correlation coefficient. p>0.05, Pearson Correlation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
191
6.4.3 EFFECT OF NSAIDS ON RAGE LEVELS IN HUMAN DIABETIC SUBJECTS 
6.4.3.1 Effect of NSAIDs on RAGE levels in Type 2 diabetes 
Human Type 2 diabetic subjects with NSAID treatment regime showed a significant reduction 
in platelet and monocyte RAGE expression compared to human Type 2 diabetic subjects not 
taking NSAIDs (Figure 6-14).  
 
6.4.3.2 Effect of NSAIDs on RAGE protein levels in Type 1 diabetes 
Human Type 1 diabetic subjects with NSAID treatment regime showed a significant reduction 
in platelet and monocyte RAGE expression compared to human Type 1 diabetic subjects not 
taking NSAIDs (Figure 6-15).  
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Figure 6-14
A.  Platelet RAGE B.  Monocyte RAGE
 
 
Figure 6-14 
Quantitative densitometry of RAGE protein expression in the presence of NSAIDs in human subjects 
(Type 2 diabetes, non age-matched) 
Non age-matched analysis of RAGE expression in Type 2 diabetes in the presence of NSAIDs. Panel A: Platelet 
RAGE protein expression was measured in human Type 2 diabetic subjects with and without NSAIDs. Panel B: 
Monocyte RAGE protein expression measured in human Type 2 diabetic subjects with and without NSAIDs. A 
rat platelet or monocyte standard control was run with each Western blot and the density of all sample bands was 
expressed as a percentage of the corresponding standard control. Values represent the mean, S.E. and number of 
subjects. * significant difference from Type 2 diabetes not taking NSAIDs, p<0.05, 1-way ANOVA (Dunn’s 
multiple comparison test). 
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Figure 6-15
A.  Platelet RAGE B.  Monocyte RAGE
 
 
Figure 6-15 
Quantitative densitometry of RAGE protein expression in the presence of NSAIDs in human subjects  
(Type 1 diabetes) 
Analyses of RAGE expression in Type 1 diabetes in the presence of NSAIDs. Panel A: Platelet RAGE protein 
expression was measured in human Type 1 diabetic subjects with and without NSAIDs. Panel B: Monocyte 
RAGE protein expression measured in human Type 1 diabetic subjects with and without NSAIDs. A rat platelet 
or monocyte standard control was run with each Western blot and the density of all sample bands was expressed 
as a percentage of the corresponding standard control. Values represent the mean, S.E. and number of subjects. * 
significant difference from Type 2 diabetes not taking NSAIDs, p<0.05, 1-way ANOVA (Dunn’s comparison 
test); # significant difference from Type 2 diabetes not taking NSAIDs, p<0.05, 1-way ANOVA (Tukey’s 
multiple comparison test). 
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6.5 DISCUSSION 
Non-enzymatic glycosylation macromolecules such as proteins, enzymes and lipids results in 
the formation of irreversible AGEs (Maillard 1912; Brownlee et al. 1988). The consequence 
of AGE formation is reduced enzyme activity, alteration in protein structures and altered 
protein interactions (Facchiano et al. 2002; Verzijl 2002; Badenhorst 2003). Increasing 
evidence suggests that the engagement of AGEs to specific receptors such as RAGE plays a 
pivotal role in the accelerated vascular dysfunction observed in diabetic animal models (Park 
et al. 1998; Kislinger et al. 1999; Kislinger et al. 2001).  
 
The present study investigated the presence of RAGE in diabetes since RAGE up-regulation 
can be induced by AGEs (Schmidt et al. 1999; Buenting et al. 2001). The two cell types 
chosen in this study were platelets and monocytes, which were isolated from human Type 1 
and Type 2 diabetic subjects. Previous work has shown elevation in RAGE in a variety of 
animal tissues including the VSMCs, endothelial cells, heart and aorta (Sun et al. 1998), 
lacrimal glands (Alves et al. 2005) of STZ-treated rats, a Type 1 diabetic animal model. In 
humans, mononuclear cells of Type 2 diabetic patients with vascular complications also have 
elevated RAGE (Buchs et al. 2004), but otherwise there have been few human studies in 
platelets or monocytes.  
 
6.5.1 RAGE LEVELS IN TYPE 2 DIABETES 
6.5.1.1 Platelet RAGE in Type 2 diabetes 
The result of the present study found that RAGE levels in platelets were significantly, but 
only slightly increased (15%) in Type 2 diabetes. After age-matching, however, increased 
RAGE levels were no longer statistically significant (Figure 6-6). RAGE levels were only 
weakly correlated with age (Figure 6-5) therefore, the lack of significance is most likely due 
to the decrease in sample size in the age-matching process, particularly since the elevation 
prior to age-matching was modest. To the best of our knowledge, the present study was the 
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first to measure platelet RAGE levels in Type 2 diabetes with meaningful sample sizes. 
Previously only a small study by Buenting et al. (2001) reported the presence of RAGE in 
platelets in both human diabetic and non-diabetic subjects (n=9 and n=2, respectively), but no 
meaningful conclusions could be made. 
 
There is clear evidence of platelet hyperactivity in Type 2 diabetes (Section 3.4.1.2), but it is 
unclear whether increased RAGE levels in platelets could play a role since platelets are 
devoid of genetic material and the most prominent RAGE actions are related to changes in 
gene expression (Yan et al. 1994). There is, however, a possibility that the pre-platelet stage 
of megakaryocytes may be affected. This may alter platelet architecture and signaling 
pathways, which persist in matured platelets. Alternatively, lack of nuclear material does not 
necessarily preclude up-regulation of proteins and receptors in platelets. There is evidence for 
enhanced expression of proteins such as P-selectin, CD 40 ligand, and receptors such as 
thromboxane receptor α in platelets, which are pre-formed and stored in the α granules in 
platelets. Upon activation, these proteins/receptors are then redistributed to the surface of the 
platelets (Stenberg et al. 1985; Berman et al. 1986; Henn et al. 1998; Nurden et al. 2003).  
 
6.5.1.2 Monocyte RAGE in Type 2 diabetes 
The present study showed that human Type 2 diabetic subjects have significantly increased 
monocyte RAGE levels compared with human control subjects (13%). Age-analysis found 
that monocyte RAGE expression remained significantly elevated in human Type 2 diabetic 
subjects compared with age-matched human control subjects (Figure 6-6). There was no 
correlation between age and RAGE expression in monocytes (Figure 6-5). In the literature, 
several studies reported that RAGE was up-regulated in diabetes. For example, Buchs et al. 
(2004) observed increased RAGE expression in peripheral blood mononuclear cells of human 
Type 2 diabetic subjects with vascular complications compared to human diabetic subjects 
without complications. Other studies also observed increased RAGE levels in various 
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tissue/cell types. For example, RAGE was up-regulated in endothelium, VSMCs, 
monocyte-derived macrophages and cardiac myocytes of a bovine diabetic model (Brett et al. 
1993). In STZ-induced Type 1 diabetic mice, RAGE expression was found to be up-regulated 
in the aorta and kidney compared with non-diabetic animal (Kislinger et al. 2001).  
 
Enhanced RAGE expression may be crucial to the development of atherosclerosis in diabetes. 
Several animal studies have reported that treatment of diabetic mice with advanced 
atherosclerosis with soluble RAGE (a RAGE inhibitor) suppressed the development of 
atherosclerosis (Park et al. 1998; Wendt et al. 2006). Monocyte infiltration and conversion to 
macrophages are pivotal steps in atheroma formation and hence monocyte RAGE may be 
important. The engagement of RAGE-bearing monocytes by AGE ligands can lead to 
chemotaxis (Schmidt et al. 1993) and monocyte infiltration to the endothelial monolayer 
(Kirstein et al. 1990; Vlassara et al. 1992). In atherosclerotic plaques isolated from human 
Type 2 diabetic subjects, Cipollone et al. (2003) observed an enhanced macrophage and T cell 
infiltration compared to non-diabetic plaques accompanied by increased RAGE expression. 
Further immuno-staining showed that active macrophages in these plaques actually expressed 
RAGE. Cipollone and colleagues further reported increased activation of NF-κB in diabetic 
plaques and this showed a strong concordance with RAGE expression, although further 
studies are needed to determine a direct relationship. 
 
Interestingly, increased RAGE expression in monocytes may potentially link to 
COX-mediated pathways as Cipollone et al. (2003) found that increased RAGE was 
co-localized with increased COX-2, PGE synthase and MMP expression in the activated 
macrophages derived from diabetic atherosclerotic plaques. Another study by Bucciarelli et al. 
(2002) showed that COX-2 antigen levels were reduced in the aorta of diabetic mice in the 
presence of soluble RAGE. The present study, however, did not observe a correlation between 
monocyte RAGE and monocyte COX-2 expression (Figure 6-7). It is important to note that 
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the present study did not study macrophages and the differences between the two cell types 
may account for the different experimental findings.  
 
6.5.2 RAGE LEVELS IN TYPE 1 DIABETES 
6.5.2.1 Platelet RAGE in Type 1 diabetes 
Increasing evidence suggests that RAGE up-regulation in some cell types is involved in 
long-term diabetic complications in Type 1 diabetes. For example, in animal models, RAGE is 
implicated in diabetic nephropathy (Jensen et al. 2006) possibly through induction of TGF-β 
and cytokines that promote the trans-differentiation of epithelial cells to form myofibroblasts 
resulting in eventual diabetic nephropathy (Oldfield et al. 2001). A large study involving eight 
hundred and thirty eight subjects further found that 82 Ser allele of the RAGE gene is a risk 
allele for developing advanced nephropathy (Prevost et al. 2005).  
 
The present study found an increase in RAGE levels in platelets isolated from human Type 1 
diabetic subjects (38%, Figure 6-10). Age was not a confounding factor as RAGE was not 
correlated with age in these subjects (Figure 6-9). Of all cells studied (platelets and monocytes) 
in both Type 1 and Type 2 diabetic patients, this was the largest change observed. Whether 
this plays a role in platelet hyperactivity in diabetes remains to be seen. 
 
6.5.2.2 Monocyte RAGE in Type 1 diabetes 
The current study reported an increase (23%) in RAGE expression in monocytes isolated from 
human Type 1 diabetic subjects (Figure 6-10). This increase was not affected by the age of the 
subjects (Figure 6-9). Burke et al. (2004) found that an increased presence of RAGE 
expressed macrophages around and within necrotic cores of atherosclerotic plaques in human 
Type 1 diabetic subjects, which is consistent with the current observation, although another 
study by Miura et al. (2004) reported that monocyte expression of RAGE mRNA did not 
significantly differ between human control and human Type 1 diabetic subjects. 
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A study in murine RAW 264.7 macrophage cell line reported up-regulation of COX-2 
expression by AGEs (Lin et al. 2002). A similar study was also reported by Shanmugam et al. 
(2003). S100b, a specific RAGE ligand, was found to induce COX-2 mRNA and protein 
expression, but not COX-1 in cultured human monocytes isolated from human Type 1 diabetic 
subjects. The elevated expression of RAGE in monocytes in the current study was not 
correlated with monocyte COX-2 expression (Figure 6-12). Further, there was no correlation 
between monocyte COX-2 expression and AGEs as measured by plasma hemoglobin A1C (an 
AGE) (Figure 6-13). Despite lack of correlations, enhanced RAGE expression in monocytes 
as seen in the present study, which may further differentiate into macrophages, may contribute 
to the development of macro-vascular complications in diabetes (see Section 6.5.1.2). 
 
6.5.2.3 AGE production and RAGE expression in diabetes 
One clinical measure of AGEs is plasma hemoglobin A1C. In the present human study, this 
was elevated in both Type 1 and Type 2 diabetic subjects (Tables 4-1 and 5-1). AGEs have 
been suggested to stimulate RAGE expression (Schmidt et al. 1999). Changes in RAGE 
expression observed in the current study were small making it difficult to see any correlation 
between plasma hemoglobin A1C and RAGE (Figures 6-8 and 6-11). However, in the case of 
platelet RAGE in Type 1 diabetes where RAGE expression increased by 38% (the maximum 
effect seen in any cell, Figure 6-10), a relationship to plasma hemoglobin A1C was evident 
with an R2 of 0.38 (Figure 6-11). 
 
6.5.3 EFFECT OF NSAIDS ON RAGE LEVELS IN HUMAN DIABETIC SUBJECTS 
Accelerated atherosclerosis and micro-vascular diseases such as retinopathy and nephropathy 
are common complications associated with diabetes (Kannel & McGee 1979; see Review by 
Schuster & Duvuuri 2002). The underlying mechanisms of these chronic diabetic 
complications have been discussed in details in Section 3.4 and in the introduction of this 
chapter, Section 6.1. One of the mechanisms involves the signaling of RAGE. RAGE has 
   
199
been implicated in chronic inflammation. Ligands such as AGEs can bind to RAGE and result 
in increased IL-2 expression and cell proliferation in lymphocytes and increased IL-1β and 
TNF-α in mononuclear phagocytes (Hofmann et al. 1999; see Review by Schafer & 
Heizmann 1996). NSAIDs, notably aspirin, are successfully used clinically to reduce pain and 
inflammation in chronic conditions such as arthritis and in some cases to reduce the risk of 
cardiovascular diseases in high risk groups including diabetes by inhibiting the activity of 
COX enzymes (see Review by Vane & Botting 2003; for more details see Section 4.5.4). This 
preliminary study investigated the effect of NSAIDs on RAGE levels in both Type 1 and Type 
2 diabetes. 
 
6.5.3.1 Effect of NSAIDs on RAGE levels in human diabetic subjects 
RAGE levels in platelets and monocytes in human diabetic subjects receiving NSAID 
treatment were significantly lower than that of human non-diabetic controls indicating that 
NSAIDs may reduce RAGE expression (Figures 6-14 and 6-15). The mechanisms involved in 
down-regulation of RAGE by NSAIDs are unclear, although fluorescent-induced AGE 
formation has been shown to be down-regulated in rat tail tendon by ibuprofen (Menzel & 
Reihsner 1996) and similarly AGE formation in human corneal and scleral collagen with age 
was reduced by aspirin (Malik & Meek 1994). These data suggest that potentially RAGE 
expression could be down-regulated through reduced AGE/RAGE interaction, which may be 
of importance in lowering the development of diabetic complications.  
 
To the best of our knowledge, a reduction of RAGE level in platelets and monocytes in 
diabetic subjects by NSAIDs is a novel finding. Down-regulation of RAGE can potentially 
affect a variety of down stream signaling transduction pathways involving NF-κB, MMP, 
TGF-β and TNF-α, which have been shown in various cell types including monocytes and 
mesangial cells (Throckmorton et al. 1995; Li & Schmidt 1997; Bierhaus et al. 2001; 
Cipollone et al. 2003; see Review by Collins 1993). The current findings suggest that the use 
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of NSAIDs may reduce the risk of cardiovascular events in diabetic subjects through these 
RAGE-mediated signaling pathways  
 
6.6 CONCLUSIONS 
Moderate to small increases in RAGE levels were observed in platelets and monocytes in both 
Type 1 and Type 2 diabetes. Increased RAGE levels were reduced by the treatment of 
NSAIDs in human diabetic subjects, suggesting RAGE may be in fact a crucial player in the 
inflammatory process in diabetes. The ability of NSAIDs to down-regulate RAGE may be of 
importance in the management of diabetic complications. 
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